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"It is the same in the case of numberless pathological lesions
which are real experiments, by which physicians and physiologists
profit, without any purpose on their part to produce the lesions,
which result from disease. I emphasise this idea now, because it
will be useful to us later, to prove that medicine includes real
experiments which are spontaneous, and not produced by physicians".
Claude Bernard (1813 - 1878)
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Insulin-induced hypoglycaemia in man provokes an integrated hormonal and
metabolic response to restore normoglycaemia. Secretion of counterregulatory hormones
promote hepatic glycogenolysis and gluconeogenesis, and mobilise substrates from
extra-hepatic tissues. Both adrenergic and cholinergic neural mechanisms are
activated by hypoglycaemia, but their contributions to the control of metabolic
recovery are not clear. Activation of the sympatho-adrenal system does not appear to
be essential for blood glucose recovery.
The effect of acute hypoglycaemia on pancreatic beta cell function in response
to a subsequent meal was studied in normal subjects. Suppression of endogenous insulin
secretion following hypoglycaemia persisted until ingestion of a meal at 210 minutes
after insulin injection. After the meal carbohydrate intolerance was associated with
an abnormal pattern of insulin secretion, characterised by a delay in the early
post-prandial rise of plasma insulin and late hyperinsulinaemia. Investigations of
the possible underlying mechanisms implicated glucopenia of the pancreatic beta cells.
The contributions of adrenergic and cholinergic mechanisms to metabolic recovery
from hypoglycaemia were studied in tetraplegic subjects with a pre-ganglionic
sympathectomy (adrenergic denervation), one group of whom were given atropine (combined
adrenergic denervation and cholinergic blockade). Blood glucose recovery was impaired
only in the tetraplegic subjects given atropine. Both tetraplegic groups demonstrated
a reduced blood lactate response, a delayed rise of plasma free fatty acids and an
absent cyclic AMP response. Changes in pancreatic glucagon and C-peptide following
hypoglycaemia were appropriate to blood glucose values, and were not influenced
significantly by islet denervation. Stimulation of glucagon secretion occurred
independent of cholinergic vagal control. In the tetraplegic subjects given atropine,
the plasma Cortisol response was impaired and the pattern of ACTH secretion was
abnormal, suggesting possible blockade of central cholinergic receptors at hypothalamic
level. This Cortisol deficiency may explain the delayed blood glucose recovery in
these subjects.
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SUMMARY
Chapter 1 Metabolic and hormonal responses to acute hypoglycaemia
in man
The first clinical descriptions of hypoglycaemia followed the
introduction of insulin for the treatment of diabetes mellitus,
and early investigators demonstrated that activation of the sympatho¬
adrenal system was involved in the metabolic response. The restoration
of normoglycaemia following insulin-induced hypoglycaemia results
from the production of glucose by hepatic glycogenolysis and gluconeogenesis,
while substrates for gluconeogenesis are released from extrahepatic
tissues. Glycogenolysis in muscle liberates lactate, lipolysis in
adipose tissue releases free fatty acids (FFA) and glycerol, and
glucogenic amino acids are released from muscle, of which alanine is
the most important. The principal metabolic pathways in the production
of glucose are described.
The important counterregulatory hormones which are secreted in
response to hypoglycaemia are adrenaline, noradrenaline, pancreatic
glucagon, growth hormone and Cortisol. Catecholamines promote hepatic
and muscle glycogenolysis and lipolysis in adipose tissue, mainly via
beta-adrenergic mechanisms. Glucagon acts by stimulating hepatic
glycogenolysis and gluconeogenesis. The actions of Cortisol and
growth hormone on metabolic processes following hypoglycaemia are not
defined clearly, but these hormones may exert a permissive action on
the effects of other counterregulatory hormones.
The release of counterregulatory hormones leads to the production
of glucose stored as hepatic glycogen, and the mobilisation of substrates
for gluconeogenesis, as an integrated metabolic response to hypoglycaemia
to maintain the supply of glucose which is essential for cerebral function.
SUMMARY
Chapter 2 Neural control of the recovery from acute hypoglycaemia
The anatomical organisation and chemical subdivisions of the
autonomic nervous system are described briefly with reference to
the involvement of adrenergic and cholinergic mechanisms in the
metabolic recovery from hypoglycaemia. Sympathetic and parasympathetic
centres which respond to hypoglycaemia are located within the hypothalamus.
The two principal methods for inducing a glucopenic stress are the
administration of intravenous insulin and the infusion of 2-deoxy-D-glucose,
a competitive inhibitor of glucose.
The methods of investigating adrenergic mechanisms in the response
to hypoglycaemia include the measurement of plasma and urinary
catecholamines, pharmacological blockade of adrenergic receptors, and
the effect of hypoglycaemia on either adrenalectomised or sympathectomised
subjects. These studies show that circulating catecholamines promote
the haemodynamic changes which occur in response to hypoglycaemia, and
adrenergic mechanisms mediate the mobilisation of FFA and lactate.
However activation of the sympatho-adrenal system alone does not appear
to be essential for blood glucose recovery from hypoglycaemia.
Cholinergic mechanisms have been studied using pharmacological
blockade with atropine and ablation studies which produce parasympathetic
denervation (vagotomy). The cholinergic manifestations of hypoglycaemia
are mediated via the parasympathetic and sympathetic divisions and
include haemodynamic changes, salivation, sweating, vasodilatation
and the secretion of certain gastrointestinal and pancreatic hormones,
including pancreatic polypeptide. In particular, evidence is presented
which suggests that the secretion of pancreatic glucagon is influenced
by vagal (cholinergic) innervation.
SUMMARY
Chapter 3 Rationale and aims of experimental investigations of
hypoglycaemia in man
This chapter describes the rationale for the experimental
studies described in Chapters 4-8. These studies are concerned
with two areas related to metabolic recovery from acute hypoglycaemia
in man. A brief introduction to each area of investigation is
provided and the aims of the studies are outlined.
(1) The effect of acute hypoglycaemia on pancreatic beta cell
function in response to a subsequent meal: the development of an
assay for plasma C-peptide has provided an index of endogenous insulin
secretion during insulin-induced hypoglycaemi a. This has demonstrated
prolonged suppression of pancreatic beta cell secretion following
hypoglycaemia in man. Previous studies have suggested that glucose
intolerance may occur after hypoglycaemia at varying times after insulin
administration. The effect of hypoglycaemia on pancreatic beta cell
function in man in response to a subsequent meal has not been examined
previously.
(2) Neural control of pancreatic islet cell function and the metabolic
and hormonal responses to hypoglycaemia: tetraplegic subjects, who
have a pre-ganglionic sympathectomy,provide a human model for studying
the effect of adrenergic denervation on pancreatic islet cell function
in response to hypoglycaemia. The addition of atropine to these
subjects to produce cholinergic blockade enables an assessment of
cholinergic mechanisms, and no human studies have examined previously
the effect of combined sympathetic and parasympathetic blockade on
recovery mechanisms from insulin-induced hypoglycaemia. The relative
contribution of the principal counterregulatory hormones to metabolic
recovery from hypoglycaemia can also be examined.
SUMMARY
Chapter 4 The effect of acute hypoglycaemia on the pancreatic
beta cell response to a meal In man
The plasma concentrationsof C-peptide, insulin and glucose
weremeasured in nine healthy subjects during insulin-induced
hypoglycaemia followed by a meal. Identical observations were made
in the same subjects after an equivalent period of fasting without
hypoglycaemia (control study). Endogenous secretion of insulin
was suppressed following administration of exogenous insulin, and
this persisted long after the blood glucose concentration had returned
to normal. After the meal blood glucose rose to a peak at 60 min and
was still raised at 120 min, compared to the small transient rise of
blood glucose observed in the control study. This carbohydrate
intolerance was associated with an abnormal pattern of insulin
secretion, characterised by a delay in the early post-prandial rise
of plasma insulin, and a pronounced elevation two hours after the meal.
Acute hypoglycaemia may thus induce an abnormal pattern of
insulin secretion in response to a subsequent meal, with the development
of impaired carbohydrate tolerance in normal subjects.
SUMMARY
Chapter 5 The mechanism of the abnormal pancreatic beta cell
response to food following acute hypoglycaemia in man
Following acute insulin-induced hypoglycaemia, an abnormal
pattern of insulin secretion in response to a meal was confirmed
in six normal subjects. This was characterised by an initial
impairment of insulin secretion and late hyperinsulinaemia. Post-prandial
gastrointestinal hormone levels were normal following hypoglycaemia in
these subjects. In four other subjects, the administration of intravenous
glucose prior to the meal partially reversed the abnormal pattern of
insulin secretion. In two normal subjects, aminophylline infusion
before the meal did not improve the abnormal secretory response of
insulin. In two subjects with a total pre-ganglionic sympathectomy,
the patterns of response of blood glucose, plasma insulin and C-peptide
were similar to those observed following hypoglycaemia in normal subjects.
It is unlikely therefore that either an abnormal entero-insular axis, an
elevation of plasma catecholamine concentrations or depletion of
cyclic AMP within the pancreatic beta cells have a primary role in the
production of this phenomenon. This effect of hypoglycaemia on
post-prandial insulin secretion may be caused, at least in part, by
glucopenia of the pancreatic beta cells.
SUMMARY
Chapter 6 Manifestations of acute hypoglycaemia in subjects
with pre-gang]ionic sympathectomy with and without
cholinergic blockade
The effects of acute insulin-induced hypoglycaemia were observed
on 11 normal subjects, six tetraplegic subjects and six tetraplegic
subjects given atropine. The tetraplegic subjects without atropine
experienced mild neuroglycopenia only, whereas tetraplegic subjects
given atropine experienced severe and prolonged neuroglycopenia.
The normal haemodynamic changes and sweating were absent in the
tetraplegic subjects, but a small gradual increase in pulse rate was
noted following hypoglycaemia. Systolic and diastolic blood pressures
were subnormal. The adequacy of cholinergic blockade in the tetraplegic
subjects given atropine was confirmed by a sustained elevation in
pulse rate. The normal rise in haematocrit in response to hypoglycaemia
was absent in the tetraplegic subjects, and mean basal plasma
noradrenaline was lower than in normal subjects with no measurable
response to hypoglycaemia.
The haemodynamic changes in normal subjects were mediated by
activation of the sympatho-adrenal system. In tetraplegic subjects
the increase in heart rate may be caused by a withdrawal of vagal cardiac
tone in response to the fall in blood pressure, resulting from the
inability to initiate activation of the sympathetic nervous system in
response to hypoglycaemia. In normal subjects the sweating response to
hypoglycaemia appears to be mediated by a sympathetic cholinergic
mechanism and not by circulating catecholamines.
SUMMARY
Chapter 7 Plasma substrate responses to acute hypoglycaemia
in man: adrenergic and cholinergic mechanisms
The contributions of adrenergic and cholinergic mechanisms
to the metabolic recovery from acute hypoglycaemia induced by insulin
wereexamined in 11 normal subjects, six tetraplegic subjects (adrenergic
denervation) and six tetraplegic subjects given atropine (combined
adrenergic denervation and cholinergic blockade).
Blood glucose recovery was impaired only in the tetraplegic
subjects given atropine. The blood lactate response was reduced and
the rise of plasma free fatty acids was delayed in both groups of
tetraplegic subjects, in whom the normal rise of plasma cyclic AMP
was also absent.
Blood glucose homeostasis was impaired therefore during combined
adrenergic denervation and cholinergic blockade. The impaired blood
lactate and plasma free fatty acid responses in the tetraplegic subjects
indicate the role of adrenergic mechanisms in the activation of muscle
glycogenolysis and adipose tissue lipolysis. The absent response of
plasma cyclic AMP implicates mediation by catecholamines in the
activation of hepatic adenyl cyclase in response to hyDoalycaemia.
SUMMARY
Chapter 8 Hormonal response to acute hypoglycaemia in man:
neural control of pancreatic islet cell function
and hormonal mediation of metabolic homeostasis
The role of autonomic neuro-regulation of pancreatic islets
in response to hypoglycaemia was examined in 11 normal subjects,
six tetraplegic subjects (adrenergic denervation) and six tetraplegic
subjects given atropine (combined adrenergic denervation and cholinergic
blockade). Changes in plasma pancreatic glucagon and C-peptide
following hypoglycaemia were appropriate to blood glucose values and
were not influenced significantly by islet denervation. Thus,
neuro-regulation of human pancreatic islet function in response to
hypoglycaemia may be of limited importance, and stimulation of pancreatic
glucagon secretion apparently can occur in the absence of cholinergic
vagal control.
Growth hormone levels were higher in both tetraplegic groups
in response to hypoglycaemia. The normal rise in plasma pancreatic
polypeptide was absent in the tetraplegic subjects given atropine, which
confirms the role of vagal cholinergic control of secretion of this
hormone. The plasma Cortisol response was impaired in the tetraplegic
subjects given atropine despite a greater degree of hypoglycaemia, and
in these subjects the pattern of ACTH secretion was abnormal. A
blockade of central cholinergic receptors producing impaired activation
of ACTH secretion at hypothalamic level may explain, at least in part,
the delayed restoration of normoglycaemia in the tetraplegic subjects
given atropine.
PART I THEORETICAL BACKGROUND
CHAPTER 1
METABOLIC AND HORMONAL RESPONSES
TO ACUTE HYPOGLYCAEMIA IN MAN
CHAPTER 1
METABOLIC AND HORMONAL RESPONSES TO ACUTE HYPOGLYCAEMIA IN MAN
1. Historical perspective
2. The recovery from acute hypoglycaemia





B. Counterregulatory hormonal response to hypoglycaemia
C. Effects of counterregulatory hormones on metabolic





D. The integrated hormonal and metabolic response for
blood glucose recovery from hypoglycaemia
1.1
1• HISTORICAL PERSPECTIVE
The biblical account of Esau is thought to be the first recorded
description of symptomatic hypoglycaemia in man (Genesis, Ch. 25,
v. 29 - 34). Despite prolific investigation of carbohydrate metabolism
during the nineteenth century by Claude Bernard and others, the
lack of accurate methods to measure blood glucose prevented an
exposition of acute hypoglycaemia in man until the impetus provided
by the introduction of insulin therapy in 1922. Hypoglycaemia had
been recognised earlier as a biochemical anomaly associated with
phosphorus poisoning and the administration of drugs such as hydrazine.
The mildly hypoglycaemic effect of salicylates was described by
Ebstein in 1876, and in 1916 Fischler and his collaborators described
symptoms of excitement, convulsions, collapse and coma which
accompanied the low blood sugar produced by phlorizin. They described
this condition as "glycoprival intoxication".
The development of the concept of hormones by Bayliss and
Starling (1902 - 1906) stimulated further attempts to extract insulin
from the pancreas. Georg Zuelzer prepared pancreatic extracts and
administered them to dogs between 1903 and 1914, but the "toxic"
phenomena which occurred included loss of consciousness and
convulsions, which with hindsight were probably caused by hypoglycaemia.
His experiments, although successful, tragically were misinterpeted
and had to be abandoned at the outbreak of the First World War. A
similar fate overtook the Roumanian, Paulesco, who in 1916 had an
effective though less purified pancreatic extract at his disposal.
Publication of his findings was delayed for years by the First World
War, and was eclipsed by work from Canada. In the summer of 1921,
the Canadian orthopaedic surgeon, Frederick Banting, and a
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medical student Charles Best, demonstrated that the injection of a
crude pancreatic extract lowered the blood glucose of pancreatectomised
dogs. They observed that insulin could not only lower the blood
glucose of normal and diabetic animals, but that it could also produce
signs of cerebral dysfunction, including convulsions and coma, that
could be reversed by restoring blood glucose to normal (Banting et a!.,
1922).
The therapeutic application of insulin for the treatment of
human diabetes provoked the first detailed descriptions of the
symptoms and signs of acute hypoglycaemia in man (Fletcher and
Campbell, 1922; Banting et a!., 1923). Profuse sweating, dilatation
of the pupils, skin pallor and an increase in pulse rate were noted
to accompany subjective sensations of anxiety, emotional instability
or excitement, coldness and faintness. As the level of blood glucose
decreased further, signs of dysarthria, disorientation and confusion
preceded the eventual loss of consciousness. The treatment recommended
by these authors was the administration of food or orange juice, and
the injection of "epinephrin" if the patient was unconscious.
The clinical signs of hypoglycaemia implied an increase in
activity of the sympathetic nervous system, and in 1924 two groups
of investigators described independently the stimulatory effect of
hypoglycaemia on adrenal medullary secretion. The Boston physiologist
Walter Cannon and his associates observed that insulin-induced
hypoglycaemia produced a release of "adrenin" into the circulation
of unanaesthetised cats (Cannon et al., 1924). The effect on the
denervated heart was used as an index of circulating hormone from
the adrenal medulla. The removal of one adrenal gland with concurrent
denervation of the other prevented release of this hormone, as did
correction of the blood glucose with dextrose. Houssay et al., (1924)
used cross-circulation experiments in dogs to show a similar secretion
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from the adrenal medulla in response to hypoglycaemia. This
endocrine response could also be prevented by sympathetic denervation
of the adrenal glands or the intravenous injection of glucose.
These early classical experiments of the endocrine response to
hypoglycaemia indicated a role for the sympatho-adrenal system in
the metabolic recovery from hypoglycaemia, and this was confirmed
by further studies on adrenalectomised and sympathectomised animals
(Britton et al., 1928; Dworkin, 1931; Schlossberg et al., 1933;
Freeman et al., 1934). The practical difficulties of developing
reliable assays for adrenaline and noradrenaline hindered further
progress in this area for several decades. Von Euler and Luft (1952)
eventually showed that the urinary excretion of catecholamines was
increased following hypoglycaemia in man.
The hyperglycaemic effect of adrenaline was observed in animals
at the beginning of this century (Blum, 1901) and subsequent
investigators were aware that activation of the sympatho-adrenal
system in response to hypoglycaemia promoted release of glucose by
the liver. Cannon et al., (1924) stated that "both the nerve impulses
(sympathetic) and the secreted adrenin have the effect of liberating
sugar from the liver into the circulation, thus tending to restore
the disturbed equilibrium. This may be regarded as a first line of
defense against a falling glycemic concentration". The central
role of the liver in the preservation of glucose homeostasis had
already been postulated byClaude Bernard in 1876 with his concept
of maintenance of the "milieu interieur". He had earlier described
glycogen as a temporary storage form of carbohydrate and had
discovered the ability of the liver to maintain blood glucose levels
in the absence of carbohydrate in the diet, thus invoking the concept
of carbohydrate homeostasis (Bernard, 1853). This was demonstrated
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conclusively by the production of severe hypoglycaemia following
total hepatectomy in dogs with its consequent adverse effect on
cerebral function (Mann and Magath, 1921; 1922). These early
observations were refined by Soskin et a!., (1938) who showed that
the perfused dog liver removed glucose from portal venous blood
when the glucose concentration was high, and conversely the perfused
liver produced glucose when the portal blood glucose was low.
Although glucagon had been identified as a potential
glucoregulatory hormone in 1923 (Kimball and Murlin, 1923), the
role of glucagon and other counterregulatory hormones in the metabolic
response to hypoglycaemia had to await the development of modern
radioimmunoassay techniques in the early 1960's.
Finally the participation of neural factors in the metabolic
recovery from hypoglycaemia had been suspected since the original
observation byClaude Bernard in 1849 that hyperglycaemia develops
in experimental animals after puncture of the floor of the fourth
ventricle. Paul Langerhans described an innervation of the pancreatic
islets in his doctoral thesis in 1869, but research into neural
regulation of pancreatic islet function was discouraged by the
failure of early studies to show that denervation of the pancreas
had any effect on the regulation of blood glucose (Allen, 1922).
Subsequent research in the modern era has shown however that
pancreatic endocrine function can be modulated by neural influences,
although the contribution of the autonomic nervous system to the
control of pancreatic endocrine responses to hypoglycaemia is far
from clear. The pancreatic islets are exposed to a complex array of
metabolic,endocrine and neural influences which control normal
pancreatic endocrine secretion, and presumably modify the responses
to abnormal metabolic states such as hypoglycaemia.
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2. THE RECOVERY FROM ACUTE HYPOGLYCAEMIA
Under normal conditions the predominant metabolic fuel used
by the central nervous system is glucose. The brain metabolises
6G of glucose per hour (Reinmuth et al., 1965), and its daily
requirement has been estimated to be 110 - 145G, (Owen et al., 1967).
A rapid fall in blood glucose affects the central nervous system
in a similar way to a decrease in arterial oxygen, producing
immediate effects on neuronal activity. Prolonged hypoglycaemia
produces irreversible structural damage, causing loss of brain
stem function and death. Because of the vital importance of glucose
for cerebral function, several homeostatic mechanisms exist to
maintain normoglycaemia, and severe hypoglycaemia therefore
represents an unphysiological state that does not normally occur
during life.
The normal range of blood glucose after an overnight fast
usually varies from 3.0 - 5.5 mmol/1 (approximately 55 - lOOmg/lOOml),
and traditionally in clinical practice hypoglycaemia has been
considered to occur when the blood glucose falls below 2.5 mmol/1.
The physiological response to acute hypoglycaemia is triggered
by a fall in blood glucose below 2.9 mmol/1 in normal human subjects
(DeFronzo et al., 1974; Young et al., 1974), although recent studies
suggest that there is no absolute threshold of blood glucose required
to activate the counterregulatory systems (Cryer, 1980). The
magnitude of the counterregulatory response appears to be inversely
related to the absolute concentration of blood glucose, so that a
decrease of blood glucose to a hypoglycaemic level releases more
counterregulatory hormones than a decrease of blood glucose from
a high level to one within the physiological range (Santiago et al., 1980).
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A. METABOLIC PROCESSES FOR RESTORING NORMOGLYCAEMIA
The prime necessity in the metabolic response to hypoglycaemia
is the immediate provision of glucose. This is released rapidly
from the liver following the activation of hepatic glycogenolysis
and gluconeogenesis. In extrahepatic tissues, glycogenolysis in
skeletal muscle liberates lactate, and 1ipolysis in adipose tissue
provides free fatty acids (FFA). Protein hydrolysis releases
glucogenic amino acids from muscle, which provide substrate for
hepatic gluconeogenesis. The principal glucogenic amino acid is
alanine. The main pathways of carbohydrate utilisation and glucose
production are shown in Fig. 1.1. The mechanisms which initiate
and regulate these processes are incompletely understood, and will
be discussed in Chapter 2.
Glycogenolysis: The control of hepatic glycogenolysis has recently
been reviewed comprehensively (Hems and Whitton, 1980). The
degradation of glycogen is catalysed by glycogen phosphorylases.
The product is glucose-l-phosphate; the glucose carbon skeleton
derived from liver glycogen can therefore follow the pathways of
the hexose phosphates (Fig. 1.1) to free glucose, end products of
glycolysis and products of acetyl Coenzyme A (CoA) metabolism.
The main product of hepatic glycogenolysis in response to hypoglycaemia
is free glucose which is released rapidly into the blood.
In skeletal muscle, activation of phosphorylase promotes
glycogenolysis to glucose-6-phosphate, but glucose is not formed
in the absence of a muscle glucose-6-phosphatase. The glycolytic
and oxidative breakdown of the glucose-6-phosphate produces lactate
which diffuses into the blood and provides a significant precursor





















Fig. 1.1 Main metabolic pathways in the liver involved in
glucose production in response to hypoglycaemia,
with the direction of response indicated by the
thicker arrows. The enzymes which regulate the
principal steps in glucose synthesis or glycolysis















glucose-6-phosphate and glucose occurs in the liver (the "Cori cycle")
and in starvation may account for 20 - 40 per cent of hepatic glucose
output (Kreisberg et al., 1970).
Gluconeogenesis: The liver is capable of producing glucose from
various substrates including lactate, pyruvate, glycerol, the
glucogenic amino acids and odd-chain fatty acids. All these substances
are glucogenic, and their conversion to glucose requires several key
enzyme systems which enable the liver to produce new glucose-6-phosphate
from non-carbohydrate sources. The main synthetic enzymes involved
in glycolysis and gluconeogenesis in the liver are shown in Fig. 1.1.
Regulation of these processes occurs at certain stages of the pathway,
and usually at sites where two or more enzymes are involved. Because
of the enzyme pyruvate carboxylase, pyruvate can be converted
directly into oxaloacetate, and phosphoenolpyruvate (PEP) carboxylase
catalyses the formation of PEP from oxaloacetate. Substances which
can be transformed to oxaloacetate can therefore be used for
gluconeogenesis; lactate and alanine thereby can enter the gluconeogenic
pathway. The activity of pyruvate carboxylase is regulated by the
concentration of acetyl-CoA (Scrutton and Utter, 1968), which is
abundant when fatty acid metabolism is enhanced. This is one of
several regulatory devices which favour gluconeogenesis.
Lipolysis: Hypoglycaemia induces the activation of lipase in adipose
tissue, thus stimulating the lipolysis of triglycerides and the
release of free fatty acids and glycerol. Glycerol can enter the
gluconeogenic pathway via conversion to alpha-glycerolphosphate,
but is thought to be a relatively minor gluconeogenic substrate
(Cahill, 1970). Free fatty acids are oxidised in the liver to
two-carbon fragments and acetyl-CoA (Fig. 1.1) and provide substrate
for glucose synthesis.
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Glucogenic amino acids: A significant proportion of newly-formed
glucose originates from glucogenic amino acids derived from protein
hydrolysis. Studies in prolonged starvation have indicated that
alanine is quantitatively the most important three-carbon precursor
(other than lactate) for hepatic gluconeogenesis (Felig et al., 1969;
Owen et al., 1969). Data from the infusion of labelled substrates
in man after an overnight fast indicate that alanine (Garber et al.,
1976) and lactate (Kreisberg et al., 1970) each contribute approximately
one-seventh of the total glucose production.
The contribution of alanine to glucose production in response
to hypoglycaemia has been described in detail by Garber et al., (1976)
using isotope dilution techniques to measure the simultaneous
turnover of glucose and alanine, and their precursor-product
interrelationships. In the steady state prior to insulin administration
the amount of glucose derived from alanine was only 13 per cent,
which is consistent with measurements using arterio-hepatic venous
catheterisation techniques in fasting man (Felig et al., 1970). Total
glucose production and gluconeogenesis from alanine was inhibited
markedly after insulin injection. Although gluconeogenesis from
alanine returned to basal values within 30 minutes of insulin
administration, it did not rise above basal until 60 minutes after
insulin. However by this time total glucose production had doubled,
and it seems likely that the initial increase in total glucose
production resulted principally from accelerated glycogenolysis and
not from gluconeogenesis. The contribution of alanine to gluconeogenesis
increased steadily in the second hour after insulin administration,
but did not derive entirely from an increased rate of alanine delivery
to the liver, since the alanine inflow was increased by only 15-20
1.10
per cent, ihe increased rate of gluconeogenesis appeared therefore
to result from a redirection of intrahepatic alanine metabolism.
B. CQUNTERREGULATORY HORMONAL RESPONSE TO HYPQGLYCAEMIA
Acute hypoglycaemia in man is characterised by diverse changes
in plasma substrate and hormone concentrations which are accompanied
by simultaneous haemodynamic responses. Several hormones are
secreted in response to acute hypoglycaemia but few of these have
metabolic actions which can potentially reverse hypoglycaemia. The
hormones which are secreted in response to hypoglycaemia and are
considered also to have significant counterregulatory effects include
the catecholamines, adrenaline and noradrenaline (Vendsalu, 1960;
Christensen et a!., 1975), pancreatic glucagon (Gerich et al., 1974),
growth hormone (Roth et al., 1963) and Cortisol (Landon et al., 1963;
Greenwood et al., 1966).
The temporal sequence of release of these hormones in response
to acute hypoglycaemia has been examined in man (Gerich et al., 1974;
Garber et al., 1976). After the intravenous injection of insulin
(0.15 units/kg body weight), a significant increase of plasma
adrenaline is observed at 20 minutes and plasma noradrenaline at
25 minutes, with maximal levels of both catecholamines occurring at
50 minutes (Garber et al., 1976). Plasma glucagon increases
significantly at 30 minutes with a maximal response at 40 minutes,
plasma Cortisol rises at 30 minutes with a maximal response at
60 minutes, but growth hormone increases relatively slowly after
insulin, with a significant increment at 40 minutes and a peak
concentration at 60 minutes. Gerich et al., (1974) demonstrated
that the peak response of glucagon precedes those of Cortisol
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and growth hormone by 15 to 30 minutes. In contrast, a significant
increase in plasma glucagon has been reported prior to the rise
in plasma catecholamine levels and the onset of glucose counterregulation
by Rizza et al., (1979a),but in this study a much smaller dose of
insulin (0.04 units/kg) was used to induce hypoglycaemia. The
temporal sequence of hormonal secretion in relation to the compensatory
increase in glucose production suggests a role for all of these
hormones in maintaining glucose homeostasis, but the individual
contribution of each hormone has not been clearly defined.
C. EFFECTS OF COUNTERREGULATORY HORMONES ON METABOLIC PATHWAYS
AND SUBSTRATE AVAILABILITY
Insulin produces hypoglycaemia by stimulating the hepatic and
peripheral uptake of glucose, and by profoundly inhibiting total
glucose production (Garber et al., 1976). Insulin inhibits protein
breakdown and decreases net amino acid release (Pozefsky et al., 1969;
Blackshear et al., 1974) which inhibits the inflow of glucogenic
amino acids into the blood. It also inhibits glycerol and lactate
release in functionally hepatectomised rats (Blackshear et al., 1974)
and has a marked anti1ipolytic action. This has been demonstrated
in vitro in adipose tissue and is due at least in part to a reduction
in cyclic AMP (cAMP) levels with a consequent decrease in activity
of cAMP-dependent protein kinase and hormone-sensitive lipase
(Soderling et al., 1973). Infusion of physiological amounts of
insulin into the forearms of fasting human subjects inhibits the net
release of free fatty acids, presumably from adipose tissue
(Pozefsky et al., 1969).
The counterregulatory hormones antagonise the actions of insulin
and act to increase glucose production and decrease glucose utilisation.
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Catechol amines: Adrenaline and noradrenaline promote rapid
glycogenosis in the liver to provide glucose, glycogenolysis in
muscle to liberate lactate, and lipolysis in adipose tissue to
provide FFA (Young and Landsberg, 1977). Substrates thereby are
provided for hepatic gluconeogenesis which is enhanced by
catecholamine-induced effects at several stages of the gluconeogenic
pathway. Catecholamines are potent lipolytic agents and also
promote ketogenesis. While ketogenesis is usually attributed to
the stimulation of lipolysis, catecholamines may stimulate ketogenesis
through direct or indirect (hormone-mediated) effects on hepatic
metabolism (Schade and Eaton, 1979).
Catecholamines appear to exert their effects in the liver
via interaction with adrenergic receptors, and not via mediation
by cAMP. In vitro studies of rat liver have demonstrated that beta-
adrenergic blockade with propranolol inhibits the increase in cAMP
induced by adrenaline, without preventing the increase in phosphorylase
activation and hepatic glycogenolysis (Sherline et al., 1972).
Tolbert et al., (1973) showed that propranolol, while blocking cAMP
accumulation, did not prevent the stimulation of gluconeogenesis
by adrenaline in isolated liver cells. They also showed that the
beta agonist, isoproterenol, raised cAMP concentrations without
stimulating gluconeogenesis, which was however stimulated by the
alpha agonist, phenylephrine. It was concluded that the alpha-receptor
effects of adrenaline include an increase in phosphorylase activity
with an associated decrease in glycogen synthetase activity, thus
leading to hepatic glycogenolysis (Hutson et al., 1976; Cherrington
and Exton, 1976). Glucose uptake by muscle is decreased (Groen et al.,
1966; Abramson and Arky, 1968) and glucose clearance from the
circulation is reduced by catecholamines (Pvizza et al., 1979b).
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Catecholamines also enhance glycerol and lactate output from peripheral
tissues by interaction with beta-adrenergic receptors in adipose
tissue and muscle (Exton, 1979). This interaction is thought to
activate adenyl cyclase and cAMP-dependent enzymes which promote
glycolysis, lactate production and lipolysis.
Recent evidence has indicated that the direct effects of
adrenaline on glucose delivery and clearance in man are mediated
mainly by beta-adrenergic mechanisms (Rizza et al., 1979b; Deibert
and DeFronzo, 1979; Rizza et al., 1980) while indirect effects
resulting from the inhibited secretion of insulin are mediated by
alpha-adrenergic mechanisms.
Glucagon: Glucagon exerts potent effects on hepatic metabolism but
has minimal effects on peripheral tissues. It converts hepatic
glycogen phosphorylase from its inactive to its active form to promote
glycogenolysis (Pari 11 a et al., 1974), but has no effect on muscle
phosphorylase. It rapidly activates gluconeogenesis from lactate,
pyruvate, alanine and glycerol in the perfused rat liver and in
isolated rat hepatocytes and rapidly inhibits hepatic glycolysis
(Exton, 1979). These effects can be mimicked by exogenous cAMP and
are preceded by a rise in this nucleotide with activation of
cAMP-dependent protein kinase (Cherrington and Exton, 1976). The
actions of glucagon are therefore thought to be mediated via cAMP.
However, efforts to link cAMP or protein kinase to the phosphorylation
or activation of specific gluconeogenic enzymes have not been successful,
and the precise sites of action of glucagon in this process remain
undetermined.
Glucagon is thought to influence the redirection of hepatic
alanine metabolism during gluconeogenesis (Chiasson et al., 1975),
since glucagon has been shown to stimulate hepatic gluconeogenesis
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from alanine without increasing alanine extraction by the liver.
The effect of a physiological deficiency of glucagon has been shown
in the dog by suppression of endogenous glucagon by somatostatin
14
infusion (Jennings et al., 1977). The conversion of C-alanine
14
to C-glucose was decreased under these conditions, but gluconeogenesis
returned to normal when physiological levels of plasma glucagon
were restored. Finally, glucagon increases intrahepatic 1ipolys is,
probably via cAMP activation (Bewsher and Ashmore, 1966).
Cortisol: The contribution of Cortisol to blood glucose recovery
from hypoglycaemia is not well defined. It stimulates the release
of amino acids from extrahepatic tissues, thus providing increased
substrate for gluconeogenesis, while decreasing the sensitivity of
peripheral tissues to insulin and reducing the peripheral uptake
of glucose (Baxter and Forsham, 1972). In adipose tissue Cortisol
promotes lipolysis, augmenting the effect of growth hormone in vitro
(Fain, 1967). In addition, Cortisol exerts permissive effects on
the actions of glucagon and catecholamines on hepatic glycogenolysis
and gluconeogenesis (Exton et al., 1972). Gluconeogenesis is
influenced by the effects of Cortisol on the catechol amine-mediated
release of lactate from skeletal muscle and glycerol from adipose tissue
(Steele, 1975). A gluconeogenic response to adrenaline or glucagon
was not observed in the livers of fasted adrenalectomised rats, and
neither gluconeogenesis nor glycogenolysis in livers from fed
steroid-deficient rats was stimulated by low levels of these hormones
(Exton et al., 1972). Cortisol deficiency thus appears to impair
the sensitivity of gluconeogenesis and glycogenolysis to the stimulatory
action of adrenaline and glucagon.
Growth hormone: Although growth hormone has not been shown convincingly
to alter gluconeogenesis or glycogenolysis directly, it does appear
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to antagonise some actions of insulin, and it decreases peripheral
glucose utilisation (Fineberg and Merimee, 1974). Growth hormone
increases fatty acid and glycerol release in vivo and in vitro by
enhancing triglyceride breakdown and depressing lipogenesis (Fain, 1967;
Gerich et a!., 1976), but this effect is slow and apparently involves
protein synthesis. Studies of hypophysectomised rats suggest that
in the absence of growth hormone,ami no acid utilisation for
gluconeogenesis in the liver is enhanced, which would indicate a
long-term inhibitory action of growth hormone on hepatic gluconeogenesis
(Tolman et al., 1973). Although glucose production is not increased
acutely by growth hormone or Cortisol (Exton et al., 1970), both
hormones may assist glucose production by inducing hepatic resistance
to insulin through interference with insulin-receptor binding (Kahn
et al., 1978). The overall importance of growth hormone to blood
glucose recovery from hypoglycaemia is debatable, and recently its
role has been questioned (Feldman et al., 1975; Rizza et al., 1979a).
D. THE INTEGRATED HORMONAL AND METABOLIC RESPONSE FOR BLOOD
GLUCOSE RECOVERY FROM HYPOGLYCAEMIA
The numerous factors which stimulate and regulatethe metabolic
recovery from hypoglycaemia operate simultaneously and interact in a
variety of ways in the intact organism. Having outlined the metabolic
pathways and the actions of the individual hormones which are involved
in the metabolic recovery from hypoglycaemia, the integrated response
can now be reviewed. The principal metabolic events which occur
following hypoglycaemia are presented in Fig. 1.2.
After the initial effects of exogenous insulin to induce acute
hypoglycaemia, a compensatory increase in glucose production occurs
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Fig. 1.2 The main metabolic events which occur in response to
~
hypoglycaemia induced by insulin. The effects of the
principal counterregulatory hormones on metabolic
processes are indicated (dotted lines).
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rapidly in the liver to restore normoglycaemia, despite the persisting
presence of significant levels of plasma insulin at that time
(Garber et a!., 1976). Hepatic glucose output rises while glucose
uptake in peripheral tissues is decreased. The dramatic early
increase in hepatic glucose output appears primarily to reflect
glycogenolysis in the liver. This increase in hepatic glucose production
by the stimulation of hepatic glycogenolysis and gluconeogenesis is
activated by catecholamines and glucagon, with Cortisol exerting a
permissive influence. Catechol amines, by their effects on lipolysis
in adipose tissue and glycogenolysis in skeletal muscle, also
stimulate the provision of substrates suitable for gluconeogenesis.
This is demonstrated by the marked increase in circulating lactate,
free fatty acids and glycerol.
Although plasma alanine levels do not change significantly
following hypoglycaemia, and only minor changes in alanine flux occur
between the liver and the blood, gluconeogenesis from alanine rises
gradually and continually to suprabasal levels, between one and two
hours after insulin administration (Garber et al., 1976). Although
growth hormone and Cortisol may contribute to the increase in glucose
production by a more permissive role such as the induction of hepatic
resistance to insulin binding, the alteration of substrate availability
or the promotion of enzyme induction, neither hormone increases
glucose production acutely (Exton et al., 1970).
There is evidence to indicate that endogenous insulin secretion
is suppressed during the recovery from hypoglycaemia (Sando et al., 1970;
Turner et al., 1973b;Horwitz et al., 1975b),and this may represent
a further homeostatic mechanism to encourage normal blood glucose
recovery. The effect of hypoglycaemia on endogenous insulin secretion
will be discussed further in chapters 3 and 4.
CHAPTER 2
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The regulation of the metabolic recovery from hypoglycaemia
is not well understood. The relationships between the endocrine
responses, the changes of substrate concentrations in tissues and
plasma and the activation of neural mechanisms which are stimulated
by glucopenic stress, are complex. Many neural factors can influence
the metabolic responses to hypoglycaemia, and both classical
divisions of the autonomic nervous system can be implicated. The
relative contribution of each division is unclear; studies of neural
mechanisms involved in metabolic recovery from hypoglycaemia in
animals and man have produced conflicting results, caused in part
by considerable species difference.
Before reviewing the separate effects of adrenergic and
cholinergic mechanisms on the metabolic recovery from hypoglycaemia,
the anatomical organisation and the chemical subdivisions of the
autonomic nervous system are described briefly.
1. AUTONOMIC NERVOUS SYSTEM
A. ANATOMICAL ORGANISATION: The autonomic nervous system is
influenced by receptors within the brain, with many autonomic functions
being controlled by the hypothalamus (Johnson and Spalding, 1974).
The peripheral motor pathways of the autonomic nervous system contain
pre- and post-ganglionic neurons. The cell bodies of the pre-ganglionic
neurons are located in the visceral efferent column of the spinal
cord, or the homologous motor nuclei of the cranial nerves (Ganong, 1979).
Their axons synapse on the cell bodies of post-ganglionic neurons
which then supply visceral effectors. The two classical divisions




Fig. 2.1 The PARASYMPATHETIC and SYMPATHETIC divisions of the
peripheral autonomic nervous system.
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(a) Parasympathetic division: The cranial outflow of the
parasympathetic division supplies the visceral structuresin the
head via the oculomotor (III), facial (VII) and glossopharyngeal (IX)
nerves, and in the thorax and upper abdomen via the vagus (X) nerve.
The pelvic viscera are supplied via the sacral outflow (S2 - 3).
The pre-ganglionic fibres end on post-ganglionic neurons located on
or near the viscera (Fig. 2.1).
(b) Sympathetic division: The axons of the sympathetic
pre-ganglionic neurons leave the spinal cord with the ventral roots
of the first thoracic (Tl) to the second or third lumbar (L2 - 3)
spinal nerves. They enter the paravertebral sympathetic ganglion
chain where the post-ganglionic neurons are located. The axons of
the post-ganglionic neurons pass to viscera in the sympathetic nerves.
The post-ganglionic sympathetic nerves to the head originate in
the cranial extension of the sympathetic ganglion chain and travel
to the effectors via blood vessels.
B. CHEMICAL SUBDIVISIONS: The autonomic nervous system can be
subdivided on the basis of the chemical mediator or neurotransmitter
released at synaptic junctions, into (a) CHOLINERGIC neurons, in
which the transmitter is acetyl choline, and (b) ADRENERGIC neurons,
in which the transmitter is noradrenaline.
(a) Cholinergic neurons: These include all pre-ganglionic
neurons, anatomical parasympathetic post-ganglionic neurons, and
anatomical sympathetic post-ganglionic neurons which innervate
sweat glands and produce vasodilatation in blood vessels in skeletal
muscle.
(b) Adrenergic neurons: These comprise all remaining
post-ganglionic sympathetic neurons. The adrenal medulla is essentially
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a modified sympathetic ganglion capable of synthesising adrenaline,
in which the post-gang!ionic cells have lost their axons and have
become specialised for secretion directly into the bloodstream.
C. CHOLINERGIC AND ADRENERGIC RECEPTORS: The properties of the
cholinergic receptors differ depending on their location. Muscarine
has little effect on autonomic ganglia but mimics the stimulatory
■ action of acetyl choline on smooth muscle and glands. These actions
are termed muscarinic, and can be blocked by atropine. In sympathetic
ganglia, small amounts of acetyl choline stimulate post-ganglionic
neurons, while large amounts block transmission from pre- to post¬
ganglionic neurons. These effects are unaffected by atropine, but
are mimicked by nicotine, and are called nicotinic actions.
The receptors on which noradrenaline and adrenaline act are
separated into two categories on the basis of different sensitivities
to certain drugs. Adrenergic receptors are designated alpha and
beta (Ahlquist, 1948) according to their relative sensiti vity to
agonists and antagonists, and can be subdivided into al pha -j, alpha.,,
beta-j and beta£ depending on their location (Steer, 1977). The
clinically important alpha-effects are vasoconstriction, intestinal
relaxation and dilatation of the pupil. Blocking agents include
phentolamine, thymoxamine and phenoxybenzamine. The important
beta-effects are vasodilatation, especially in muscles, an increase
in the rate and force of contraction of the heart, and bronchial
relaxation. Blocking agents include propranolol (non-selective)
and metoprolol (beta-j-selecti ve).
The effects of beta receptor stimulation are produced by
activation of adenylate cyclase with a consequent increase in
intracellular cyclic AMP. Studies attempting identification of the
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intracellular mediator for alpha-adrenergic processes have been
inconclusive.
D. HYPOTHALAMIC CONTROL CENTRES IN HYPOGLYCAEMIA: The stimulus
within the central nervous system which initiates the autonomic
response to hypoglycaemia is probably intracellular glucopenia,
but the precise areas which control the sympathetic and parasympathetic
responses to hypoglycaemia are unknown. Ablative studies in animals
have demonstrated that sub-hypothalamic areas in the medulla oblongata,
cervical and thoracic spinal cord may initiate an adrenal medullary
response to hypoglycaemia in the presence of surgical decentralisation
(Crone, 1965; Goldfien, 1966), but at present there is no evidence
for the existence of similar centres in man. Electrical stimulation
experiments in the rat have suggested the existence of a centre in
the ventromedial nucleus of the hypothalamus which activates the
adrenergic response to hypoglycaemia (Frohman and Bernardis, 1971).
Stimulation of the dorsomedial nuclei and posterior hypothalamic
areas produces increased secretion of catecholamines from the adrenal
medulla (Goldfien and Ganong, 1962), and the descending pathways
from the hypothalamus to the lateral cell columns of the spinal
cord (T1 - L2) have been identified for the sympathetic division
(Johnson and Spalding, 1974). However, although a relationship
has been identified between the hypothalamus and sympathetic
(adrenergic) function there is very little evidence for a
"parasympathetic" centre within the hypothalamus (Ganong, 1979),
and little is known about the central connections of the parasympathetic
system in man.
There is limited evidence for the existence of central adrenergic
and cholinergic receptors, located within the hypothalamus, which are
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implicated in the activation of autonomic neural function in
response to hypoglycaemia. Alpha and beta-adrenergic receptors
have been described within the central nervous system (Frohman
and Stachura, 1975), and control of the secretion of some anterior
pituitary hormones which are released in response to hypoglycaemia
(for example ACTH), appears to be mediated, at least in part, by
noradrenergic mechanisms within the hypothalamus. The secretion of
corticotrophin-releasing hormone (CRH) in rats, dogs and possibly
man, is decreased by the action of noradrenaline on alpha-adrenergic
receptors within the hypothalamus, thus controlling the secretion
of ACTH (Weiner and Ganong, 1978). In addition to central
noradrenergic inhibition of CRH, in the murine hypothalamus there
is evidence to implicate a cholinergic mechanism in the regulation
of CRH secretion (Jones et al., 1976). A similar noradrenergic
system, mediated via alpha-adrenergic receptors, can increase the
secretion of growth hormone in rats, dogs and in man (Weiner and
Ganong, 1978).
2. METHODS OF INDUCING GLUCOPENIA
Although alcohol has been used to induce hypoglycaemia in
normal human subjects after a prolonged fast (Turner et al., 1973a),
this is not a practical method for numerous or rapid studies of
metabolic recovery from hypoglycaemia, nor can it induce a consistent
or profound degree of hypoglycaemia. Two methods of inducing acute
glucopenia are commonly employed to investigate metabolic changes
in response to hypoglycaemia.
(a) Insulin: hypoglycaemia in man is usually induced by the
administration of short-acting insulin by intravenous injection in a
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dose of 0.1 to 0.15 units/kg body weight. This usually lowers
blood glucose to hypoglycaemic levels within 20 to 40 minutes and
is widely used as a test of the hypothalamic-pituitary-adrenal
axis (Greenwood et a!., 1966).
(b) 2-deoxy-D-glucose (2-DG): intracellular glucopenia
can be induced by the administration of this glucose analogue which
is not metabolised, but acts as a competitive inhibitor of glucose.
In normal subjects the intravenous infusion of 2-DG produces
hyperglycaemia, fatty acid mobilisation, enhanced excretion of
catecholamines and the release of growth hormone (Grasso et al., 1968).
There is also a marked rise of the plasma concentrations of lactate
and Cortisol (Brodows et al., 1973). This glucose analogue is an
effective inhibitor of insulin secretion (Goldsmith et al., 1970)
and therefore allows assessment of several metabolic parameters
without the effect of a concomitant change in insulin secretion
and plasma insulin concentrations. It is important to appreciate
however that 2-DG infusion produces a greater hypoglycaemic stress
than exogenous insulin (Young and Landsberg, 1977), and the possibility
that 2-DG and insulin are fundamentally different stimuli cannot
be excluded.
3. ADRENERGIC MECHANISMS IN THE RESPONSE TO HYPOGLYCAEMIA
(a) Methods of investigation: Investigations of the role
of adrenergic mechanisms and the sympatho-adrenal system in the
metabolic and hormonal responses to hypoglycaemia have utilised
different types of experimental approach:
(i) the measurement of urinary or plasma concentrations of
catecholamines in response to hypoglycaemia,
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(ii) the effect of pharmacological adrenergic denervation
on the metabolic recovery from hypoglycaemia using
ganglion-blocking drugs or drugs which specifically
blockade alpha or beta-adrenergic receptors,
(iii) the effect of hypoglycaemia on adrenalectomised animals
or human subjects, and
(iv) the effect of hypoglycaemia on sympathectomised animals
or man.
Pharmacological interruption of sympathetic activity at the
level of peripheral ganglia using drugs such as hexamethoniurn should
prevent both adrenal medullary and post-ganglionic sympathetic
responses to hypoglycaemia, but the dose used may not achieve
complete blockade (Billington et al., 1954; DiSalvo et a!., 1956),
and the degree of pharmacological blockade cannot be quantified
precisely. Furthermore, certain ganglionic and adrenergic-blocking
agents actually have intrinsic sympathomimetic activity (Dollery
et al., 1969).
Hypoglycaemia is the only state which is recognised to produce
preferential secretion of adrenaline, which becomes the predominant
circulating catecholamine. This implies a selective activation
of the adrenal medulla. Denervation of the adrenal glands or
adrenalectomy abolishes the acute release of adrenaline in response
to hypoglycaemia (Goldfien, 1966). In adrenalectomised subjects
the primary source of circulating noradrenaline is from the peripheral
sympathetic nerve endings. The study of adrenalectomised animals
or man therefore permits an examination of the sympathetic response
to hypoglycaemia in the absence of adrenomedullary catecholamines.
Patients who have undergone bilateral splanchnicectomy and
surgical removal of the sympathetic chain effectively have adrenal
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denervation and a peripheral sympathectomy (French and Kilpatrick,
1955). Traumatic lesions of the cervical spinal cord in man,
producing functional transection of the major motor and sensory
tracts with tetraplegia, are associated with a complete pre-ganglionic
sympathectomy when the lesion is above the first thoracic segment
(Fig. 2.1). This provides an excellent model for the evaluation
of adrenergic mechanisms in vivo. The adrenal glands and the
peripheral sympathetic nervous system are disconnected simultaneously
from the CNS, and the pre-ganglionic site of the lesion should
preclude the possibility of denervation hypersensitivity of peripheral
adrenergic receptors.
(b) Secretion of catecholamines: After the classical experiments
of Cannon et al., (1924) and Houssay et al., (1924) which implicated
the activation of adrenal medullary secretion in the response to
hypoglycaemia, nearly thirty years elapsed before an increase in the
urinary excretion of catecholamines could be measured reliably
following hypoglycaemia in man (Von Euler and Luft, 1952). The
subsequent development of satisfactory assays for plasma adrenaline
and noradrenaline enabled the demonstration of the dramatic rise
in plasma catecholamines which occurs in response to hypoglycaemia
in man (Vendsalu, 1960; Goldfien et al., 1961; Wallace and Harlan,
1965; Christensen et al., 1975; Garber et al., 1976). A close
correlation has been demonstrated between the degree of hypoglycaemia
and the rise of plasma adrenaline, which can increase by 25 to 50
times from basal levels (Christensen et al., 1975). Plasma noradrenaline
hasbeen shown to increase by two to threefold (Christensen et al.,
1975; Garber et al., 1976).
The increase in plasma noradrenaline concentration is derived
from the adrenal medulla in addition to release from the sympathetic
2.10
nerve endings (Bloom et al., 1975). The measurement of urinary or
plasma catecholamines therefore has a limited value in differentiating
the separate contributions of adrenal medullary secretion and
peripheral sympathetic neural activity in response to hypoglycaemia.
(c) Effect of pharmacological blockade: Ganglionic blockade
with drugs such as hexamethoniurn has been shown to reduce the rises
of blood lactate and plasma free fatty acids which are stimulated
by hypoglycaemia in man (Billington et al., 1954; DiSalvo et al.,
1955; Werk et al., 1961), but with the exception of one study
(Laurence and Stacey, 1952), no significant impairment of blood
glucose recovery was observed. In these studies the changes in pulse
rate and blood pressure associated with hypoglycaemia were absent,
and sweating was not observed (Laurence and Stacey, 1952).
The introduction of propranolol, a non-selective beta-adrenergic
blocking agent, allowed a re-examination of the specific contribution
of adrenergic receptors to metabolic recovery from hypoglycaemia.
In dogs blood glucose recovery from insulin-induced hypoglycaemia
was not impaired by propranolol, but the addition of simultaneous
alpha-adrenergic blockade with phenoxybenzamine produced a marked
delay in blood glucose recovery (Cowell and Hetenyi, 1959). One
study of the effect of adrenergic blockade in normal man demonstrated
a normal blood glucose recovery from acute hypoglycaemia during the
infusion of propranolol or phentolamine, but the effect of both
drugs in combination was not studied (Walter et al., 1974). However
most human studies have shown that beta-adrenergic blockade with
propranolol does impair blood glucose recovery from hypoglycaemia,
and virtually abolishes the rise of free fatty acids, glycerol
(Abramson et al., 1965; Blackard and Heidingsfelder, 1968) and
blood lactate (Abramson and Arky, 1968). The effect of beta blockade
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on blood glucose recovery from hypoglycaemia has been confirmed
in both normal (Deacon and Barnett, 1976; Davidson et a!., 1977)
and diabetic man (Deacon et al., 1977; Lager et al., 1979). There
is no clear reason for the discrepancy between the findings of
Walter et al., (1974) and the other studies of non-selective beta
blockade on blood glucose recovery from hypoglycaemia, but it may
reside in methodological differences. The administration of the
i
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beta-j (selective) blocking agents, metoprolol (Davidson et al ., 1977)
and atenolol (Deacon and Barnett, 1976) did not delay blood glucose
recovery significantly in normal subjects, and metoprolol did not
impair blood glucose recovery from hypoglycaemia in patients with
insulin-dependent diabetes (Lager et al., 1979).
Propranolol produces a marked bradycardia and a rise in both
the systolic and diastolic blood pressures during hypoglycaemia in
normal subjects (Lloyd-Mostyn and Oram, 1975) and these effects were
much less pronounced with metoprolol (Davidson et al., 1977; Lager et al.,
1979). This difference in action may result from the unopposed action
of alpha receptors during the administration of propranolol thus
encouraging vasoconstriction, whereas with metoprolol the vasodilating
beta^ receptors may still be stimulated by catecholamines.
The effect of non-selective beta blocking agents on blood
glucose recovery from hypoglycaemia may operate via inhibition of
muscle glycogenolysis and adipose tissue lipolysis, both of which
are mediated by beta receptors (Abramson and Arky, 1968). The
diminished supply of glucogenic substrates such as lactate, alanine
and glycerol would presumably decrease the rate of gluconeogenesis
in response to hypoglycaemia. Hepatic glycogenolysis was considered
to be mediated via an alpha-adrenergic effect (Abramson and Arky, 1968;
Blackard and Hubbell, 1970) and should therefore be unaffected by
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propranolol. However, recent studies utilising glucose clamp
techniques (Deibert and Defronzo, 1979) or somatostatin infusions
(Rizza et a 1., 1979a; Rizza et al., 1980), which prevent changes
in circulating substrate or hormone concentrations, have demonstrated
that infusions of adrenaline stimulate glucose production and inhibit
glucose clearance in man predominantly by beta-adrenergic receptor
mechanisms. The hyperglycaemic response to catecholamines may
i
therefore be mediated primarily by beta-adrenergic receptors, although
the putative involvement of a mixed population of alpha, beta and
unclassified receptors has also been proposed (Kuo et al., 1977;
Saitoh and Ui, 1976).
(d) Effect of adrenalectomy: Adrenalectomy has had no
demonstrable effect on blood glucose recovery from insulin-induced
hypoglycaemia in man (Ginsburg and Paton, 1956; Von Euler et al., 1961;
Ensinck et al., 1976; Brodows et al., 1976). However the administration
of 2-DG to induce intracellular glucopenia in adrenalectomised human
subjects did not produce the usual degree of hyperglycaemia observed
in normal subjects (Wegienka et al., 1966; Brodows et al., 1975).
and the elevationsof blood lactate and plasma free fatty acids were
abolished (Brodows et al., 1975). Several studies have examined
the effect of administering 2-DG to adrenalectomised rats and dogs,
but while the increase in blood glucose was diminished consistently,
the plasma free fatty acid response was variable (Young and
Landsberg, 1977). Hypoglycaemia in adrenalectomised subjects is not
associated with a change in pulse rate and blood pressure (Ginsburg
and Paton, 1956), which suggests that the haemodynamic changes
observed in normal subjects during hypoglycaemia are related to the
release of adrenal medullary catecholamines.
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(e) Effect of sympathectomy: In adreno-medul1ectomised
rats which were treated with reserpine to produce a functional
(total) sympathectomy, insulin-induced hypoglycaemia was more
pronounced than in normal rats, and blood glucose recovery was
severely impaired (Sacca et al., 1977). Early investigations of
human subjects, who had undergone thoracolumbar sympathectomy for
hypertension, showed no evidence of insulin sensitivity or impairment
of blood glucose recovery from hypoglycaemia (Simeone and Vavoudes,
1948; French and Kilpatrick, 1955). Blood glucose recovery was
also normal in tetraplegic subjects in whom cervical cord lesions
had produced a complete pre-ganglionic sympathectomy (Palmer et al.,
1976; Brodows et al., 1976), and both basal insulin secretion and
glucose-mediated insulin release were also normal in these subjects
(Brodows et al., 1974).
By contrast the administration of 2-DG to sympathectomised
human subjects to induce glucopenic stress, was characterised by
no detectable rise in glucose compared with the hyperglycaemia
observed in normal subjects (Brodows et al., 1973). There was
also no rise in plasma catecholamines, free fatty acids or lactate
compared with the pronounced changes which normally are observed.
This was consistent with the absence of a FFA rise when 2-DG was
administered to sympathectomised rats (Richardson and Hokfelt, 1964).
The severity of the glucopenic stress induced by 2-DG is probably not
comparable to insulin-induced hypoglycaemia, and this may account
in part for the apparent discrepancies between the metabolic responses
to either form of glucopenic stimulus either in animals or in
human subjects with altered sympatho-adrenal function.
A fall in both the systolic and diastolic blood pressure v/as
demonstrated during hypoglycaemia in patients with a bilateral
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sympathectomy (T7 - L3), although normal vasodilatation remained
present in the upper limbs where the innervation was intact
(French and Kilpatrick, 1955). A preceding unilateral cervical
sympathectomy has been shown to decrease the blood flow in the
hand of the affected side, and prevent the vasodilatation which
is observed in normal subjects (Allwood et al., 1957; Middleton
and French, 1974). The increased hand blood flow associated with
hypoglycaemia is thought to result from a release of vasocontrictor
tone. Acute hypoglycaemia thereby induces vasodilatation in the
hand which usually counteracts and obscures any simultaneous
vasoconstriction caused by the release of adrenaline (Middleton and
French, 1974).
These studies indicate that circulating catecholamines promote
the haemodynamic changes which occur in response to hypoglycaemia,
and adrenergic mechanisms mediate the mobilisation of free fatty
acids and lactate. However, activation of the sympatho-adrenal system
does not appear to be essential for blood glucose recovery from
hypoglycaemia in man.
4. CHOLINERGIC MECHANISMS IN THE RESPONSE TO HYPOGLYCAEMIA
Most studies of acute hypoglycaemia have investigated the
adrenergic manifestations of the hypoglycaemic reaction and the
endocrine responses related to activation of the sympatho-adrenal
system. There is evidence however for the production of widespread
autonomic neural activity in response to hypoglycaemia which involves
cholinergic mechanisms in both the sympathetic and parasympathetic
divisions.
(a) Methods of investigation: The role of cholinergic
innervation in the metabolic and hormonal responses to hypoglycaemia
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has been investigated by:
(i) pharmacological blockade using atropine or related
drugs, and
(ii) ablation studies producing parasympathetic denervation
(mainly vagotomy)
It is extremely difficult to achieve complete cholinergic
blockade with atropine in human subjects without administering
doses which will produce toxic side-effects, but the relative effect
of partial cholinergic denervation can be demonstrated.
(b) Cholinergic manifestations of the hypoglycaemic reaction:
Haemodynamic changes: The existence of a "parasympathetic response"
to hypoglycaemia was suggested by the description of the occasional
occurrence of bradycardia and mild hypotension, which is sometimes
accompanied by nausea and vomiting in some patients with insulin-dependent
diabetes (Sussman et al., 1963). This was observed to precede the
typical "sympathetic response" which characterises the hypoglycaemic
reaction. This evidence was inconstant and circumstantial, but
bradycardia which could be abolished by atropine has been described
following hypoglycaemia in normal subjects under beta-adrenergic
blockade with propranolol (Lloyd-Mostyn and Oram, 1975). A late
bradycardia has been observed in sympathectomised subjects which
occurred when the blood pressure was lower than basal values (French
and Kilpatrick, 1955), and thus would preclude the induction of
bradycardia by a baroreceptor mechanism. These haemodynamic
observations suggest a primary vagal activation in response to
hypoglycaemia.
Salivation: Profuse salivation was noted to be a feature of the
hypoglycaemic reaction in sympathectomised cats (Dworkin, 1931b), and
toxic quantities of insulin produced marked salivation in dogs
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(Ponirowsky and Ischunina, 1929). The flow rate of parotid saliva
is controlled by cholinergic parasympathetic activity in the
glossopharyngeal nerves (Garrett, 1975), and increased salivation
has been demonstrated to coincide with the nypoglycaemic reaction
in man (Corrall et al., 1976).
Sweating: Sweating is a constant feature of the hypoglycaemic
reaction in normal subjects. It is mediated via cholinergic sympathetic
activity and not by circulating catecholamines. Sweating persists
after adrenal denervation (French and Kilpatrick, 1955) and after
adrenalectomy (Ginsburg and Paton, 1956). It is abolished by atropine
(given systemically or locally by iontophoresis), and after ulnar
nerve blockade sweating was absent in the anaesthetised area (French
and Kilpatrick, 1955).
Vasodilatation: Hypoglycaemia provokes increased cholinergic
vasodilator activity in skeletal muscle (Allwood and Ginsburg, 1959),
and an increase in blood flow was demonstrated in the forearm and
calf of normal human subjects both in neurologically intact and in
sympathectomised limbs in response to hypoglycaemia (Allwood et al.,
1957). The unilateral infusion of intra-arterial atropine during
insulin-induced hypoglycaemia significantly reduced the forearm
vasodilator response, indicating the role of cholinergic sympathetic
fibres which produce vasodilatation in skeletal muscle.
(c) Gastro-intestinal and pancreatic hormone secretion: Insulin-
induced hypoglycaemia has been a standard stimulatory test of vagally-
mediated gastric acid secretion for many years, thus providing a
suitable measure of the efficacy of surgical vagotomy. In normal
subjects, pancreatic polypeptide is secreted in response to hypoglycaemia
and this is abolished by vagotomy (Schwartz et al., 1976; Adrian
et al., 1977; Floyd et al., 1977) and diminished by atropine (Schwartz
et al., 1978). Pancreatic polypeptide is also released after
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stimulation of the vagus nerves in anaesthetised pigs, and this
response can be inhibited both by hexamethoniurn and by atropine,
but it is unaffected by alpha or beta-adrenergic blockade (Schwartz
et a!., 1978). It is apparent therefore that the secretion of
pancreatic polypeptide, particularly in response to hypoglycaemia,
is mediated by vagal cholinergic stimulation. In dogs a direct
stimulatory influence of vagal activation on gastrin secretion has
been demonstrated, but in man the vagal contribution to gastrin
secretion is defined less clearly (Young and Landsberg, 1977).
The effect of hypoglycaemia on glucagon secretion has been
studied in animals and man. In calves, section of the splanchnic
nerves or the administration of atropine alone had no effect on
the blood glucose recovery from hypoglycaemia, and caused only a
delay in the peak response of pancreatic glucagon (Bloom et al.,
1974a). Section of the splanchnic nerves combined with atropine
blockade markedly reduced insulin tolerance in these animals,
producing severe and prolonged hypoglycaemia. The rise of plasma
pancreatic glucagon virtually was abolished. Section of both vagus
nerves in calves also reduced insulin tolerance and the pancreatic
glucagon response to hypoglycaemia (Edwards and Bloom, 1978).
Stimulation of the thoracic vagus nerves produced a significant
release of glucagon in adrenalectomised calves with co-existing
splanchnic nerve section (Bloom et al., 1974a). When 2-DG was used
as the hypoglycaemic stimulus in normal calves, an abrupt rise of
blood glucose, glucagon, insulin and pancreatic polypeptide was
observed (Edwards and Bloom, 1978). Section of the splanchnic nerves
plus atropine administration again abolished the rise in pancreatic
glucagon (and pancreatic polypeptide) in response to 2-DG, and the
normal rise in blood glucose was greatly diminished.
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In normal human subjects the administration of atropine produced
a small decrease in plasma pancreatic glucagon after an overnight
fast, and the normal rise of plasma glucagon after stimulation by
arginine was reduced (Bloom et al., 1974b). The effect of insulin-induced
hypoglycaemia in patients who had undergone a truncal (total) vagotomy
for duodenal ulcer, was compared with that in patients who had
received a selective vagotomy. The normal rise of plasma pancreatic
glucagon was preserved following selective vagotomy, but appeared to
be decreased moderately after truncal vagotomy (Bloom et al., 1974b).
There is some circumstantial evidence for a possible vagal
mediation of glucagon secretion following hypoglycaemia in patients
with insulin-dependent diabetes. Although pancreatic glucagon has
been shown to be released in response to arginine in diabetic patients
with autonomic neuropathy, glucagon secretion in response to
hypoglycaemia is absent (Maher et al., 1977). The sympathetic nervous
system does not appear to be necessary for the integrity of the
glucagon response to hypoglycaemia in man (Palmer et al ., 1976;
Ensinck et al., 1976; Walter et al., 1974) and it is therefore implied
that the loss of parasympathetic innervation is responsible for the
failure of the glucagon response to hypoglycaemia in patients with
diabetic autonomic neuropathy. These studies suggest that glucagon
release from the pancreas in response to hypoglycaemia is influenced
by cholinergic mechanisms via vagal innervation.
Both classical divisions of the autonomic nervous system are
involved in the neural mechanisms which initiate or modulate the
metabolic recovery to acute hypoglycaemia in man. The relative
importance of adrenergic and cholinergic mechanisms to the substrate
and hormonal changes which have been described, requires elucidation,
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and it is possible that some responses can function independently
of neural regulation. The identification in recent years of an
extensive and complex peptidergic nervous system which appears
to have a significant though incompletely defined role in the
regulation of gastro-intestinal, and possibly pancreatic, endocrine
function (Polak and Bloom, 1978), introduces a further potential
system by which the metabolic response to hypoglycaemia may be
regulated. The significance of the peptidergic nervous system to
recovery from hypoglycaemia is at present undetermined, and could
prove ultimately to be of major importance in the modulation of the
hormonal changes which are provoked by acute hypoglycaemia.
PART II EXPERIMENTAL DATA
CHAPTER 3
RATIONALE AND AIMS
OF EXPERIMENTAL INVESTIGATIONS OF HYPOGLYCAEMIA IN MAN
3.1
The experimental studies described in succeeding chapters
are concerned with the investigation of two areas related to the
metabolic recovery from acute hypoglycaemia in man. These can be
categorised as:
1. the effect of acute hypoglycaemia on pancreatic beta cell
function in response to a subsequent meal,
and
2. neural control of pancreatic islet cell function and the
metabolic and hormonal responses to hypoglycaemia.
This chapter provides a brief introduction to each area of investigation,
and outlines the aims of the experimental investigations.
1. THE EFFECT OF ACUTE HYPOGLYCAEMIA ON PANCREATIC BETA CELL
FUNCTION IN RESPONSE TO A SUBSEQUENT MEAL
A basic principle of endocrine homeostasis is that hormones are
subject to feedback inhibition by a variety of mechanisms, and for
many years it was assumed tacitly that insulin secretion is inhibited
by hypoglycaemia (Goodner and Porte, 1972). The possible existence of
a feedback inhibition of insulin secretion by insulin itself, has
been however the subject of several studies and considerable controversy.
Assessment of the secretion of endogenous insulin in man during
hypoglycaemia has been restricted by an inability to interpret plasma
concentrations of immunoreactive insulin, because of the cross-reaction
of exogenous mammalian insulin with endogenous human insulin in the
insulin radioimmunoassay. Attempts to circumvent this problem have
included the induction of hypoglycaemia with alcohol (Turner et al.,
1973a), and the use of exogenous insulins which differ from mammalian
insulins in their immunological specificity but which possess
comparable biological activity. Fish insulin has been used to induce
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hypoglycaemia in dogs (Sando et al., 1970) and in man (Turner et al.,
1973b), and in both species a fall in endogenous plasma insulin
concentrations was demonstrated during hypoglycaemia.
The development of a radioimmunoassay for connecting (C-)
peptide (Melani et al., 1970), which is secreted by the pancreatic
beta cell in an equimolar concentration with insulin (Horwitz et al.,
1975a), provided an accurate index of endogenous insulin secretion
in the presence of exogenous insulin (Rubenstein et al., 1969). When
porcine insulin was infused intravenously into normal human subjects
to induce hypoglycaemia, plasma C-peptide decreased below basal levels,
and remained low for 80 minutes after the infusion of insulin had
been discontinued (Horwitz et al., 1975b). The delayed recovery of
plasma C-peptide following hypoglycaemia indicated that the pancreatic
beta cells were releasing neither C-peptide nor insulin at their
basal rate of secretion, and this prolonged suppression of endogenous
insulin secretion continued despite the restoration of blood glucose
to its preceding basal value. Similar findings in response to
hypoglycaemia have been reported both in normal and in thyrotoxic
subjects (Shima et al., 1976), and the demonstration of a failure of
insulin-induced hypoglycaemia to suppress plasma C-peptide is a
useful diagnostic test for insulinoma (Service et al., 1977).
The effect of hypoglycaemia on the capacity of the pancreatic
beta cell to secrete insulin in response to the subsequent ingestion
of food has received little attention. Somogyi (1951) described
impaired tolerance to oral glucose ingested 50 minutes after insulin
administration, but this was attributed to the presence of hormones
that are released in response to hypoglycaemia and which antagonise
the actions of insulin. Ohgawara et al., (1973) infused fish insulin
into normal subjects for three to eight hours, and observed a
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diminished insulin secretory response to subsequent loading with
intravenous glucose. A similar infusion of fish insulin for one
hour did not produce this effect on insulin secretory capacity.
The response of the pancreatic beta cell to the ingestion of
food following hypoglycaemia has not been reported previously. The
experimental studies which are described in chapters 4 and 5 attempt
to answer the following questions:
(a) What is the effect of hypoglycaemia on pancreatic beta
cell function in response to a subsequent meal?
(b) If the pattern of insulin secretion following hypoglycaemia
is abnormal in response to a meal, what is the possible mechanism?
2. NEURAL CONTROL OF PANCREATIC ISLET CELL FUNCTION AND THE
METABOLIC AND HORMONAL RESPONSES TO HYPOGLYCAEMIA
Acute hypoglycaemia is associated with stimulation of the
pancreatic alpha cells to secrete glucagon (Gerich et al., 1974)
and a concurrent prolonged suppression of the secretion of insulin
by the pancreatic beta cells (Horwitz et al., 1975b; Service et al.,
1977). By studying the neural regulation of pancreatic islet cell
function during hypoglycaemia, it is possible to identify the
contribution of adrenergic and cholinergic mechanisms which influence
or regulate the secretion of insulin and pancreatic glucagon.
The pancreatic islets receive an extensive supply of efferent
sympathetic and parasympathetic nerve fibres (Bencosme, 1959; Woods
and Porte, 1974). Studies in animals have shown that stimulation of
the parasympathetic innervation leads to the secretion of insulin,
but under resting conditions, parasympathetic influences have little
effect on insulin release, which is inhibited tonically by sympathetic
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alpha-adrenergic activity (Woods and Porte, 1974). The role of
the autonomic innervation of the pancreatic islets in the control
of glucagon secretion is not defined clearly, but both the sympathetic
and parasympathetic divisions appear to contribute to the maintenance
of glucagon secretion in the basal state (Edwards and Bloom, 1978).
Despite attempts to elucidate the putative neural mechanisms
which control pancreatic islet cell function, no human studies have
examined previously the effect of combined sympathetic and
parasympathetic blockade on the recovery from insulin-induced
hypoglycaemia. Tetraplegic subjects, who have a complete pre-ganglionic
sympathectomy, provide a suitable human model to study the effects
of adrenergic denervation on the metabolic recovery from hypoglycaemia
and on pancreatic islet cell secretion. The administration of
atropine to these tetraplegic subjects, producing concurrent cholinergic
blockade, allows an assessment of cholinergic mechanisms in this
situation. The relative contribution of the principal counterregulatory
hormones to metabolic recovery from hypoglycaemia can also be examined.
Studies of acute hypoglycaemia in tetraplegic subjects with and
without the administration of atropine are described in Chapters 6, 7
and 8.
The experimental protocols were approved by the Medical Ethics
Committee of the Western General Hospital, Edinburgh, where the
studies were performed. Informed consent for each study was obtained
from all subjects. The tetraplegic patients were recruited for
these investigations from the Spinal Injuries Unit, Edenhall Hospital,
Musselburgh, East Lothian.
CHAPTER 4
THE EFFECT OF ACUTE HYPOGLYCAEMIA
ON THE PANCREATIC BETA CELL RESPONSE TO A MEAL IN MAN
Chapter 4
The effect of acute hypoglycaemia on the pancreatic beta cell
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The development of a specific radioimmunoassay for human
C-peptide has enabled the study of endogenous insulin secretion
in vivo during hypoglycaemia induced by the administration of
exogenous insulin (Horwitz et a!., 1975a). The demonstration in
man of impaired tolerance to oral glucose after insulin administration
(Somogyi, 1951) was complemented by the observation that the insulin
secretory response to a glucose load was decreased after the
prolonged infusion of fish insulin (Ohgawara et a!., 1973). These
observations have been extended by examining the response of the
pancreatic beta cell to a meal after preceding hypoglycaemia in man.
SUBJECTS AND METHODS
Eleven healthy subjects (9 male, 2 female), age range 20 - 29 years
(mean 23.8 years),were studied supine. All subjects were within
ten per cent of their ideal body weight (mean 96 per cent, range
91 - 102 per cent). Nine of the subjects (nos. 3 - 11) were studied
on two separate occasions with an interval of at least one week. The
first two subjects (nos. 1 and 2) participated only in the hypoglycaemia
study.
(I) Hypoglycaemia study: After an overnight fast crystalline beef
insulin, 0.15 units/kg body weight, was administered as a bolus by
rapid intravenous injection, and serial blood samples were taken via
an indwelling teflon cannula for estimation of blood glucose (Hill and
Kessler, 1961), plasma immunoreactive insulin,assayed against a human
insulin standard, RD10 (Ashby and Speake, 1975),and plasma C-peptide
immunoreactivity using an anti-synthetic human C-peptide guinea pig
serum, Ml230 (Heding, 1975). Blood samples were withdrawn in the
basal state and at frequent intervals for 210 minutes after the injection
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of insulin. Nine of the subjects (nos. 3 - 11) were then given
a standard mixed meal containing 30 G. protein, 85 G. carbohydrate
and 40 G. fat, which was consumed within 15 minutes. Blood
sampling was continued for a further 120 minutes.
(II) Control (fasting) study: Nine subjects (nos. 3-11) were
restudied after an interval of at least one week. The standard meal
was given following an overnight fast plus an equivalent period of
fasting without the administration of insulin. Similar measurements
of blood glucose, plasma insulin and C-peptide were made from serial
blood samples, commencing immediately prior to ingestion of the
standard meal.
Pulse and blood pressure weremeasured at two minute intervals
in all subjects until 60 minutes after the administration of insulin,
and thereafter at 5 minute intervals.
The timing of the onset of the hypoglycaemic reaction in each
subject coincided with an increase in pulse rate and the appearance
of neuroglycopenic symptoms. In man a wide individual variation
exists in the time of onset of the hypoglycaemic reaction after insulin
administration, and in this study, it varied from 20 to 30 minutes
after insulin. To account for the individual biological variation
in the timing of blood samples during the recovery from hypoglycaemia,
the clock timer was reset at the time of the onset of the hypoglycaemic
reaction in each study, to ensure that subsequent blood sampling
was timed from this point. In all figures which depict the changes
of the metabolic parameters measured in these studies, the mean values
at the time of the hypoglycaemic reaction are represented at 30 minutes
after insulin.
Measurement of sweat production: The rate of sweat production was
measured using a micro-hygrometer in four subjects. This was determined
4.1 Diagram of apparatus used for the measurement of
sweat production.
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by evaporating the sweat in a stream of dry nitrogen and measuring
the moisture content of the resulting mixture (unpublished method).
The apparatus is represented in diagrammatic form in Fig. 4.1, and
consists of three main parts:
(1) A flow meter, with which a measured flow of 800 ml/min
is maintained by means of a regulatory valve on a
cylinder of dry nitrogen.
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(2) A test capsule (area 9.6 cm ) placed on the skin through
which dry nitrogen passes.
(3) A thermal conductivity meter that measures the difference
in conductivity between the dry gas going to the cell
and the moist gas leaving it. This is based on the
Gow-Mac Unit 9454 with W-2 elements (Gow-Mac Instruments,
Shannon, Eire).
The capsule was strapped over the right hypochondriurn at the start
of the experiment. Recordings were made on a servoscribe RE511.20
machine (MacFarlane Robson Ltd., Blaydon-on-Tyne, Co. Durham,
NE21 4LT). The area under the curve on the chart gives a measure of
total sweat production. The meter was calibrated in mg of water
-2 -1
released cm min by injecting water on to a filter paper on a plate
maintained at 45° in a modified chamber. The method has a precision
of 4.9 per cent (S.E. of repeated observations, n = 4).
Statistical methods: Results are expressed as mean + one standard
error of the mean (SEM). Statistical significance was determined
using Student's t test for paired data.
RESULTS
Clinical manifestations of hypoglycaemia: All subjects experienced
the typical symptoms of hypoglycaemia between 20 and 30 minutes after
1
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Fig. 4.2 Pattern of sweating response during hypoglycaemia in
four normal subjects. The onset of the hypoglycaemic
reaction is signified by R, and the time from R is
recorded on the horizontal axis.
TABLE4.2
SWEATINGRESPONSETHYPOGLYCAEMIA
TOTALSWE TTIMEFONS TSW TING
SUBJECTmgcm-2(R=Reaction) 1.92R-Jmin 24.2R+lJmin 3.9R+min 414.0Coincidental
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Fig. 4.3 Haemodynamic changes in a normal subject. The changes
in pulse rate and blood pressure in response to
hypoglycaemia are shown, with the concurrent blood
glucose concentrations following injection of insulin.
INSULIN (0.15 u NORMAL SUBJECT(PS)/kg)
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the injection of insulin (mean 24 min). Individual times are shown
in Table 4.1. Symptoms included profuse sweating and mild neuroglycopenia
with a sensation of hunger and mild drowsiness. The changes in
sweat production in four subjects are shown in Fig. 4.2 and the total
-2
sweat produced (mg cm ) is shown in Table 4.2. The onset of sweating
was sudden in all subjects and occurred within 1.5 minutes of the
reaction. The total duration of increased sweating varied between
20 and 55 minutes.
The haemodynamic changes of hypoglycaemia were exhibited by
all subjects. A transient tachycardia coincided with the nadir of the
blood glucose and lasted for only 10 to 15 minutes. The increase in
pulse rate of individual subjects is shown in Table 4.1. An increase
in systolic blood pressure was accompanied by a fall in diastolic
pressure with a consequent widening of pulse pressure in all subjects.
A typical example of these haemodynamic changes is shown in Fig. 4.3
(subject no. 5).
Blood glucose: The mean blood glucose concentrations in both the
hypoglycaemia and control studies are shown in Table 4.3. In the
hypoglycaemia study the mean fasting blood glucose fell from
3.9 + 0.1 to 1.2 + 0.1 mmol/1 at the time of the acute hypoglycaemic
reaction, and regained the fasting level by 150 min after the
injection of insulin (Fig. 4.4). Following the meal, the mean blood
glucose rose to a peak of 8.4 + 0.3 mmol/1 at 60 min and was still
raised (7.5 + 0.3 mmol/1) at 120 min post-prandially.
In the control study the mean blood glucose of the nine subjects
studied reached a peak value of only 5.1 + 0.2 mmol/1 at 30 min after
the meal, and regained the fasting level (3.6 + 0.3 mmol/1) by
60 min post-prandially (Table 4.4). The difference in the mean blood
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TIME (mini
Fig. 4.4 Blood glucose concentration (mean + SEM) following
injection of insulin, and in response to a subsequent
meal (hypoglycaemia study), and in response to a meal
alone after an equivalent period of fasting (control
study) (n = 9).
TABLE4.3













































































































































3.8+0 1 4.4+0 1 5.1+0 2 3.6+0 3 3.5+0 2
0.35+01 0.70+04 1.76+0 08 1.65+0 18 1.16+0 4
9.1+0 6 29.0+3.6 72.4+5.2 51.0+7.2 29.5+4.
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glucose concentrations following the meal between the two studies
was highly significant at 30, 60 and 120 min (p < 0.001).
Plasma C-peptide: The mean plasma C-peptide concentrations in the
hypoglycaemia and control studies are shown in Table 4.3. In the
hypoglycaemia study the mean plasma C-peptide fell rapidly after
administration of insulin, from a fasting level of 0.39 + 0.04 nmol/1
(range 0.20 to 0.69 nmol/1) to the effective detection limit of
the assay (0.06 nmol/1), 60 min after the injection of insulin
(Fig. 4.5). It remained low throughout the period of blood glucose
recovery and at 210 min after insulin was only 0.11 + 0.03 nmol/1.
C-peptide levels rose following the meal reaching 1.72 + 0.24 nmol/1
at 60 min and 2.58 + 0.47 nmol/1 at 120 min post-prandially (Fig. 4.6).
In the control study, mean plasma C-peptide rose from 0.35 + 0.01
nmol/1 to a peak of 1.76 + 0.08 nmol/1 at 30 min, falling to 1.16 + 0.14
nmol/1 at 120 min (Table 4.4). The differences in the mean plasma
C-peptide concentrations between the two studies were significant
(p < 0.001) at 15, 30 and 120 min after the meal.
Plasma insulin: The mean plasma insulin concentrations in the
hypoglycaemia and control studies are shown in Table 4.3. In the
hypoglycaemia study the expected rise in plasma after the injection of
exogenous insulin was observed (Fig. 4.7), and was followed by an
exponential fall. At the time of the meal the plasma insulin had
returned to the fasting level. After ingestion of food, mean plasma
insulin rose from 8.3 + 1.3 mil/1 to 81.6 + 12.7 mU/1 at 60 min and
123.5 + 14 mll/1 at 120 min.
In the control study, the mean plasma insulin rose from
9.1 + 0.6 mU/1 to 72.4 + 0.5 mU/1 at 30 min, falling to 51.0 + 7.2 mU/I




g. 4.5 Plasma C-peptide concentration (mean + SEM) in response
to hypoglycaemia (n = 11). The normal basal range in
these normal subjects is shown (shaded bar) and the




Fig. 4.6 Log plasma C-peptide concentration (mean + SEM) in
the hypoglycaemia and control studies (n = 9).
CPR = C-peptide immunoreactivity. The effective
detection limit of the assay is shown by a dotted
line.
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Fig. 4.7 Plasma insulin concentration (mean + SEM) in the
hypoglycaemia and control studies (n = 9).
IRI = immunoreactive insulin.
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in plasma insulin between the two studies were statistically significant
(p <0.001) at all four times of measurement after the meal.
DISCUSSION
The rapid fall of blood glucose following administration of
insulin and the typical recovery pattern from hypoglycaemia were
observed in all subjects, with normoglycaemia being restored by 150
minutes. The plasma insulin concentrations after the administration
of exogenous insulin closely resemble those reported by Garber et al.,
(1976), and had fallen to within the fasting range prior to ingestion
of the meal. The decline in the mean plasma insulin concentration
during recovery from hypoglycaemia was not however comparable with the
marked fall in plasma C-peptide concentration to undetectable levels,
and is inconsistent with the short half-life of insulin in plasma.
Appropriately low levels of plasma insulin were observed in three
subjects with concentrations falling to less than 6.0 mU/1 by 150
minutes after the administration of insulin, but it is difficult to
explain the overall discrepancy between mean plasma insulin and
C-peptide concentrations prior to the meal.
The prolonged suppression of plasma C-peptide concentration
(and thus of endogenous insulin secretion) following insulin-induced
hypoglycaemia is consistent with similar observations using insulin
infusions (Horwitz et al., 1975b; Service et al., 1977). This prolonged
suppression of insulin secretion may be a homeostatic mechanism to
allow maintenance of a normal blood glucose concentration while glycogen
stores are being replenished by increased hepatic gluconeogenesis.
This possibility is supported by isotope infusion studies in man which
have shown that hepatic glucose production from alanine is greatly
increased two hours after the injection of insulin (Garber et al., 1976).
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Impaired tolerance to oral glucose, ingested 40 to 50 minutes
after the administration of insulin, was described both in normal
and in insulin-dependent diabetic subjects (Somogyi, 1951), and
was attributed to the secretion of hormones which antagonise the
actions of insulin. The time of administration of the oral glucose
after insulin would have coincided with the peak responses of the
major counterregulatory hormones in response to hypoglycaemia, in
particular with those of the catecholamines and glucagon (Chapter 1).
These hormones would counteract the effect of insulin at this time
after hypoglycaemia, and certainly could promote glucose intolerance
at this stage of the metabolic recovery from hypoglycaemia. However,
impairment of tolerance to oral glucose (100 G), administered 2\ hours
after intravenous insulin, has also been demonstrated (Yalow et al.,
1969) and was thought to correlate with the magnitude of the growth
hormone response during the preceding hypoglycaemia. This impaired
tolerance to oral glucose was associated with hyperinsulinism but
there was no delay in the initial insulin secretory response to oral
glucose when compared with control oral glucose tolerance tests in
the same subjects without preceding hypoglycaemia. The impaired oral
glucose tolerance following hypoglycaemia described by Yalow et al.,
(1969) is similar to the carbohydrate intolerance after ingestion of
a mixed meal following hypoglycaemia in the present studies. (The
growth hormone response to hypoglycaemia in the normal subjects in
the present study is presented in Chapter 8 (Fig. 8.6). A peak
concentration was achieved at 90 minutes after insulin administration,
and the mean plasma growth hormone level had almost returned to basal
levels by the time of ingestion of the meal).
In the present study the prolonged suppression of pancreatic
beta cell secretion after injection of exogenous insulin was demonstrated
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at 210 minutes by the persistence of a low concentration of plasma
C-peptide, which had not regained the basal value despite restoration
of normoglycaemia. It was pertinent therefore to examine the
pancreatic beta cell response to the ingestion of food at this time
interval after the administration of insulin to induce hypoglycaemia.
Insulin secretion in response to a meal following hypoglycaemia was
abnormal and was associated with impaired carbohydrate intolerance.
In the present study an initial delay in the secretion of insulin after
the meal was observed following hypoglycaemia, and must be responsible
in part for the elevated post-prandial blood glucose levels. The
hypersecretion of insulin observed 120 minutes after the meal may
be a direct response to sustained hyperglycaemia.
The pattern of insulin secretion in these normal subjects
exposed to preceding hypoglycaemia bears a marked similarity to the
secretory response of insulin to oral glucose in patients with
mild insulin-independent diabetes (Yalow and Berson, 1960; Seltzer et al.,
1967; Bagdade et al., 1967). In mild diabetes, the initial secretion
of insulin is delayed following both oral and intravenous glucose,
but subsequent hyperinsulinaemia occurs in concert with prolonged
hyperglycaemia. This excessive secretion of insulin is not observed
in patients with diabetes of greater severity, despite higher blood,
glucose levels (Seltzer et al., 1967). One can speculate therefore
that hypoglycaemia may temporarily affect pancreatic beta cell
secretion in normal subjects via a mechanism similar to that present
in patients with mild diabetes, although in the diabetic state it
is likely that many other pathogenetic factors are involved.
Sustained stimulation by glucose produces a biphasic pattern
of insulin secretion from the pancreatic beta cell in vivo (Cerasi
and Luft, 1967; Porte and Pupo, 1969) and in vitro (Grodsky et al., 1967;
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Curry et al., 1968). Phase 1 consists of a rapid surge of insulin
secretion which reaches a peak value within a few minutes and then
declines. In man (Cerasi and Luft, 1967) and in the rat (Curry
et al., 1968) this is followed by a slower progressive rise in
the rate of insulin secretion which is designated phase 2. The
abnormal pattern of insulin secretion in mild diabetes is thought
to result from an abnormality of phase 1 of the insulin secretory
response (Cerasi and Luft, 1969; Grodsky, 1975), and it is possible
that in the normal subjects exposed to preceding hypoglycaemia in
this study, the abnormal insulin secretion in response to food
principally implicates phase 1 of insulin secretion. This hypothesis
is supported by peri fusion studies of rat pancreatic islets, which
demonstrate that the insulin secretory response to glucose is reduced
markedly following prolonged exposure to a low basal concentration
of glucose (Ashby and Shirling, 1980), which presumably induces a
degree of intracel lular glucopenia within the pancreatic islets. In
this in vitro model, both phases of insulin secretion were affected,
but the phase 1 response was impaired to a greater extent.
The present study may be of relevance to the interpretation
of the impairment of diabetic control in patients with insulin-dependent
diabetes, where rebound hyperglycaemia follows hypoglycaemia (Somogyi,
1959a; 1959b). Although some pancreatic beta cell reserve does
exist in the early years of insulin-dependent diabetes (Binder and
Faber, 1978), the majority of these diabetic subjects have insignificant
endogenous insulin secretion. It seems unlikely therefore that
the "Somogyi phenomenon" can be explained by suppression of beta cell
secretion following insulin-induced hypoglycaemia, which has been
demonstrated in subjects with normal endocrine pancreatic function.
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The possible mechanisms underlying the abnormal secretion of
insulin in normal subjects in response to a meal after hypoglycaemia
will be examined in Chapter 5.
/
CHAPTER 5
THE MECHANISM OF THE ABNORMAL PANCREATIC BETA CELL RESPONSE
TO FOOD FOLLOWING ACUTE HYPOGLYCAEMIA IN MAN
Chapter 5
The mechanism of the abnormal pancreatic beta cell response to
food following acute hypoglycaemia in man
Introduction
Subjects and Methods:
1. Entero-insular axis: gastro-intestinal hormones
2. Effect of pancreatic beta cell glucopenia: glucose infusion
3. Effect of pancreatic beta cell cyclic AMP depletion: aminophylline
infusion








In the previous chapter (Chapter 4) the abnormal function of
the pancreatic beta cell in response to a meal following acute
hypoglycaemia, was described in normal man. Following the ingestion
of food, carbohydrate intolerance was associated with an abnormal
pattern of insulin secretion, characterised by a delay in the early
post-prandial rise of plasma insulin and an elevation two hours
later. Possible mechanisms underlying this altered pattern of
post-prandial insulin secretion following hypoglycaemia include:
(1) disordered function of the entero-insular axis following
hypoglycaemia,
(2) intrinsic pancreatic beta cell dysfunction caused by
glucopenia,
(3) pancreatic beta cell dysfunction caused by cyclic AMP
depletion,
(4) inhibition of beta cell secretion by catecholamines
released during hypoglycaemia, and
(5) inhibition of endogenous insulin secretion by insulin
itself via feedback regulation.
In the hypoglycaemia study described in Chapter 4, plasma
insulin levels had returned to within the normal basal range prior
to ingestion of the meal, therefore the possible existence of a
short-loop feedback mechanism on endogenous insulin secretion was
not examined. The relative contributions of the other possible
mechanisms were studied by the investigations described in this chapter.
SUBJECTS AND METHODS
The basic protocol has been described in Chapter 4. A hypoglycaemia
study and a control (or fasting) study was performed in each subject,
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and the following possible mechanisms were investigated, using
modifications to the protocol as described.
(1) Entero-insular axis: gastro-intestinal hormones. Serial
blood samples were taken during the hypoglycaemia and control studies
in six normal, non-obese male subjects who participated in the study
described in Chapter 4 (subjects no. 6-11, Table 4.1), age range
21 - 29 years. Radioimmunoassays were made (Dr. S.R. Bloom's
laboratory) of plasma enteroglucagon (Thompsonand Bloom, 1976),
motilin (Bloom et al., 1976), neurotensin (Blackburn and Bloom,
1979), gastrin (Russell et al., 1976), gastric inhibitory peptide
(Sarson et al., 1980) and pancreatic polypeptide (Adrian et al., 1976).
Cross-reactivity of the antisera raised to the various peptides
assayed was less than 0.5 per cent. Antiserum R59, which showed
a high degree of cross-reactivity with ileal extracts, and fully
detected gravimetrically-determined glicentin, was used to measure
total plasma glucagon. Enteroglucagon concentration was derived
by subtraction of the pancreatic glucagon concentration measured
by the pancreatic specific antiserum RCS5 (Bloom, 1974), from total
plasma glucagon.
(2) Effect of pancreatic beta cell glucopenia: glucose infusion: A
possible effect of hypoglycaemia on pancreatic beta cell function
was evaluated by the administration of intravenous glucose to four
other normal subjects (3 male, 1 female; Table 5.4) using a modification
of the basic protocol. At 150 minutes after the injection of insulin,
dextrose (0.5 g/kg body weight) was infused intravenously over three
minutes in a total volume of 250 ml (Soeldner, 1971) either following
hypoglycaemia or after an equivalent period of fasting. Serial
measurements were made of blood glucose, plasma insulin and plasma
C-peptide (as described in Chapter 4). After the i.v. glucose load,
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blood glucose was determined at 10 minute intervals for 60 minutes
prior to the ingestion of the standard meal. In the control
(fasting) study an identical infusion of dextrose was given at an
equivalent time prior to the standard meal, and similar measurements
were made.
(3) Effect of pancreatic beta cell depletion of cAMP: aminophylline
infusion: A possible effect of depletion of cyclic AMP within the
pancreatic beta cell in the production of the abnormal pattern of
insulin secretion following hypoglycaemia, was investigated in
two of the normal subjects. These two male subjects (aged 21 and
23 years) were given aminophylline after hypoglycaemia in an attempt
to inhibit phosphodiesterase activity within the pancreatic beta cells,
to replenish the intracellular concentration of cyclic AMP and enhance
a normal pattern of insulin secretion in response to food. Aminophylline,
250 mg i.v., was administered as a bolus injection 150 minutes after
insulin, which was followed by an infusion of aminophylline, 4 mg/min,
for 60 minutes prior to the meal. Serial measurements were made of
blood glucose, plasma insulin and plasma C-peptide concentrations.
(4) Effect of catecholamine inhibition: The effect of hypoglycaemia
on insulin secretion in response to a meal was examined in two male
subjects (aged 22 and 44 years) with traumatic transection of the
cervical spinal cord above the sympathetic outflow. This produces
a pre-ganglionic sympathectomy, and further studies utilising this
human model of adrenergic denervation will be discussed in detail
in Chapters 6-8. Serial measurements were made of blood glucose,
plasma insulin and plasma C-peptide concentrations. Plasma
noradrenaline was assayed (Henry et al., 1975) in the basal state and
45 minutes after the administration of insulin.
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Statistics: Results are expressed as mean + 1 S.E.M. Statistical
significance was assessed using Student's t test for paired data.
The rate of glucose disappearance, following intravenous
infusion of glucose was calculated using the method described by
Duncan (1956).
RESULTS
(1) G.I. Hormones. The mean blood glucose, plasma insulin and
C-peptide concentrations of the group of six normal subjects were
determined in both the hypoglycaemia and control studies. The
serial changes in these parameters were identical to the patterns
observed in the larger group of 11 normal subjects (Chapter 4)
and are shown in Fig. 5.1. The changes in plasma pancreatic glucagon
levels in this group of six subjects are illustrated in Fig. 5.2.
Plasma pancreatic glucagon rose from a mean basal value of
8.2 + 1.2 pmol/1 to a peak of 36.6 + 9.5 pmol/1 at 60 min after
the administration of insulin (p < 0.001), returning towards basal
values prior to the meal. Although there was a tendency for plasma
pancreatic glucagon to rise following the meal in the control study,
there was no significant difference between the control and
hypoglycaemia studies in the post-prandial response of pancreatic
glucagon.
The mean values of the individual gastro-intestinal hormones
in the same six subjects are shown during the hypoglycaemia study
(Table 5.1) and control study (Table 5.2). There was a pronounced
rise in plasma pancreatic polypeptide in response to hypoglycaemia
(Fig. 5.3) with a peak value at 60 min after insulin, and a further
smaller rise in response to food, which did not differ from the
5.5
. 5.1 Blood glucose, plasma insulin and C-peptide concentrations
(mean + SEM) in six normal subjects, in response to
hypoglycaemia followed by a standard meal (hypoglycaemia
study |—|), and in response to a standard meal without
preceding hypoglycaemia (control study §--§).
5.6
Fig. 5.2 Plasma pancreatic glucagon concentrations (mean + SEM)
in response to hypoglycaemia (insulin administered
at time 0) followed by a standard meal ( $—$) and
in response to a standard meal without preceding
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Fig. 5.3 Plasma pancreatic polypeptide concentrations (mean + SEM)
in response to hypoglycaemia (insulin administered it
time 0) followed by a standard meal at 210 min ( $—$ ),
and in response to a standard meal without preceding
hypoglycaemia (<£__£). (n = 6).
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Fig. 5.4 Plasma gastrin concentrations (mean + SEM) in response
to hypoglycaemia (insulin administerid at time 0)
followed by a standard meal at 210 min ( $—$ ), and
in response to a standard meal without preceding
hypoglycaemia (§--<£). (n = 6).
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Fig. 5.5 Plasma concentrations
hormones in six normal
( $ $ ) and control (
administered at time 0
(mean + SEM) of gastro-intestinal
subjects in the hypoglycaemia
) studies. Insulin was
, and the meal at 210 min.
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control study. A gradual but statistically insignificant rise
during hypoglycaemia was observed in plasma gastrin (Fig. 5.4)
(andmotilin)levels, but the other G.I. hormones remained unchanged
during hypoglycaemia (Fig. 5.5). There was no difference in the
pattern of G.I. hormone secretion after the meal when the hypoglycaemia
and control studies were compared.
(2) Glucose infusion. The changes in blood glucose, plasma insulin
and C-peptide in the four subjects who received i.v. glucose 60 minutes
before the meal are shown in Table 5.3 and illustrated in Fig. 5.6.
Following the i.v. infusion of glucose, the peak blood glucose level
was comparable in both the hypoglycaemia and control studies, but
the mean level then fell to a significantly lower level in the control
study both at 50 and at 60 minutes after the injection of glucose
(p <0.05). In all four subjects the rate of glucose disappearance,
Kbg' (Duncan» 1956) was slower during the hypoglycaemia study (Table 5.4).
The mean K. was lower in the hypoglycaemia study, but did not
achieve statistical significance when compared with the mean in
the control study. Following the meal, the mean blood glucose levels
were significantly higher after preceding hypoglycaemia than mean
blood glucose in the control study at all times of measurement (p < 0.001).
However, both the incremental rise from the different pre-prandial
mean blood glucose levels and the subsequent pattern of glucose
tolerance were similar in both the hypoglycaemia and control studies.
This differs markedly from the post-prandial blood glucose levels
observed after hypoglycaemia alone (Fig. 5.6: shaded area).
Mean plasma insulin and C-peptide concentrations both rose in
response to the infusion of glucose, and in individual subjects the
incrementsof plasma insulin and of C-peptide weresmaller following
hypoglycaemia. The mean increment of plasma insulin in response to
5.13
Fig. 5.6 Intravenous glucose was administered 150 min after
insulin injection to four normal subjects, prior to
a standard meal (hypoglycaemia study J—$) and after
an equivalent period of fasting (control study §--§).
Blood glucose, plasma insulin and C-peptide concentrations
(mean + SEM) are shown. The shaded area represents the
mean + SEM of normal subjects (n = 9, Table 4.3)
following insulin administration without i.v. glucose.
TABLE5.3
































































































































































































































































this glucose infusion was 23 + 7 mll/1 in the hypoglycaemia study,
compared to 37 + 12 mll/1 in the control study. This difference
did not achieve statistical significance in this small group of
subjects. In response to the meal (preceded by parenteral glucose)
the patterns of insulin secretion were similar in the hypoglycaemia
and the control studies, but significantly higher mean values of
plasma insulin and C-peptide were observed in the subjects following
hypoglycaemia at 90 and at 120 minutes after the meal (p < 0.001).
Following hypoglycaemia plus the glucose infusion the rises in
plasma insulin and C-peptide were more rapid during the first 15
minutes after the meal in comparison with the equivalent rises after
hypoglycaemia alone (Fig. 5.6).
(3) Aminophylline infusion. The effect of an infusion of
aminophylline prior to the meal on the individual blood glucose, plasma
insulin and C-peptide levels of two normal subjects is shown in Fig. 5.7.
There was no significant effect on the post-prandial pattern of
insulin secretion after hypoglycaemia, and glucose intolerance after
the meal was observed in both subjects. The shaded area represents
the mean + one standard deviation of the group of six normal subjects.
(4) Catecholamines. The pattern of blood glucose, plasma insulin
and C-peptide observed in two subjects with pre-ganglionic sympathectomy,
in response to the meal following hypoglycaemia, are shown in Fig. 5.8.
Post-prandial hyperglycaemia was again present, and was accompanied
by a delayed hypersecretion of insulin and C-peptide. The pattern in
these two subjects with adrenergic denervation was similar to that
observed in normal subjects after hypoglycaemia. The plasma
noradrenaline concentrations in the two tetraplegic subjects did not
increase significantly in response to hypoglycaemia. The basal
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Fig. 5.7 Intravenous aminophylline was administered 150 min
after insulin injection to two normal subjects, and
the infusion of aminophylline was continued for
60 min prior to the standard meal. Blood glucose,
plasma insulin (IRI) and C-peptide (CPR) concentrations
of each subject are shown. The shaded areas represents
the mean + SD of normal subjects (n = 9) during the
hypoglycaemia study without aminophylline administration.
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g. 5.8 Individual blood glucose, plasma insulin and C-peptide
concentrations in two subjects with a pre-ganglionic
sympathectomy, in response to a standard meal following
hypoglycaemia. (Time represented from 210 min after
insulin injection). The shaded area represents the
response (mean + 2SEM) in normal subjects following
hypoglycaemia in response to the standard meal (n =9).
The response to a meal after fasting (mean + SEM) in
the same normal subjects is also shown ( )•
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after insulin were less than 25 and 61 ng/1 respectively. The
basal values in thesetetraplegic subjects were much lower than
those observed in normal subjects in whom there wasalso a marked
response to hypoglycaemia (Chapter 6).
DISCUSSION
The investigation of acute hypoglycaemia in normal human
subjects has demonstrated that the intravenous administration of
short-acting insulin has a profound effect on subsequent insulin
secretion by the pancreatic beta cell. This suppression of endogenous
insulin secretion persists for a considerable period (at least three
hours in the present studies) after the induction of hypoglycaemia.
Impaired tolerance to oral glucose during the recovery from hypoglycaemia
(Somogyi, 1951; Yalow et al., 1969) has been shown to occur also
after ingestion of a mixed meal (Chapter 4). The present studies of
the possible mechanisms underlying the abnormal secretion of insulin
after hypoglycaemia, suggest that this is not caused by a reduced
secretion of gastro-intestinal hormones in response to a meal. The
impaired tolerance to parenteral glucose following hypoglycaemia
also indicates that the underlying mechanism does not involve an
abnormality of the entero-insular axis.
Following hypoglycaemia, the diminished insulin secretory response
to intravenous glucose suggests that pancreatic beta cell function may
be affected directly by the preceding hypoglycaemia. The early
subnormal secretion of insulin after the meal, the later hypersecretion
of insulin and the degree of post-prandial glucose intolerance were
all less marked after the intravenous glucose load. Thus the impaired
capacity of the pancreatic beta cell following hypoglycaemia to respond
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to a meal, appeared to be reversed partially by a preceding
intravenous infusion of glucose, which suggests that glucopenia
of the pancreatic beta cells may be a causal factor.
Intracellular cyclic AMP has been implicated in the process
of insulin secretion (Sharp, 1979) and intracel1ular depletion of
thisnucleotide might explain the abnormal secretory pattern of
insulin following hypoglycaemia. The administration of a
phosphodiesterase inhibitor, aminophylline, to decrease the
intracellular degradation of cyclic AMP, has been reported to improve
the deficient insulin secretory response to intravenous glucose
in a group of patients with "pre-diabetes" (Cerasi and Luft, 1959).
These "pre-diabetic" subjects had a diminished insulin response
to intravenous glucose compared with that of normal subjects. The
dose of aminophylline used by Cerasi and Luft (1969) is comparable
with the present study. They administered 200 mg intravenously as
a priming dose, followed by 200 mg for 60 minutes as a continuous
infusion prior to the performance of an intravenous glucose tolerance
test. In the study by Cerasi and Luft (1969), aminophylline alone
had no effect on the plasma insulin concentration, but improved the
initial response of insulin to intravenous glucose in these "pre-diabetic"
subjects. It was concluded that an increase in the intracellular
concentration of cyclic AMP, promoted by aminophylline, restored
phase 1 of insulin secretion, while phase 2 was not influenced.
However, aminophylline did not enhance insulin secretion in normal,
non-diabetic subjects (Cerasi and Luft, 1969), and in the present
study had no effect on the defective post-prandial pattern of insulin
secretion following hypoglycaemia. This suggests that the prolonged
disturbance of pancreatic beta cell function after hypoglycaemia is not
mediated by depletion of intracellular cyclic AMP in normal subjects.
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Plasma catecholamines, which inhibit insulin secretion and
rise markedly during hypoglycaemia (Garber et a!., 1976), could
also cause suppression of pancreatic beta cell function. The
pattern of insulin secretion in response to a meal after preceding
hypoglycaemia is similar to that observed during and after the
intravenous infusion of adrenaline, whereby insulin secretion is
suppressed until the infusion of adrenaline is discontinued
(Robertson and Porte, 1973; Turner et al., 1977). Insulin secretion
is delayed initially during the recovery period after the adrenaline
infusion is discontinued, but hypersecretion of insulin occurs
subsequently. The normal rise of plasma catecholamines in response
to hypoglycaemia does not occur in tetraplegic subjects, and has
been demonstrated by measurement of plasma noradrenaline (Palmer et al.,
1976) and plasma adrenaline (Mathias et al., 1979). The plasma
noradrenaline concentrations did not rise following hypoglycaemia
in the two tetraplegic subjects in the present study, and the
post-prandial pattern of insulin secretion was similar to that observed
in normal subjects following hypoglycaemia. This suggests that an
adrenergic mechanism is not responsible for the abnormal pancreatic
beta cell function after hypoglycaemia.
The possibility that insulin directly inhibits its own secretion
has been studied by other investigators by maintaining normoglycaemia
with a glucose infusion during the administration of insulin. The
partial suppression of plasma C-peptide without the production of
hypoglycaemia was interpreted as evidence for the existence of a
direct negative feedback mechanism (Liljenquist et al., 1978;
Service et al., 1978), but was not confirmed by Shima et al., (1977).
However, in the present study, the mean plasma insulin concentration
had returned to within the normal basal range prior to the ingestion
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of the meal. While a feedback mechanism by insulin itself is
unlikely to explain the abnormal post-prandial secretion of
insulin after acute hypoglycaemia, it is not possible to prove
that the initial high plasma insulin concentration does not
influence the pancreatic beta cells for several hours.
In summary, the present investigations suggest that the
abnormal function of the pancreatic beta cell following acute
hypoglycaemia in normal man is mediated in part by intracellular
glucopenia and not by an abnormality of the entero-insular axis,
intracellular cyclic AMP depletion of the beta cell, or an inhibition
of insulin secretion by circulating catecholamines.
CHAPTER 6
MANIFESTATIONS OF ACUTE HYPOGLYCAEMIA IN SUBJECTS WITH
PRE-GANGLI ONIC SYMPATHECTOMY WITH AND WITHOUT CHOLINERGIC BLOCKADE
Chapter 6
Manifestations of acute hypoglycaemia in subjects with pre-ganglionic
sympathectomy with and without cholinergic blockade
Introduction
Subjects and Methods: Protocol








Few pathological conditions in man produce a degree of autonomic
denervation that either can be considered to be complete or can be
quantified with accuracy. The effect of autonomic denervation on
metabolic processes has been studied in patients with autonomic
neuropathy of varying causes, such as diabetes mellitus or the
Shy-Drager syndrome, but in all of these conditions the autonomic
neuropathy is patchy and incomplete, and may involve either the
sympathetic or the parasympathetic division to varying degrees.
Traumatic transection of the cervical spinal cord above the sympathetic
outflow (T1 - L2) produces a total pre-ganglionic sympathectomy, and
provides a valuable method to evaluate adrenergic mechanisms in vivo
in response to hypoglycaemia in man. The administration of atropine
to these tetraplegic subjects produces a significant degree of
cholinergic blockade, and permits examination of the contribution
of adrenergic and cholinergic neural activity to the homeostatic
recovery from hypoglycaemia in man. The experimental model provided
by the tetraplegic subject is represented diagrammatically in Fig. 6.1.
The effects of insulin-induced hypoglycaemia were studied either
without atropine (adrenergic denervation) or with atropine (combined
adrenergic denervation and cholinergic blockade).
SUBJECTS AND METHODS
In the studies described in Chapters 6-8, three groups of
subjects were investigated.
Group A: NORMAL subjects. The 11 normal healthy subjects (9 male,
2 female) described previously in Chapters 4 and 5, were used
as a control group.
6.2
TETRAPLEGIA TETRAPLEGIA & ATROPINE
. 6.1 Diagrammatic representation of the experimental
model in tetraplegia. The parasympathetic and
sympathetic innervation of an organ (e.g. pancreas,
liver etc.) is shown. The dotted lines represent
the sites of denervation of each division of the
autonomic nervous system. The tetraplegic subject
(left) has a pre-gang1ionic sympathectomy producing
adrenergic denervation alone. The administration of
atropine (right) produces pharmacological blockade of
cholinergic activity in addition to adrenergic
denervation.
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Group B: TETRAPLEGIC subjects. Six non-obese male subjects, with
complete post-traumatic transection of the cervical spinal cord
above C7 of not less than six months duration (range 6 months -
19 years) were studied. The age range was 21 - 44 years;
clinical details of both tetraplegic groups (groups B and C)
are shown in Table 6.1.
Group C: TETRAPLEGIC subjects given ATROPINE. Six non-obese male
tetraplegic subjects (two from group B and four others) with
similar post-traumatic transection of the spinal cord (duration
4 months - 5 years), age range 19 - 28 years, were studied.
None of the tetraplegic subjects had a family history of diabetes
mellitus and all were otherwise well at the time of study. They were
taking no medications at the time of each investigation.
Protocol: All subjects were studied supine after an overnight fast,
and blood samples were taken via a teflon cannula situated in an
arm vein. Basal blood samples were taken for 30 minutes before the
administration of crystalline beef insulin, 0.15 units/kg body weight,
which was given as a bolus by intravenous injection. This dose of
insulin was used for each subject in all three groups. The tetraplegic
subjects in group C were given atropine, 15 pg/kg body weight, which
was administered 30 minutes before the insulin. The effectiveness
of the cholinergic blockade was assessed by serial measurements of
pulse rate, which was recorded at two minute intervals along with the
blood pressure. Cholinergic blockade was maintained by a repeat
injection of atropine if the pulse rate began to fall significantly.
Serial blood samples were taken at intervals. Specific assays
of substrate and hormone concentrations are described principally in
TABLE6.1





































































Chapters 7 and 8. Serial blood samples were taken for the measurement
of haematocrit by the Coulter counter, and two samples were taken
from each subject for the radioimmunoassay of plasma noradrenaline
(Henry et al., 1975). Because the availability of this assay was
limited, serial estimations of plasma noradrenaline concentrations
were not made, but were measured in the basal state, and at 45 minutes
after insulin, which should coincide with the peak rise of plasma
catecholamines in response to hypoglycaemia (Christensen et al., 1975;
Garber et al., 1976). Plasma noradrenaline concentration could not
be measured with accuracy below 25 ng/1 (pg/ml) with the assay
described, but for statistical purposes values less than 25 ng/1
were assumed to equal 25 ng/1. The values are expressed as mean + 1 S.E.M.
The presence of sweat production was measured in two tetraplegic
subjects without atropine (I.J. and P.F.) using the micro-hygrometer
method described in Chapter 4.
RESULTS
Clinical manifestations of hypoglycaemia
Subjective symptoms: The tetraplegic subjects experienced only mild
neuroglycopenia compared with the normal subjects who experienced
typical symptoms of hypoglycaemia within 30 minutes of insulin
administration. The group of tetraplegic subjects given atropine
(group C) experienced neuroglycopenic symptoms which were more severe
and prolonged, and in studies with two of these patients the
investigation had to be terminated by giving parenteral glucose
because of severe neuroglycopenia.
Haemodynamic changes: In the tetraplegic subjects without atropine
(group B) no sudden tachycardia occurred to coincide with the nadir
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of the blood glucose (as observed in the normal subjects), but
a gradual increase in pulse rate was noted in response to hypoglycaemia
in the tetraplegic subjects in group B. The pulse rate rose from
a mean basal rate of 62 beats/min (range 50 - 80) to a maximum of
72 beats/min (range 58 - 96), but the time after insulin at which
the maximal pulse rate was attained was not consistent within the
group. This varied from 25 to 60 minutes after insulin injection,
and did not correspond to the nadir of the blood glucose concentration.
Basal values of systolic, diastolic and mean blood pressure were
subnormal in the supine tetraplegic subjects. A small decrease in
both systolic and diastolic pressures was noted following hypoglycaemia,
but this was not a consistent response. The typical haemodynamic
changes during hypoglycaemia in a tetraplegic subject without atropine
are shown in Fig. 6.2 (subject P.F.).
The tetraplegic subjects lack a normal sympathetic cardiac
innervation, and in group C the adequacy of cholinergic blockade was
confirmed by a sustained elevation in pulse rate following the
administration of atropine (Fig. 6.3). The pulse rate rose from a
mean basal rate of 61 beats/min (range 36 - 72) to 89 beats/min
(range 64 - 100). In three subjects a second dose of atropine was
given between 100 and 135 minutes after the initial atropine injection
to maintain the increased pulse rate. No alteration in pulse rate
was observed in this group which could be attributed to the hypoglycaemia.
The blood pressure changes in the tetraplegic subjects given atropine
(group C) were variable. Immediately after the induction of cholinergic
blockade, there was an initial rise both in systolic and diastolic
pressures, followed by a decrease in the systolic and diastolic






































g, 6.2 Haemodynamic changes in a tetraplegic subject in
response to insulin-induced hypoglycaemia. The changes
in pulse rate and blood pressure are shown with the
concurrent blood glucose concentrations.
6.8
TIME (MIN)
6.3 Pulse rate in individual tetraplegic subjects given
atropine, which was injected intravenously at points
marked A. Insulin was administered at time 0 minutes.
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of changes in pulse rate and blood pressure were not consistent
within this group.
Haematocrit: The normal rise in haematocrit which is observed
in response to hypoglycaemia, was absent in the cetraplegic subjects
without atropine (group B) (Fig. 6.4). Haematocrit changes were
not measured in group C.
Sweating: Visible sweating was absent in all tetraplegic subjects
with or without atropine administration. The measurement of sweat
production in two tetraplegic subjects using the micro-hygrometer
confirmed the complete absence of sweating in response to hypoglycaemia.
Plasma noradrenaline: Plasma noradrenaline was measured in response
to hypoglycaemia in six normal subjects. In this control group,
the plasma noradrenaline concentration rose from a mean basal value
of 201 + 103 ng/1 (pg/ml) to 430 + 114 ng/1 at 45 min after insulin
administration (Fig. 6.5). In both tetraplegic groups, the mean
basal values were lower than the control group. In the tetraplegic
group without atropine (n = 6) the mean basal value was 25+6 ng/1
with a mean value of 31 +6 ng/1 at 45 min after insulin. In the
tetraplegic group given atropine (n =6), the mean basal value was
63 + 24 ng/1, with a mean value at 45 min of 48 + 21 ng/1. There
was therefore no demonstrable response to hypoglycaemia in both
tetraplegic groups. Using the Wilcoxon rank test, there was a
significant difference between the control group and both tetraplegic
groups at 45 min after insulin (p < 0.01).
DISCUSSION
Evidence for complete disruption of the efferent sympathetic
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Fig. 6.4 Changes in haematocrit in response to insulin-induced
hypoglycaemia in the group of tetraplegic subjects
without atropine (group B). The changes in six normal














Fig. 6.5 Plasma noradrenaline concentrations (mean + SEM) in
response to hypoglycaemia. Insulin was administered










sweating and tachycardia in response to hypoglycaemia, and by the
low basal noradrenaline levels which failed to rise following
hypoglycaemia. The latter confirms the findings of Palmer et al.,
(1976). The normal increase in plasma coagulation factor VIII
activity in response to hypoglycaemia, which is mediated via an
adrenergic mechanism, is also absent in these tetraplegic subjects
(Corrall et al., 1980), which supports the evidence for a total
pre-ganglionic sympathectomy. Although the administration of atropine
in the described dosage probably does not achieve complete cholinergic
blockade, it does allow an assessment of the residual cholinergic
mechanisms in these sympathectomised subjects. The adequacy of
pharmacological blockade of cardiac cholinergic receptors with
atropine was confirmed by the persistent elevation of pulse rate
in the tetraplegic subjects.
In normal subjects insulin-induced hypoglycaemia produces a
rise in systolic blood pressure, a fall in diastolic pressure and
a transient tachycardia (French and Kilpatrick, 1955; Lloyd-Mostyn
and Oram, 1975). The normal cardiovascular changes are thought
to result from stimulation of the sympatho-adrenal system, associated
with an increase in circulating catecholamines and a reduction in
neurogenic vasoconstrictor tone (Middleton and French, 1974). These
haemodynamic changes are absent following hypoglycaemia in adrenalectomised
subjects (Ginsburg and Paton, 1956) and in normal subjects during
ganglionic blockade with hexamethoniurn (Laurence and Stacey, 1952;
DiSalvo et al., 1956). However the tachycardia is thought to be
unrelated to circulating levels of plasma adrenaline (Christensen
et al., 1975), and in patients with splanchnic nerve section with
division of the sympathetic nerves below T7, a rise in heart rate
was observed in response to hypoglycaemia without a rise in the urinary
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excretion of adrenaline (French and Kilpatrick, 1955). The
sympathetic cardiac innervation would still be intact in such
subjects, and the tachycardia may therefore be the result of increased
activity in the cardiac sympathetic nerves. Furthermore, the increase
in heart rate is transient in normal subjects and returns to basal
levels while the plasma adrenaline concentration is still elevated
(Christensen et al., 1975).
Subnormal basal levels of systolic and diastolic blood pressures
have been observed previously in tetraplegic subjects (Mathias et al.,
1976). In the present study, the decrease both in the systolic and
in the diastolic pressures was relatively small in the tetraplegic
subjects without atropine, and only a small gradual increase in
heart rate was observed. This is consistent however with the rise in
heart rate and fall in pulse pressure in tetraplegic patients in
response to hypoglycaemia which has been described by Mathias et al.,
(1979). These investigators surmised that the increase in heart rate
was caused by a baroreceptor-induced reflex, mediated by a withdrawal
of vagal cardiac tone in response to the fall in blood pressure. The
latter may result from an inability to initiate an increase in
sympathetic nervous activity by reflex means in response to hypoglycaemia
despite a presumed decrease in intravascular volume caused by insulin
(Gundersen and Christensen, 1977; Mackay et al., 1978). In the
present study there was no significant increase in haematocrit in
response to insulin-induced hypoglycaemia in the tetraplegic subjects,
so it is possible that a decrease in intravascular volume, secondary
to the administration of insulin, does not occur in sympathectomised
subjects.
Insulin has been shown to have effects on the cardiovascular
system even in the absence of hypoglycaemia. In normal subjects, and
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in diabetic subjects without autonomic neuropathy, intravenous
insulin can cause an increase in heart rate, particularly in the
upright position (Miles and Hayter, 1968; Page et al., 1976).
This occurs within five to ten minutes of insulin injection. In
diabetic patients with autonomic neuropathy, the administration of
insulin can cause profound hypotension (Miles and Hayter, 1968;
Page and Watkins, 1976). A decrease in plasma volume and an associated
rise of haematocrit in response to insulin was demonstrated in
diabetic subjects without autonomic neuropathy, but was absent in
diabetic patients with neuropathy (Mackay et al., 1978). It is
proposed therefore that the fall in plasma volume promotes the increase
in heart rate in these uncomplicated diabetic patients without
autonomic neuropathy, since there is a close relationship between
the fall of plasma volume and the rise of plasma noradrenaline
following insulin (Gundersen and Christensen, 1977). In the present
study, both the haematocrit and the plasma noradrenaline concentrations
failed to rise in the tetraplegic subjects, so this explanation could
not explain the gradual increase in heart rate which was observed.
Similarly a normal rise in heart rate after insulin administration
has been described in diabetic patients with nephropathy in whom there
was no measurable rise in plasma noradrenal ine (Christensen et al.,
1980). This is consistent with a study which showed that in rabbits
the action of insulin occurred independently of the autonomic nervous
system (Jacobsen and Christensen, 1979).
The sweating that is a constant feature of the normal hypoglycaemic
reaction has been attributed to circulating catecholamines (Freinkel,
1975; Hall et al., 1974). In normal subjects however, the sudden
onset of sweating is synchronous with the initial rise in pulse rate
(Chapter 4) and precedes the peak in plasma catecholamines
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(Christensen et al., 1975). The total absence of sweating in
response to hypoglycaemia in the patients with a pre-ganglionic
sympathectomy, and the persistence of sweating in adrenalectomised
patients (Ginsburg and Paton, 1956) and patients with adrenal
denervation (French and Kilpatrick, 1955) suggests that adrenaline
is not involved in the sweating response, and favours mediation
via a sympathetic cholinergic mechanism.
CHAPTER 7
PLASMA SUBSTRATE RESPONSES TO ACUTE HYPOGLYCAEMIA IN MAN:
ADRENERGIC AND CHOLINERGIC MECHANISMS
Chapter 7









The metabolic response to acute hypoglycaemia in man has been
described in Chapter 1. This is characterised by an initial fall
in blood glucose which is restored to basal levels by the activation
of hepatic glycogenolysis and gluconeogenesis. These processes
are accompanied by a rise in blood lactate levels secondary to
muscle glycogenolysis and an elevation of plasma free fatty acids
following 1ipolysis in adipose tissue. Acute hypoglycaemia is
associated with activation of the sympathoadrenal system which
produces classical autonomic symptoms, and stimulation of post-ganglionic
cholinergic nerves, which has been outlined in Chapter 2.
In this chapter and in Chapter 8, studies are described in
which the contributions of adrenergic and cholinergic activity to
the homeostatic recovery mechanism from acute hypoglycaemia have been
examined in man.
METHODS
The subjects who were described in Chapter 6 were studied using
an identical protocol (insulin dose 0.15 units/kg body weight; atropine
dose 15 pg/kg).
Group A: Normal subjects (n = 11)
Group B: Tetraplegic subjects (n = 6)
Group C: Tetraplegic subjects given atropine (n = 6)
Blood samples were withdrawn 30 minutes prior to the injection of
insulin, and at intervals of 30 minutes for 210 minutes after insulin
administration. Serial measurements were made of blood glucose
(Hill and Kessler, 1961), blood lactate (Hohorst, 1970), plasma free
fatty acids (FFA) (Baird et al., 1967) and plasma cyclic AMP (Brown et al.,
1972).
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Statistics: Results are expressed as mean + the standard error of
the mean (SEM). Statistical significance between groups of subjects
was estimated using Student's t test for unpaired data (between
groups) or paired data (within group). The data presented in this
chapter was distributed normally about the mean value.
RESULTS
Blood glucose: The changes in mean blood glucose in all three groups
of subjects are presented in Table 7.1 and illustrated in Fig. 7.1.
Following insulin administration, the rate of fall of blood glucose
was slower in the two groups of tetraplegic subjects, both of which
were significantly different from the normal group at 30 min (p < 0.001),
with a lesser degree of hypoglycaemia being attained. At this time
(30 min) there was also a significant difference between the two
groups of tetraplegic subjects (p < 0.05). In the tetraplegic subjects
without atropine (group B) blood glucose recovery proceeded at a
similar rate to the normal group, and during the recovery phase the
small difference between these groups was not statistically significant.
In the tetraplegic subjects given atropine (group C), the
blood glucose rise following hypoglycaemia was much slower than in
the other two groups, with a significant impairment of blood glucose
recovery. There was a significant difference in the mean blood glucose
values compared with the normal group at 60 min (p < 0.01), 90 min
(p < 0.001) and 150 min (p < 0.001) after insulin. Blood glucose
levels in individual tetraplegic subjects given atropine are shown in
Fig. 7.2. Blood glucose recovery was impaired in all subjects, and
two subjects developed symptoms of severe neuroglycopenia which




Fig. 7.1 Blood glucose concentrations (mean + SEM) in normal
subjects (n = 11), tetraplegic subjects (n = 6) and
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Fig. 7.2 Individual blood glucose concentrations in tetraplegic
subjects given atropine (group C) in response to
intravenous insulin. The range of blood glucose
concentrations in tetraplegic subjects without atropine
(group B, n = 6) is shown by the shaded area.
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Blood lactate: In the normal subjects blood lactate increased
to a peak value at 60 min (p < 0.001 vs mean basal value of normal
group) then declined to basal levels by 150 min (Fig. 7.3). The
mean blood lactate concentrations in the normal group and in the
tetraplegic group without atropine (group B) are shown in Table 7.2.
In the tetraplegic subjects without atropine, a small rise of blood
lactate was observed at 30 min (p < 0.02 vs mean basal value), but
the mean blood lactate was significantly lower than the normal group
at 60 min (p < 0.05). Blood lactate concentrations were measured
in two tetraplegic subjects given atropine and the individual
values are shown in Table 7.2. These values were similar to the
levels observed in the tetraplegic group without atropine.
Plasma FFA: The mean values of plasma FFA are shown in Table 7.3
and are depicted in Fig. 7.4. In all three groups the plasma FFA
fell after insulin administration for 30 min. A subsequent rise
to values above basal was observed in the normal group, and a similar
but delayed pattern was present in both tetraplegic groups. This
delay was more pronounced in the tetraplegic group given atropine
(group C).
Plasma cAMP: Mean plasma cAMP concentrations are shown in Table 7.4
and are illustrated in Fig. 7.5. In the normal group the mean plasma
cAMP increased rapidly to a peak more than double the mean basal
value at 30 min (p < 0.01). This rise was absent in both tetraplegic
groups.
The temporal relationship of the changes in these parameters
can be compared in all three groups in a composite figure (Fig. 7.6).
7.7
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Fig, 7.3 Blood lactate concentrations (mean + SEM) in normal
subjects (n = 11) and tetraplegic subjects (group B,
n = 6) in response to insulin-induced hypoglycaemia.
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STATISTICAL SIGNIFICANCE pVALUE AvsB
GROUPC(TWOINDIVIDUALS) TETRAPLEGICSUBJECTSPLUSA OPINE SUBJECT.H.SUBJECTG.S.
0
30 60 90
120 150 180 210
0.98 1.33 2.00
0.07 0.08 0.21
1.57+0 20 1.18+0 3 0.97+0 0.90+09 0.89+07
1.03 1.35 1.38
0.08 0.14 0.07
1.20+0 1 0.99 0.88 0.87 0.87
0.06 0.03 0.07 0.07
N.S.
<0.05 <0.1 N.S. N.S. N.S. N.S.
0.90 1.50 1.38 0.98 0.84
1.08 1.33 1.50 1.32 1.18 1.06
03
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Fig. 7.4 Plasma free fatty acid concentrations (mean + SEM) in
normal subjects (n = 7), tetraplegic subjecti (n = 6)
and tetraplegic subjects given atropine (n = 5) in
response to insulin-induced hypoglycaemia.
TABLE7.3





























































































Fig. 7.5 Plasma cyclic AMP concentrations (mean + SEM) in normal
subjects (n = 7), tetraplegic subjects (n = 5) and
tetraplegic subjects given atropine (n = 6) in response
to insulin-induced hypoglycaemia.
TABLE7.4































































































The slower fall in blood glucose following insulin and the
lesser degree of hypoglycaemia compared to normal subjects, suggests
a relative resistance to insulin in the tetraplegic subjects, and
this may be related to chronic inactivity (Lipman et al., 1970).
Palmer et al., (1976) attempted to circumvent this relative
insensitivity to insulin by administering a larger dose of insulin
(0.2 units/kg body weight) to tetraplegic subjects, but were still
unable to achieve a degree of hypoglycaemia equivalent to that of
normal subjects. In the present study the normal and the tetraplegic
subjects received the same dose of insulin (0.15 units/kg body weight).
The blood glucose recovery proceeded at a normal rate in the
tetraplegic subjects without atropine. The absence of a catecholamine
response to hypoglycaemia in these sympathectomised subjects (Chapter 6)
does not appear to impede the restoration of normoglycaemia. This is
consistent with a normal blood glucose recovery from hypoglycaemia
in adrenalectomised subjects (Ginsburg and Paton, 1956; Von Euler
et al., 1961; Brodows et al., 1976; Ensinck et al., 1976; Gerich
et al., 1979), in sympathectomised subjects (Palmer et al., 1976;
Brodows et al., 1976) and in normal subjects during either separate
(Clarke et al., 1979) or combined (Rizza et al., 1979a) alpha and
beta adrenergic blockade.
Ablative studies in animals have suggested the existence of
sub-hypothalamic centres in the cervical and thoracic spinal cord
which may initiate a metabolic response to hypoglycaemia (Crone, 1965;
Goldfien, 1966). In the present study it is possible that hypoglycaemia
could activate a counterregulatory mechanism via a spinal cord reflex
below the level of transection. In human subjects with tetraplegia
7.14
Fig. 7.6 Changes in blood glucose, blood lactate, plasma free
fatty acids and plasma cyclic AMP concentrations
(mean + SEM) in response to insulin-induced hypoglycaemia
in normal subjects and in tetraplegic subjects with or
without atropine. Insulin was administered at time
0 minutes.
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however, the infusion of 2-deoxy-D-glucose to induce intracellular
glucopenia did not provoke the rise of blood glucose which is
observed in normal subjects (Brodows et al., 1973). It is unlikely
therefore that a spinal reflex in man could be invoked to explain
the normal blood glucose recovery in the tetraplegic subjects without
atropine in the present study.
The administration of atropine to the tetraplegic subjects
was associated with a greater fall of blood glucose in response to
insulin, compared with the tetraplegic group without atropine. Blood
glucose recovery also was delayed significantly and this produced
severe neuroglycopenia in two of the six tetraplegic subjects.
The rise of blood lactate in normal subjects results from
muscle glycogenolysis (Haugaard et al., 1976). Plasma free fatty
acids increase when lipolysis is reactivated after an initial
inhibition by insulin (Armstrong et al., 1961). The rises of lactate
and of free fatty acids following hypoglycaemia are reduced by
adrenergic antagonists (Billington et al., 1954; Di Salvo et al., 1956;
Werk et al., 1961; Abramson et al., 1966; Abramson and Arky, 1968) and
are not observed in response to intracellular glucopenia induced
by 2-deoxy-D-glucose in sympathectomised patients (Brodows et al.,
1973; Brodows et al., 1975), thus indicating a mediation via catecholamines.
In the present study the minimal rise of blood lactate and the delayed
rise of plasma free fatty acids in the sympathectomised subjects
following hypoglycaemia can be attributed to adrenergic denervation.
Although lactate is an important precursor for hepatic gluconeogenesis
during the recovery from hypoglycaemia (Exton, 1979; Young and Landsberg,
1977), the impairment of lactate production had no effect on blood
glucose recovery in the tetraplegic subjects without atropine, and
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cannot therefore be the primary cause of the retarded glucose
recovery during cholinergic blockade in such subjects.
The absence of a rise of plasma cyclic AMP in response to
hypoglycaemia in all tetraplegic subjects in the present study
suggests that the activation of hepatic adenyl cyclase by hypoglycaemia
is mediated by catecholamines. The possible role of pancreatic
glucagon in this process can be excluded by data presented in Chapter 8,
demonstrating no deficiency of glucagon secretion in these tetraplegic
subjects in response to hypoglycaemia. In the tetraplegic group
without atropine the normal recovery of blood glucose, unaccompanied
by a rise in plasma cAMP, is consistent with evidence from in vitro
studies which indicate that gluconeogenesis may be activated independently
of this nucleotide (Sherline et al., 1972; Tolbert et al., 1973;
Kneer et al., 1974; Guder and Rupprecht, 1975), and confirms a previous
study in tetraplegic subjects (Brodows et al., 1976).
CHAPTER 8
HORMONAL RESPONSE TO ACUTE HYPOGLYCAEMIA IN MAN:
NEURAL CONTROL OF PANCREATIC ISLET CELL FUNCTION
AND HORMONAL MEDIATION OF METABOLIC HOMEOSTASIS
Chapter 8
Hormonal response to acute hypoglycaemia in man: neural control of



















Acute insulin-induced hypoglycaemia in man produces a rise
in the circulating levels of several hormones, some of which play
an important role in the restoration of normoglycaemia. The effects
of the major counterregulatory hormones were reviewed in Chapter 1.
The relative importance of each of these hormones to the initiation
and control of metabolic recovery from hypoglycaemia has not been
defined clearly, nor have the contributions of the sympathetic and
parasympathetic neural mechanisms which may influence hormonal
secretion.
The hormonal secretion of the pancreatic islets plays a central
role in the regulation of carbohydrate homeostasis. Increased alpha
cell activity in response to hypoglycaemia results in a pronounced
rise in plasma levels of pancreatic glucagon (Gerich et al., 1974),
in conjunction with a concomitant decrease in beta cell secretion of
insulin which is reflected by a reduction in plasma C-peptide
concentrations (Horwitz et al., 1975b; Service et al., 1977; Liljenquist
et al., 1978). Pancreatic islet cell function may also be influenced
by circulating catecholamines and by adrenergic and cholinergic neural
activity.
The role of the autonomic innervation in the regulation of the
metabolic response to hypoglycaemia is examined further in this chapter,
with respect to the effect of adrenergic and cholinergic mechanisms
on pancreatic islet cell function and on the secretion of counterregulatory
hormones.
METHODS
The same three groups of subjects (Group A - normal; Group B -
tetraplegia Group C - tetraplegic plus atropine) were used as described
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in Chapter 6 (Table 6.1) using an identical protocol. The same
dose of insulin (0.15 units/kg body weight) was administered to all
subjects and basal blood samples were withdrawn prior to the induction
of cholinergic blockade in Group C, and 30 minutes before the
injection of insulin in Groups A and B. Serial blood sampling was
performed at 30 minute intervals throughout the study to 210 minutes
after insulin administration.
Serial measurements were made of plasma insulin (Ashby and
Speake, 1975), plasma C-peptide (Heding, 1975), plasma pancreatic
glucagon (C-terminal glucagon-1ike immunoreactivity) (Stout et al.,
1976), plasma Cortisol (Mattingly, 1962), plasma growth hormone (GH)
(Hunter, 1976) and plasma pancreatic polypeptide (PP) (Adrian et al.,
1976). Plasma ACTH was measured using a double antibody radioimmunoassay
on unextracted plasma (Ratcliffe, J.G. and Gray, C.E., unpublished).
(In this study, plasma pancreatic glucagon was assayed by Professor
K.D. Buchanan's laboratory).
Statistics: Results are expressed as mean + the standard error of
the mean (SEM). Statistical significance between groups of subjects
was estimated using Student's t test for paired (within group) or
unpaired (between group) data, except when data was not normally
distributed about the mean value. The Wilcoxon rank test was used
to assess statistical significance for pancreatic glucagon, GH
and ACTH which were not distributed in a normal manner.
★
See appendix for ACTH assay.
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RESULTS
Plasma insulin: Following the administration of exogenous insulin,
plasma insulin rose to similar peak levels in all three groups of
subjects, followed by a similar exponential decline (Fig. 8.1).
There was no significant difference between the three groups at
each time point, and the mean values for all groups are shown in
Table 8.1.
Plasma C-peptide: The mean plasma C-peptide levels for all groups
are shown in Fig. 8.2 and Table 8.2. The mean basal C-peptide levels
were significantly higher in both groups of tetraplegic subjects
compared to the normal group (group B vs A, p < 0.001; group C vs A,
p < 0.05), but the mean basal values of groups B and C were not
significantly different. Mean plasma C-peptide fell following
insulin administration in all three groups. In the normal subjects
the mean plasma C-peptide concentration decreased to the effective
detection limit of the assay (0.06 nmol/1) by 60 min after insulin,
and had not returned to the normal basal level by 210 min, despite
the restoration of normoglycaemia. A similar pattern was observed
in the tetraplegic subjects without atropine, but the mean plasma
C-peptide levels were significantly higher than in the normal group
(p < 0.001) from 60 min onwards, consistent with the lesser degree
of hypoglycaemia attained in this group. An intermediate response
was observed in the tetraplegic group given atropine, with a decline
in the mean plasma C-peptide level to the effective detection limit
at 150 minutes.
Plasma pancreatic glucagon: The changes of mean plasma pancreatic
glucagon levels are shown in Table 8.3, and are depicted in Fig. 8.3.
Plasma pancreatic glucagon rose in response to hypoglycaemia in
8.4
Fig. 8.1 Plasma insulin concentrations (mean + SEM) following
intravenous injection of exogenous short-acting insulin
in normal subjects (n = 11), tetraplegic subjects (n = 6)
and tetraplegic subjects given atropine (n = 6).
(IRI = immunoreactive insulin).
TABLE8.1
































































































, 3.2 Plasma C-peptide concentrations (mean + SEM) in response
to insulin-induced hypoglycaemia in normal subjects
(n = 11), tetraplegic subjects (n = 6) and tetraplegic
subjects given atropine (n =6). (C.P.R. = C-peptide
immunoreactivity). The effective detection limit of
the assay is shown (dashed line).
TABLE8.2




























































































groups A and B with peak values at 60 minutes. In group C (tetraplegia
with atropine), the pancreatic glucagon secretory response was
prolonged, reaching a peak value at 90 min, which was not significantly
greater than the normal group (p <0.1) but was greater than the
tetraplegic group without atropine (p < 0.02). The percentage
increments of mean pancreatic glucagon from basal to 60 min in the
three groups of subjects (group A = 122%; group B = 41%; group C = 63%)
were proportional to the percentage fall in mean blood glucose
from the basal value to its nadir in the same groups (group A = 71%;
group B = 47%; group C = 54%). Blood glucose data has been presented
in Chapter 7 (Table 7.1).
Plasma Cortisol: A rise of plasma Cortisol following hypoglycaemia
was observed in all three groups of subjects (Table 8.4, Fig. 8.4).
This rise was very similar in the normal subjects and the tetraplegic
subjects without atropine. In the tetraplegic subjects given
atropine (group C),despite prolonged hypoglycaemia, mean plasma
Cortisol was lower at 60 min, although this difference failed to
achieve statistical significance with either group A or B (p< 0.1 > 0.
The difference was significant at 90 min compared to the normal group
(p < 0.01) but failed to achieve significance compared to the tetraplegi
group without atropine.
Plasma ACTH: In the normal group and in the tetraplegic group without
atropine, plasma ACTH levels rose to a peak value at 45 min (Fig. 8.5,
Table 8.5). A different pattern of secretion was observed in the
tetraplegic group given atropine (group C),with a slower rise to a
peak at 60 min, and a higher mean value than both other groups at
90 min, but this did not achieve statistical significance.
Plasma GH: In the normal group the expected rise in plasma GH was
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Fig. 8.3 Plasma pancreatic glucagon (C-GLI) concentrations
(mean + SEM) in response to insulin-induced hypoglycaemia
in normal subjects (n = 10), tetraplegic subjects (n = 6)
and tetraplegic subjects given atropine (n = 6).
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. 8.4 Plasma Cortisol concentrations (mean + SEM) in response
to insulin-induced hypoglycaemia in normal subjects (n = 11),
tetraplegic subjects (n = 5) and tetraplegic subjects
given atropine (n = 6). (11-OHCS = 11-hydroxy-corticosteroids).
TABLE8.4


































































. 8.5 Plasma ACTH concentrations (mean + SEM) in response to
insulin-induced hypoglycaemia in normal subjects (n =
tetraplegic subjects (n = 4) and tetraplegic subjects
given atropine (n = 6).
TABLE8.5













































































. 8.6 Plasma growth hormone (GH) concentrations (mean + SEM)
in response to insulin-induced hypoglycaemia in normal
subjects (n = 11), tetraplegic subjects (n = 5) and
tetraplegic subjects given atropine (n =6).
TABLE8.6
PLASMAGROWTHHORMONE(MEA+S )INRESPONSTNSULIN-INDUC DYPOGLYCAEMIAmU/1) GROUPABC NORMALTETRAPLEGICT APLE ICSUBJECTS TIME(min)SUBJECTSn=11)5)PLUSATROPINE6 02+0.613+85 2 309+419 102+0.6 6059+14546531+6 9074+18163653544 15038+1446727 21010+39+
8.17
the peak mean values of GH at 60 min were more than double that
of the normal group although this was not statistically significant.
The mean values for all three groups are documented in Table 8.6.
The concurrent changes in plasma glucagon, Cortisol, ACTH
and GH are shown in a composite figure (Fig. 8.7).
Plasma PP: In the normal subjects (group A) a marked rise of mean
plasma PP concentrations was observed in response to hypoglycaemia,
reaching a peak 60 min after insulin administration (Fig. 8.8 Table 8.7).
A similar rise was observed in the group of tetraplegic subjects
without atropine (group B) although the mean peak value attained was
lower, which is compatible with the lesser degree of hypoglycaemia
achieved in this group (Fig. 7.1). The plasma PP did not rise in
the group of tetraplegic subjects given atropine (group C). One
tetraplegic subject who had undergone a previous vagotomy for
treatment of a peptic ulcer was also studied (without atropine). There
was no measurable rise of PP in response to hypoglycaemia in this
subject. In view of his known vagotomy this tetraplegic subject was
not included in group B.
DISCUSSION
In the present study the adrenergic and cholinergic mechanisms
which may influence human pancreatic islet cell activity, and the
counterregulatory hormonal response to hypoglycaemia, have been examined
in vivo. It is possible that the administration of atropine in this
dosage (15 pg/kg body weight) may not achieve complete cholinergic
blockade of the pancreatic islets. However, the sustained tachycardia
in the absence of sympathetic cardiac innervation suggests that a
significant degree of cholinergic blockade with atropine was achieved. The
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Fig. 8.7 Changes in plasma pancreatic glucagon, growth hormone,
Cortisol and ACTH (mean + SEM) in response to insulin-induced
hypoglycaemia in normal subjects and in tetraplegic subjects
















g. 8.8 Plasma pancreatic polypeptide (PP) concentrations
(mean + SEM) in response to insulin-induced hypoglycaemia
in normal subjects (n = 6), tetraplegic subjects (n = 5)
and tetraplegic subjects given atropine (n =6).
TABLE8.7











































































previously to be mediated via vagal cholinergic stimulation (Schwartz
et al., 1976; Adrian et al., 1977; Floyd et al., 1977; Schwartz
et al., 1978). The abolition of the rise of plasma PP in the
tetraplegic subjects given atropine in the present study, confirms
the role of a vagal cholinergic mechanism in the control of PP
secretion, and supports the production of a significant degree of
cholinergic blockade with this dose of atropine.
Despite the limitations of his microscopy, Langerhans (1869)
observed that the pancreatic islets were supplied by nerve fibres,
and modern fluorescent and histochemical techniques have demonstrated
the presence of adrenergic and cholinergic nerve fibres supplying
the islet cells (Bencosme, 1959; Woods and Porte, 1974). Studies
in animals have demonstrated that stimulation of the parasympathetic
nervous system promotes insulin secretion, whereas pancreatic beta
cell activity is inhibited both by sympathetic nerve stimulation
and by catecholamines acting via an alpha-adrenergic receptor mechanism
(Woods and Porte, 1974). In the present study the decline of plasma
C-peptide concentration following hypoglycaemia was observed in both
groups of tetraplegic subjects, and was commensurate with the changes
of blood glucose. It is apparent therefore that pancreatic beta cell
suppression in response to hypoglycaemia in man may occur even in
the absence of normal sympathetic innervation and in the presence of
concomitant pharmacological blockade. The impairment of blood glucose
recovery in the tetraplegic subjects given atropine, cannot be explained
by a failure of the prolonged inhibition of insulin secretion which
normally accompanies the restoration of normoglycaemia (Horwitz
et al., 1975b; Liljenquist et al., 1978).
Several studies have shown that pancreatic glucagon secretion
is stimulated in vitro by adrenergic agonists (Iversen, 1973;
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Pagliara et al., 1974; Weir et al., 1974), and in vivo by the
infusion of catecholamines (Gerich et al., 1973) or by neural
stimulation (Frohman and Bernardis, 1971; Marliss et al., 1973a)
Kaneto et al., 1975). The work of Bloom et al., (1974a) in the calf
suggested a cholinergic control of pancreatic glucagon secretion
via the vagus nerve, and in this species the secretion of glucagon
in response to hypoglycaemia was delayed significantly by atropine.
The pancreatic glucagon response to acute hypoglycaemia was reduced
moderately in human subjects who had undergone truncal vagotomies,
and this was interpreted to indicate cholinergic control of pancreatic
alpha cell activity in man (Bloom et al., 1974b). This finding
was not confirmed by Palmer et al., (1979) who showed that neither
vagotomy nor cholinergic blockade had an effect on the secretion of
pancreatic glucagon in man in response to hypoglycaemia.
The previous findings of normal pancreatic glucagon release
during hypoglycaemia in patients with a pre-ganglionic sympathectomy
(Palmer et al., 1976), and in normal subjects under combined alpha-
and beta-adrenergic blockade (Rizza et al., 1979a), are confirmed by
this study. This suggests that the sympathetic nervous system plays
little part in modulating the secretion of pancreatic glucagon in
response to hypoglycaemia, and supports previous studies which suggested
that adrenergic mechanisms are not the prime mediators of pancreatic
glucagon release following hypoglycaemia in man (Walter et al., 1974;
Ensinck et al., 1976). In the present study the rise of plasma
pancreatic glucagon concentration was proportional to the degree of
hypoglycaemia attained in each group of tetraplegic subjects, and
was augmented appropriately during the prolonged hypoglycaemia which
occurred with cholinergic blockade. This indicates that under specific
conditions, appropriate pancreatic islet cell responses may be observed
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despite adrenergic denervation and pharmacological blockade of
cholinergic neural mechanisms of control. Isolated pancreatic
alpha cells in tissue culture can be stimulated to release glucagon
by low concentrations of glucose (Marliss et al., 1973b), suggesting
that hypoglycaemia may exert a direct effect via glucopenia.
Peptidergic neurones are contained within the vagus nerve
and within the extensive plexus of nerve fibres in the pancreas
(Polak and Bloom, 1978). Somatostatin-like immunoreactivity has
been demonstrated in peripheral adrenergic neurones in the guinea-pig
(Hokfelt et al., 1977) and in the D cells of human pancreatic islets
(Polak et al., 1975). Furthermore, plasma somatostatin levels are
raised during the recovery from insulin-induced hypoglycaemia in man
(Wass et al., 1980). Vasoactive intestinal polypeptide (VIP) has
been found in fibres of the vagus nerve (Polak and Bloom, 1978;
Fahrenkrug et al., 1978), and is released in response to various
physiological stimuli, including direct electrical stimulation of
the vagus nerve. VIP has also been shown to stimulate pancreatic
glucagon secretion in the perfused cat pancreas (Said, 1978). It
is possible therefore that peptidergic mechanisms may be involved
in the regulation of pancreatic islet hormone secretion, independent
of the classical dual autonomic innervation,although this assumes
that the peptidergic system is unaffected by atropine.
A marked elevation of plasma growth hormone levels was observed
in both groups of tetraplegic subjects after hypoglycaemia. However,
a normal glucose recovery has been found in the absence of a rise of
growth hormone (Greenwood and Landon, 1966; Abrams et al., 1966;
Feldman et al., 1975), and studies in man using somatostatin infusions
have indicated that growth hormone is not essential for blood glucose
homeostasis (Gerich et al., 1979; Rizza et al., 1979a). The release
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of growth hormone in response to hypoglycaemia is decreased by
alpha-receptor blockade (Blackard and Heidingsfelder, 1968; Clarke
et al., 1979), and stimulation of growth hormone may be mediated
at least in part via an alpha-adrenergic receptor mechanism. The
increased GH response in the sympathectomised subjects in response
to hypoglycaemia in the present study is consistent with the increased
GH response in normal subjects under beta blockade with propranolol
(Abramson et al., 1966) and during glucopenia induced with
2-deoxy-D-glucose in sympathectomised (Brodows et al., 1973) and
adrenalectomised patients (Brodows et al., 1975). These findings
suggest that the overall effect of adrenergic activation during
hypoglycaemia is to inhibit GH secretion via a beta receptor mechanism.
The delayed rise of plasma ACTH, and the reduced plasma Cortisol
response in the tetraplegic patients under cholinergic blockade,
were inappropriate to the severe hypoglycaemia and may have been
responsible for the impaired blood glucose recovery in these subjects,
despite the adequate secretion of pancreatic glucagon and growth
hormone. Cortisol is thought to encourage gluconeogenesis by a permissive
effect on the actions of glucagon and catecholamines to stimulate
hepatic glycogenolysis and gluconeogenesis (Exton et al., 1972) and
also by its influence upon catecholamine-induced release of lactate
from skeletal muscle and glycerol from adipose tissue (Steele, 1975).
Furthermore, synergistic interactions of glucagon, adrenaline and
Cortisol to produce hyperglycaemia have been demonstrated in the dog
(Eigler et al., 1979). In these animals when all three hormones
were infused simultaneously, the increment in blood glucose was two to
fourfold greater than the sum of the responses of the individual
hormone infusions. The infusion of Cortisol alone had no effect on
glucose production, but it markedly accentuated the hyperglycaemia
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produced by glucagon and/or adrenaline. Thus, physiological elevations
in circulating Cortisol may not have merely a permissive role on
the activity of the other counterregulatory hormones, but may prolong
their actions on the liver (Eigler et al., 1979).
Impaired blood glucose recovery from hypoglycaemia has been
described in states of primary and secondary adrenal insufficiency
(Fraser et al., 1941; De Bodo and Altszuler, 1958; Shahmanesh et al.,
1980), although diminished blood glucose recovery was not apparent
when replacement corticosteroid therapy was given prior to the
induction of hypoglycaemia (Ginsburg and Paton, 1956; Ensinck et al.,
1976; Brodows et al., 1976). In tetraplegic subjects in whom the
catecholamine response is absent, a relative deficiency of Cortisol
following hypoglycaemia may cause impairment of blood glucose recovery,
in view of its permissive and synergistic interactions with glucagon.
This may occur particularly if the availability of lactate for
gluconeogenesis is limited, as demonstrated in the present studies
(Chapter 7).
A cholinergic mechanism has been implicated in the secretion of
corticotrophin-releasing factor in the murine hypothalamus (Jones et al.,
1976). The present data suggest that a similar mechanism may exist
in man; atropine crosses the blood-brain barrier (Innes and Nickerson,
1975) and could have delayed the activation of ACTH secretion in
the tetraplegic group under cholinergic blockade.
Recovery from hypoglycaemia requires an integrated activation of
various counterregulatory mechanisms which provide substrates for
gluconeogenesis and stimulate hepatic glycogenolysis and gluconeogenesis.
The present studies indicate that in the absence of peripheral
adrenergic mechanisms alone this homeostatic process is relatively intact.
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With the administration of atropine, both classical components of
the autonomic nervous system are removed and impaired blood glucose
recovery becomes manifest. This impairment of the recovery mechanism
may be explained by a deficiency of circulating Cortisol secondary
to the blockade of central cholinergic receptors involved in the
activation of ACTH secretion. The present studies do not support a
direct role for peripheral cholinergic receptors in the activation of
pancreatic glucagon secretion in response to hypoglycaemia.
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APPENDIX
ACTH assay (Ratcliffe, J.G. and
is a double antibody radioimmunoassay
Gray, C.E., unpublished). This
on unextracted plasma:
200 pi plasma (in duplicate) - thawed immediately before assay
200 pi diluent in acidic buffer
100 pi Rabbit Anti-ACTH Antiserum (Medi-lab; Denmark)
final dilution 1 : 48,000 in EDTA buffer
100 pi '"i-human ACTH 25 pg (Dr P.J. Lowry) in acidic buffer
(prepared by chloramine-T method)
Incubate overnight at 4°C
Double antibody (Donkey anti-rabbit) precipitation overnight at 4 C
Centrifuge and count pellet
Standardisation against WHO Standard 74/555
Standard curve covers range — 10 - 20 ng/1 to 640 ng/1
High samples diluted in phosphate albumin buffer
Precision (between batch cv) —10 - 20%
The assay correlates well in general with the previous extracted
ACTH assay though there may be some discrepant situations since the
unextracted assays probably cross-react with high molecular weight
components to a greater extent than the extracted.
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Suppression of endogenous insulin secretion after acute hypoglycaetnia in man. By R. J. M.
Corrall, B. M. Frier, D. Crothers and Joyce D. Baird. Metabolic Unit, University
Department of Medicine, Western General Hospital, Edinburgh, EH4 2XU
Insulin and C-peptide are released in equimolar concentrations by the pancreatic beta cell.
The development of a radioimmunoassay for plasma C-peptide reactivity (CPR; Heding,
1975) allows the endogenous secretion of insulin to be measured in the presence of exo¬
genous insulin.
The response of the pancreatic beta cell to insulin-induced hypoglycaemia was studied in
11 normal young adults. Blood glucose and plasma CPR were measured during fasting,
and at intervals for 180 min after the onset of the acute hypoglycaemic reaction induced by
i.v. injection of insulin (0T5 units/kg body weight). Nine of these subjects were then given
a standard mixed meal and blood sampling was continued for a further 120 min. The same
meal was given to the nine subjects after fasting for an identical period without insulin
administration and blood glucose and plasma CPR levels were measured as before.
After injection of insulin the fasting blood glucose level fell from 3-93 + 0-08 (s.e.m.)
to 1-15 + 0-08 mmol/l within 20-30 min. Thereafter, in all subjects, the blood glucose con¬
centration rose to regain the fasting level by 120 min after the onset of the acute hypo¬
glycaemic reaction. After the meal, the mean blood glucose concentration rose to a peak
of 8-42 ± 0-27 mmol/l at 60 min and was still raised at 7-48 ±0-29 mmol/l at 120 min. In
contrast, after fasting without hypoglycaemia, the mean blood glucose of the same subjects
rose only slightly from 3-82 ±0-11 to 5-14 + 0-24 mmol/I at 30 min after the meal and
returned to the fasting level by 60 min postprandially. The difference in the mean blood
glucose concentration at 30, 60 and 120 min after the meal between both groups was highly
significant (P< 0-001).
In all subjects, plasma CPR fell rapidly after administration of insulin from a mean basal
fasting level of 0-39 + 0-04 pmol/ml to levels below the effective detection limit of the assay
(0-06 pmol/ml) at 30 min after the onset of acute hypoglycaemic reaction. Secretion of CPR
was completely suppressed until the reaction + 150 min and after the reaction +180 min
the mean CPR level was only 0-11 + 0-03 pmol/ml. Levels of CPR rose after the meal with
mean values of 0-76±0-15 at 30 min, 1-72 + 0-24 at 60 min and 2-58+0-47 pmol/ml at
120 min. In contrast, when the meal was given after fasting alone, mean plasma CPR rose
from 0-35+0-01 to 1-76 + 0-08 at 30 min, 1-65 ±0-18 at 60 min and fell to 1-16 + 0-14 pmol/
ml at 120 min. Mean CPR values at 30 and 120 min after the meal were significantly
different between the groups (P< 0-001).
We conclude that after insulin-induced hypoglycaemia the normal response of the beta
cell to a meal is markedly altered. Acute hypoglycaemia induces prolonged suppression of
endogenous insulin secretion which continues after ingestion of food. Insulin secretion is
sufficiently delayed to produce impaired carbohydrate tolerance.
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EFFECT OF PREGANGLIONIC SYMPATHECTOMY
ON METABOLIC RECOVERY FROM HYPO-
GLYCAEMIA
B. M. Frier, R. J. M. Corrall, J. P. Ashby, E. J. W.
McClemont and P. S. Sever
Metabolic Unit, University Department of Medicine, Western
General Hospital, Edinburgh, Edenhcll Hospital, Musselburgh,
East Lothian, Scotland, U.K., and Medical Unit, St Mary's
Hospital, London
To evaluate the role of the sympathetic nervous system in the
recovery from acute hypoglycaemia, six male subjects with
complete post-traumatic transection of the cervical spinal cord
were studied, and the results compared with 11 normal controls.
Insulin (0-15 unit/kg) was administered intravenously to fasting
subjects and sequential blood samples were assayed. The
recovery of blood glucose after hypoglycaemia was unimpaired
in the sympathectomized subjects, although a rise in blood
lactate concentration was not observed in this group. Changes in
plasma free fatty acid and glucagon concentrations were similar
in both groups. The marked increase in plasma cyclic-AMP
and plasma noradrenaline concentrations seen in normal
subjects was absent in the sympathectomized group.
This study demonstrates that, after a total preganglionic sym¬
pathectomy in man, blood glucose recovery from insulin-
induced hypoglycaemia is normal. Glucagon secretion appears
to be intact, but a rise in plasma cyclic-AMP concentrations
does not occur. The putative role of adrenergic mechanisms in
the homeostatic recovery from hypoglycaemia in man may
require re-evaluation.
Clinical Science, _57, 24P, (1979)
Attenuation of beta-cell function following acute hypoglycaemia
in man
B. M. FRIER, R. J. M. CORRALL, J. P. ASHBY and J. D. BAIRD,
Edinburgh, U.K.
The response of the pancreatic beta-cell to hypoglycaemia was studied
in 11 normal young adults (hypoglycaemia study). Blood glucose and
plasma C-peptide reactivity (CPR) were measured fasting and at inter¬
vals for 210 min after the administration of i.v. insulin (0.15 units/kg
body weight). Nine subjects were then given a standard mixed meal and
blood sampling was continued for a further 120 min. The same meal was
given to the 9 subjects after fasting for an identical period without
insulin being administered (fasting study). A normal recovery pattern
of blood glucose was observed following hypoglycaemia, and C-peptide
secretion was completely suppressed until 180 min after the injection
of insulin. After the meal, mean blood glucose in the hypoglycaemia
study rose to a significantly higher level than in the fasting study.
After hypoglycaemia, CPR secretion was much slower following the meal,
compared to the fasting group, but significantly higher plasma CPR
levels were subsequently achieved by 120 min postprandially. This ab¬
normal pattern of insulin secretion after the meal resembles the defect
observed in maturity-onset diabetes. The possible mechanisms of this
phenomenon are discussed.
Excerpta Medica, 481, 68, (1979)
Control of pancreatic islet cell function in man: investigation of adrenergic and cholinergic
mechanisms. By B. M. Frier, R. J. M. Corrall, J. P. Ashby, E. J. W. McClcmont* and D.
Shirling. Metabolic Unit. University Department ofMedicine, Western General Hospital,
Edinburgh, EH4 2XU, and*Spinal Unit, Edenhall Hospital, Musselburgh. East Lothian
The pancreatic islets receive a rich cholinergic and adrenergic innervation. We have
examined the role of the neural control of the pancreatic i and (3 cells in response to
hypoglycaemia in man.
Insulin (0-15 u./kg) was given i.v. to 11 normal subjects, six tetraplegic patients with
complete transection of the cervical spinal cord (pre-ganglionic sympathectomy alone) and
six tetraplegic patients under cholinergic blockade with i.v. atropine (total autonomic
denervation of pancreas). Levels of blood glucose, plasma insulin. C-peptide (CPR),
glucagon and noradrenaline were measured in the basal state and up to 210 min after the
injection of insulin.
Blood-glucose recovery from hypoglycaemia was impaired only in the tetraplegic patients
given atropine. Plasma CPR fell during hypoglycaemia and remained low despite
restoration of euglycaemia. Plasma glucagon increased in all three groups; the highest levels
were observed in the subjects with total autonomic denervation. In all tetraplegic subjects,
there was no rise in plasma noradrenaline in response to hypoglycaemia.
The impaired blood-glucose recovery associated with total autonomic denervation cannot
be explained by an abnormal secretion of glucagon. This study suggested that, in man. the
response of the pancreatic islets to hypoglycaemia may occur in the absence of control
through cholinergic and adrenergic mechanisms.
Journal of Endocrinology, 85, 30P - 31P, (1980)
ABNORMAL INSULIN SECRETORY RESPONSE TO
FOOD AFTER ACUTE HYPOGLYCAEMIA IN MAN:
EVIDENCE FOR /7-CELL GLUCOPENIA
R. J. M. Corrall, B. M. Frier, J. P. Ashby, T. E. Adrian
and S. R. Bloom
Metabolic Unit, University Department of Medicine, Western
General Hospital, Edinburgh, Scotland, and Department of
Endocrinology, Royal Postgraduate Medical School, London
Abnormal function of the pancreatic /?-ceil and impaired
carbohydrate tolerance have been observed in response to a
meal after actue hypoglycaemia in man (Corrall, Frier, Crothers
& Baird, 1979, Journal of Endocrinology, 81, 157p). This was
characterized by an early reduced postprandial rise in plasma
insulin and abnormally elevated levels 2 h later. This temporary
disturbance of insulin secretion was investigated as follows. (1)
Gastrointestinal hormones: serial levels of enteroglucagon,
motilin, neurotensin, gastric inhibitory peptide, gastrin and
pancreatic polypeptide were assayed in six normal subjects
during hypoglycaemia (0-15 unit of insulin/kg, intravenously)
and in response to a subsequent meal. (2) Glucose infusion: after
hypoglycaemia, glucose (0-5 g/kg) was infused intravenously
over 3 min in four normal subjects at 60 min before the meal, to
reverse possible /J-cell glucopenia. (3) Adrenergic inhibition: the
insulin secretory response to a meal after hypoglycaemia was
studied in two subjects with complete preganglionic
sympathectomy. (4) Aminophylline infusion: this was
performed to investigate a possible role of intracellular cyclic
AMP (cAMP) depletion in causing abnormal /I-cell function.
Aminophylline (250 mg intravenously and 4 mg/min for 60
min) was administered 60 min before the meal after hypo¬
glycaemia in two normal subjects.
The results do not support mediation via abnormal gastro¬
intestinal hormone secretion (entero-insular axis), adrenergic
inhibition or intracellular cAMP deficiency of the pancreatic p
cell. A partial improvement of the abnormal postprandial
pattern of insulin secretion by a preceding glucose infusion
suggests that glucopenia of the /? cell is an important factor in
the pathogenesis of this abnormality.
Clinical Science, _59, 16P, (1980)
16. Neuroendocrine Counterregulatory Mechanisms in the
Recovery from Acute Hypogiycaemia in Man
B. M. Frier, R. J. M. Corrall, J. P. Ashby, J. G. Ratcliffe, and
N. S. Brown. Metabolic Unit, University Dept. of Medicine, Wes¬
tern General Hospital & Immunoassay section, Dept. of Clinical
Chemistry, Royal Infirmary, Edinburgh and Radioimmunoassay
Unit, Dept. of Biochemistry, Royal Infirmary, Glasgow, U. K.
The recovery from acute insulin-induced hypogiycaemia (IV insu¬
lin 0.15 U/kg) was studied in 11 normal subjects, 6 subjects with
preganglionic sympathectomy (adrenergic denervation) and 6
sympathectomised subjects given atropine (combined adrenergic
denervation and cholinergic blockade). Blood glucose recovery
was impaired only in the sympathectomised subjects given
atropine. The blood lactate response was reduced and the rise in
non-esterified fatty acids was delayed in both groups of sym¬
pathectomised subjects, in whom the normal rises of plasma cyclic
AMP and noradrenaline were absent. The changes in plasma C-
peptide and glucagon levels were appropriate to prevailing blood
glucose concentrations in all 3 groups. Cortisol and ACTH
responses were impaired in the group of sympathectomised sub¬
jects given atropine and growth hormone levels were higher in
both sympathectomised groups. - Blood glucose homeostasis was
clearly impaired during combined adrenergic and cholinergic
denervation. Under such conditions appropriate islet cell
responses were retained; glucagon secretion was activated inde¬
pendent of vagal control. In the sympathectomised group given
atropine the rise in plasma Cortisol was inappropriately blunted in
response to a greater degree of hypogiycaemia. Impaired
adrenocortical activation at hypothalamic level may explain, at
least in part, the delayed restoration of normoglycaemia.
Diabetologia, J9j, 560 (1980)
Acute Hypoglycemia in Man:
Neural Control of Pancreatic Islet Cell Function
Roger J. M. Corrall and Brian M. Frier
Acute hypoglycemia is associated with stimulation of the pancreatic alpha cells and a concurrent, prolonged suppression
of insulin secretion by the beta cells. The islets receive a rich autonomic innervation arid may therefore be subject to
control by adrenergic and cholinergic mechanisms. The role of such neuroregulation of pancreatic islets in response to
hypoglycemia has been examined in normal subjects, in subjects with a preganglionic sympathectomy due to traumatic
tetraplegia, and in tetraplegic subjects given atropine to induce effective dual autonomic denervation. The normal rise of
plasma norepinephrine following hypoglycemia was absent in both groups of tetraplegic subjects, providing evidence of a
complete sympathectomy. Blood glucose recovery was significantly impaired only in the group of tetraplegic patients given
atropine. Changes in plasma C-terminal glucagon-like immunoreactivity (C-GLI) and C-peptide irnmunoreactivity (CPR)
following hypoglycemia were commensurate with blood glucose levels and were not significantly influenced by islet
denervation. These observations suggest that neuroregulation of human islet cell function in response to hypoglycemia
may be of limited importance and that stimulation of glucagon secretion may occur independent of cholinergic vagal
control.
ACUTE HYPOGLYCEMIA in man induces anincrease in the circulating levels of several
hormones, including pancreatic glucagon.1 In conjunc¬
tion with this increase in alpha cell activity, there is a
concomitant decrease in beta cell secretion of insulin,
reflected by a reduction in plasma C-peptide concen¬
trations.2"' The secretion of these two hormones, which
have a central role in the regulation of carbohydrate
homeostasis, may be influenced by many factors,
including sympathetic adrenergic and parasympa¬
thetic cholinergic neural activity, and by circulating
catecholamines. The relative contribution of these
mechanisms to the control of pancreatic islet cell
secretion during recovery from acute hypoglycemia is
not clearly defined. To examine the importance of
neural regulation, we have studied the pancreatic
endocrine response to insulin-induced hypoglycemia in
normal human subjects, and in subjects with adrener¬




Informed consent and Medical Ethics Committee approval was
obtained for studies in three groups of subjects: Group A: Eleven
normal, healthy subjects, (9 male, 2 female), age range 20-29 yr.
All were within 10% of their ideal body weight (mean 96%, range
91%-102%). Group B: Six male subjects with complete post¬
traumatic transsection of the cervical spinal cord above C7, produc¬
ing tetraplegia at least 6 mo before the study (duration of tetraple¬
gia, 6 mo to 19 yr), age range 21-44 yr. All were within 10% of their
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ideal body weight (mean 94%, range 90% -98%). Group C: Six male
tctraplegic subjects (2 from group B and 4 others), with similar
post-traumatic transscction of the cervical spinal cord (duration 4
mo to 5 yr), age range 19-28 yr. All were within 10% of their ideal
body weight (mean 97%, range 92%-104%). None of the subjects
had a family history of diabetes mellitus.
Protocol
All subjects were studied supine after an overnight fast without
preceding dietary preparation, and basal venous blood samples were
taken for 30 min through a tellon cannula situated in an arm vein.
Crystalline beef insulin, 0.15 U/kg body weight, was administered
as a bolus by intravenous (i.v.) injection. The subjects in group C
were given atropine, 15 Mg/kg body weight, which was administered
30 min before the insulin. Effective atropinization was assessed by
serial measurements of heart rate at 2-min intervals, and if neces¬
sary, atropine administration was repeated to maintain cholinergic
blockade. Serial blood samples were withdrawn at 30-min intervals
for up to 210 min after the administration of insulin, and were stored
at — 20°C before being assayed with minimal delay for blood
glucose,5 plasma immunoreactiyc insulin (IR1),6 C-peptidc immu¬
noreactivity (CPR),7 C-terminal reactive glucagon-like immunore-
aclivity (C-GLI),'1 and plasma norepinephrine concentrations.'
Statistical significance was estimated using the unpaired
Student's t test.
RESULTS
The normal subjects experienced a typical hypogly¬
cemic, reaction at approximately 30 min after the
injection of insulin, characterized by visible sweating,
tachycardia, and symptoms of neuroglycopenia. In
group B, a tachycardia.was absent"and there was no
visible sweating, but mild neuroglycopenia was experi¬
enced. The tetraplegic subjects lack a norma! sympa¬
thetic cardiac innervation and in group C the
adequacy of cholinergic blockade was confirmed by a
sustained tachycardia following the administration of
atropine. The pulse rate rose from a mean basal rate of
61 beats/minute (range 36-72) to 89 beats/minute
(range 64-100), and in 3 subjects a second dose of
atropine was given between 100 and 135 min after the
initial atropine injection to maintain the tachycardia.
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Fig. 1. Plasma norepinephrine concentrations (mean ± SEM)
in normal and tetraplegic subjects in the basal state and 45 min
after insulin administration.
In group C, no visible sweating was observed during
hypoglycemia but the neuroglycopenic symptoms were
more severe and prolonged. In two of the patients who
had received atropine the study had to be terminated
with parenteral glucose 90 min after the injection of
insulin, because of severe symptoms of neuroglycopc-
nia.
Following the injection of insulin, plasma IRl rose
to similar peak levels with a subsequent exponential
fall in all three groups of subjects. In the normal
subjects the mean norepinephrine concentration rose
to double the basal value at 45 min after insulin
administration (Fig. I). In the tetraplegic patients
(groups B and C) the basal concentrations of norepi¬
nephrine were much lower, and no significant change
was observed following hypoglycemia.
Figure 2 depicts the changes in mean blood glucose
concentration in all three groups. In both groups of
tetraplegic subjects, the fall in blood glucose after
insulin administration was slower than in the normal
subjects, and a lesser degree of hypoglycemia was
attained. At 30 min the mean blood glucose in the
normal group was significantly lower than that
recorded in the tetraplegic group without atropine (p
< 0.001), and the tetraplegic group with atropine (p <
0.001). There was a significant dilference at this time
in mean blood glucose between the two groups of
Fig. 2. Blood glucose concentrations (mean ± SEM) in normal
and tetraplegic subjects in response to i.v. insulin. In the normal
subjects "REACTION" denotes the onset of the acute tachycardia
and the symptoms of hypoglycemia.
tetraplegic subjects (p < 0.05). In group B blood
glucose recovery proceeded at a similar rate to the
normal subjects. The small difference in blood glucose
between these two groups did not achieve statistical
significance during the recovery phase. In contrast the
recovery from hypoglycemia in the tetraplegic patients
given atropine (group C) was much slower than in the
other two groups, indicating a significant impairment
of blood glucose recovery during combined adrenergic
denervation and pharmacologic cholinergic blockage.
Between groups A and C there was a significant
difference in the mean blood glucose levels at 60 min
(p < 0.01), 90 min {p < 0.001) and at I 50 min (p <
0.001). The individual blood glucose values for those
tetraplegic subjects given atropine are shown in Fig.
3.
Mean plasma CPR concentrations are shown in Fig.
4. The mean basal CPR levels were significantly
higher in both groups of tetraplegic patients compared
to the normal subjects (group B, p < 0.001; group C
p < 0.05), but the mean basal values of groups B and
C were not significantly different from each other.
Mean plasma CPR concentration fell following the
injection of insulin in all three groups. In the normal
subjects the mean plasma CPR levels decreased to the
effective detection limit of the assay and had not
returned to the normal basal level by the end of the
study, despite the restoration of euglycemia. A similar
pattern was observed in the tetraplcgic subjects with¬
out atropine, but the mean plasma CPR concentra¬
tions were significantly higher than in the normal
subjects {p < 0.001) from 60 min onwards, consistent
with the lesser degree of hypoglycemia attained in this
group. An intermediate response was observed in the
tetraplegic group given atropine, with a decline in the
mean plasma CPR level to the effective detection limit
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The mean plasma C-GLI concentrations are
depicted in Fig. 5. The mean basal plasma C-GLI level
was lower in the normal group but this difference
compared to cither tetraplegic group failed to achieve
statistical significance. Plasma C-GLI rose in response
to hypoglycemia in groups A and B with peak values at
60 min. In group C plasma C-GLI also rose, with
prolongation of the secretory response; higher concen¬
trations were observed at 60 and 90 min which were
statistically significant at 90 min in comparison with
both group A, (p < 0.05) and group B, {p < 0.02).
The percentage increments of mean glucagon values
from basal to 60 min in the three groups of subjects
(group A, 122%; group B, 41%; group C, 63%) were
proportional to the percentage fall in mean blood
glucose from basal to its nadir in the same groups
(group A, 7 1 %; group B, 47%; group C, 54%).
DISCUSSION
In this study we have examined in vivo the separate










Fig. 3. Individual blood glu¬
cose concentrations in tetra¬
plegic subjects given atropine
(group C) in response to i.v.
insulin. The range of blood
glucose concentrations in tet¬
raplegic subjects without atro¬
pine (group B) is illustrated.
influence human pancreatic islet cell activity in
response to hypoglycemia. It is possible that the
administration of atropine in this dosage may not
achieve complete cholinergic blockade of the
pancreatic islets. However, the sustained tachycardia
in the absence of sympathetic cardiac innervation
supports a significant degree of cholinergic blockade
following atropine in these subjects. Evidence for
complete disruption of the efferent sympathetic path¬
way in these tctraplcgic subjects is presented by the
absence of sweating and tachycardia in response to
hypoglycemia, and by the low basal norepinephrine
levels which failed to rise following hypoglycemia, as
found by Palmer et a 1.10 Ablative studies in animals
have suggested the existence of subhypothalamic
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Fig. 4. Plasma CPR (mean ± SEM) in normal and
tetraplegic subjects in response to i.v. insulin.
Fig. 5. Plasma C-GLI concentrations (mean ± SEM) in
normal and tetraplegic subjects in response to i.v. insulin.
NEURAL CONTROL OF PANCREATIC ISLETS
may initiate a metabolic response to hypoglycemia."
In the present study, it is therefore possible that
hypoglycemia could activate a counter;regulatory
mechanism via a spinal cord rcllcx below the level of
transsection. In human tetraplegic subjects however,
the infusion of 2-deoxy-glucose to induce intracellular
glucopenia, did not induce a rise of blood glucose levels
as observed in normal subjects.'2 It is therefore
unlikely that a spinal reflex in man could be invoked in
the present study to explain the normal blood glucose
recovery in the tetraplegic subjects (group 13).
Compared with the normal subjects, the slower fall
in blood glucose and the lesser degree of hypoglycemia
achieved in the tetraplegic subjects without atropine,
suggests a relative resistance to insulin, which may be
related to their chronic inactivity.13 Palmer et al.
attempted to circumvent this relative insensitivity to
insulin by administering a larger dose (0.2 U/kg body
weight) to their tetraplegic patients, but still did not
achieve equivalent hypoglycemia.10 In the present
study, all subjects received the same dose of insulin
(0.15 U/kg), but in the tetraplegic subjects under
cholinergic blockade (group C), blood glucose fell
lower, and recovery from hypoglycemia was signifi¬
cantly delayed compared with group B, which necessi¬
tated discontinuation of the study in two patients. This
impairment of blood glucose recovery cannot be
explained by impaired secretion of pancreatic gluca¬
gon or by a failure of the normal prolonged inhibition
of insulin secretion which accompanies the restoration
of euglycemia.2,4 Further studies are being undertaken
to determine the cause of this impairment of the
homeostatic recovery mechanism.
Langerhans observed that the pancreatic islets
receive an extensive innervation.14 Fluorescent and
histochemica! techniques have shown the presence of
both adrenergic and cholinergic nerve fibres supplying
the islet secretory cells.15 Animal studies have demon¬
strated that stimulation of the parasympathetic
nervous system promotes insulin secretion, whereas
beta cell activity is inhibited by sympathetic nerve
stimulation and by catecholamines acting via an
aipha-adrencrgic receptor mechanism.15 In man, acti¬
vation of the sympathetic nervous system occurs in
response to hypoglycemia producing a marked rise in
plasma and urinary catecholamines.U6~18 The decline
in plasma C-peptide concentration following hypogly¬
cemia was observed in both groups of tctraplcgic
subjects, and was commensurate with the changes in
blood glucose. It is apparent therefore that pancreatic
beta cell suppression in response to hypoglycemia may
occur in man even in the absence of normal sympa¬
thetic innervation and concomitant pharmacologic
cholinergic blockade.
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Several studies have shown that glucagon secretion
is stimulated in vitro by adrenergic agonists19"21 and in
vivo by the infusion of catecholamines,22 or by neural
stimulation.23 25 The work of Bloom ct al.26 in the calf
suggested a cholinergic control of glucagon secretion
via the vagus nerve, and in this species the secretion of
glucagon in response to hypoglycemia was signifi¬
cantly delayed by atropine. The glucagon response to
acute hypoglycemia was reduced in human subjects
following truncal vagotomy, which was interpreted as
evidence for a cholinergic control of alpha cell activity
in man.27 This was not confirmed by Palmer et al.28
who showed no effect of vagotomy or cholinergic
blockade on glucagon secretion in man in response to
hypoglycemia.
The previous finding of normal glucagon release
during hypoglycemia in patients with a preganglionic
sympathectomy10 and under combined alpha and beta
adrenergic blockade,29 is confirmed by this study, and
suggests that the sympathetic nervous system has a
limited involvement in modulating the secretion of
pancreatic glucagon in response to hypoglycemia. In
the present study glucagon secretion was unaffected
by co-existing cholinergic blockade and was aug¬
mented during prolonged hypoglycemia. These find¬
ings contradict the contention that human pancreatic
alpha cell function is largely controlled by vagal chol¬
inergic activity, and are consistent with the findings of
Palmer et al.28 Alpha cells in tissue culture are stimu¬
lated to release glucagon by low glucose concentra¬
tions/0 suggesting that hypoglycemia exerts a direct
effect via glucopenia. The present study indicates that
under specific conditions, appropriate islet cell
responses may be observed despite adrenergic dener¬
vation and pharmacological blockade of cholinergic
mechanisms of control.
Peptidergic neurons are contained within the vagus
nerve and within the extensive plexus of nerve fibres in
the pancreas.31 Somatostatin-like immunoreactivity
has been demonstrated in peripheral adrenergic
neurons in the guinea-pig32 and in the D cells of human
pancreatic islets.33 Furthermore, plasma somatostatin
levels are persistently raised during the recovery from
insulin-induced hypoglycemia in man.34 Vasoactive
intestinal peptide (VIP) has been found in fibres of the
vagus nerve,31'35 and is released in response to various
physiologic stimuli, including direct electrical stimula¬
tion of the vagus nerve. VIP has also been shown to
stimulate pancreatic glucagon secretion in the
perfused cat pancreas.36 It is possible therefore that
peptidergic mechanisms may be involved in the regu¬
lation of pancreatic islet hormone secretion, indepen¬
dent of the classical dual autonomic innervation.
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Summary
Following acute insulin-induced hypoglycaemia, an abnormal
pattern of insulin secretion in response to a meal has been
demonstrated in six healthy volunteers. This is characterised
by an initial impairment in insulin secretion and late hyper-
insulinaemia. Postprandial gastrointestinal hormone levels
were normal following hypoglycaemia in these subjects. In
four other subjects, the administration of intravenous glu¬
cose prior to the meal partially reversed the abnormal pat¬
tern of secretion. In two patients with a total pre-ganglionic
sympathectomy, the pattern of blood glucose, plasma insu¬
lin and C-peptide was similar to that observed following hy¬
poglycaemia in normal subjects. It is unlikely that an abnor¬
mal entero-insular axis or an elevation of plasma catechol¬
amine levels are primarily responsible for this phenomenon.
This effect of hypoglycaemia on postprandial insulin secre¬
tion may be caused by glucopenia of the pancreatic beta
cells.
Key-Words: Hypoglycaemia — Insulin Secretion — Entero-
insular Axis — Beta Cell Glucopenia
Introduction
Abnormal function of the pancreatic beta cell has been ob¬
served in response to a meal following acute hypoglycaemia
in man {Frier, Corrall, Ashby and Baird 1980). In that
study, following the ingestion of food, carbohydrate intol¬
erance was associated with an abnormal pattern of insulin
secretion, characterised by a subnormal early postprandial
rise of plasma insulin and an abnormal elevation two hours
later. Possible mechanisms underlying this altered pattern
of postprandial insulin secretion include the following:
(a) disordered function of the entero-insular axis following
hypoglycaemia, (b) intrinsic pancreatic beta cell dysfunc¬
tion caused by glucopenia and (c) inhibition of the beta
cell by catecholamines released during hypoglycaemia. In
the present study we have investigated the relative import¬
ance of these possible mechanisms.
Subjects and Methods
The following studies were approved by the Medical Ethics Com¬
mittee and informed consent was given by the subjects, all of whom
were within 10% of their ideal body weight. In all studies the sub¬
jects were investigated supine, after an overnight fast.
Protocol:
(a) Hypoglycaemia study. Crystalline beef insulin (0.15 units/kg
body weight) was injected as an intravenous bolus to induce acute
hypoglycaemia; this was experienced as typical neuroglycopenic
and autonomic symptoms by all normal subjects after 20 to 30
minutes. Serial blood samples were taken in the fasting state, and
for 210 minutes after the injection of insulin, followed by a stand¬
ard mixed meal (30 G protein, 85 G carbohydrate and 40 G fat).
Blood sampling was continued for a further 120 minutes after the
meal.
(b) Fasting Study. The same subjects were restudied after fasting
for an equivalent period without the administration of insulin and
similar measurements were made after an identical meal.
The above protocol was used for the following investigations:
1. Gastrointestinal hormones. In six normal male subjects, age
range 21-29 years, serial assays were made of plasma entero-glu-
cagon (Thomson and Bloom 1976), motilin (Bloom, Mitznegg and
Bryant 1976), neurotensin (Blackburn and Bloom 1979), gastrin
(Russell, Bloom, Fielding and Bryant 1976), gastric inhibitory pep¬
tide (Sarson, Bryant and Bloom 1980) and pancreatic polypeptide.
(Adrian, Bloom, Bryant, Polak, Heitz and Barnes 1976), during
both the hypoglycaemia and fasting studies. Cross-reactivity of the
antisera raised to the various peptides assayed was less than 0.5
per cent. Antiserum R59, which showed a high degree of cross-re¬
activity with ileal extracts, and fully detected gravimetrically-deter-
mined glicentin, was used to measure total plasma glucagon. En-
teroglucagon concentration was derived by subtraction of the pan¬
creatic glucagon concentration measured by the pancreatic specific
antiserum RCS5, from total plasma glucagon. Serial measurements
were also made of blood glucose (Hill and Kessler 1961), plasma
immunoreactive insulin (IRI) assayed against a human insulin
standard, RD10, (Ashby and Speake 1975) and plasma C-peptide
immunoreactivity (CPR) using an anti-synthetic human C-peptide
guinea pig serum, M1230 (Heding 1975).
2. Glucose infusion. A possible effect of hypoglycaemia on pan¬
creatic beta cell function was evaluated by the administration of
intravenous glucose to four other normal subjects (3 male, 1 fe¬
male; age range 22-24 years) using a modification of the above
protocol. At 150 minutes after the injection of insulin, dextrose
(0.5 G/kg body weight) was infused i.v. over three minutes in a
total volume of 250 ml (Soeldner 1971) following hypoglycaemia,
or after equivalent periods of fasting. Serial measurements were
made of blood glucose, plasma IRI and plasma CPR. After the i.v.
glucose load blood glucose was determined at 10 minute intervals
for 60 minutes prior to the ingestion of food. In the fasting study
an identical glucose infusion was given at an equivalent time prior
to the meal.
3. Catecholamines. The effect of hypoglycaemia on insulin secre¬
tion in response to a meal was examined in two male subjects
(aged 22 and 44 years) with traumatic transection of the cervical
spinal cord above the sympathetic outflow (pre-ganglionic sympa¬
thectomy). Blood glucose and plasma IRI and CPR were measured.
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Fig. 1 Blood glucose, plasma insulin and C-peptide concentrations
(Mean ± SEM) in 6 normal subjects, in response to hypoglycaemia
followed by a standard meal (hypoglycaemia study • •), and in
response to a standard meal without preceding hypoglycaemia
(fasting study o o)
Results
Following the injection of insulin the fall in blood glucose
was followed by a typical recovery pattern to a normal
mean fasting level by 150 minutes in the group of six nor¬
mal subjects (Fig. 1). Following the injection of insulin,
after an initial peak, the mean plasma IRI fell rapidly to a
level within the normal fasting range. The mean plasma
CPR concentration declined after insulin injection, and re¬
mained persistently depressed below the normal fasting
level until the meal. Following the meal, postprandial hy-
perglycaemia was associated with early subnormal insulin
and C-peptide secretion, then subsequent hypersecretion in
comparison with the fasting study (Fig. 1).
G.I. Hormones. The pattern of secretion of individual gas¬
trointestinal hormones in the same six subjects during the
hypoglycaemia and fasting studies is shown in Fig. 2.
A marked increase in pancreatic polypeptide was observed
during hypoglycaemia, but secretion of the other G.I. hor¬
mones was not significantly changed. The secretion patterns
of all these hormones in response to the meal were not
significantly different between the hypoglycaemia and
fasting studies.
Glucose infusion. The changes in mean blood glucose con¬
centration in the four subjects given i.v. glucose 60 min¬
utes before the meal are illustrated in Fig. 3. Following
the i.v. infusion of glucose the peak blood glucose level
was comparable in both the hypoglycaemia and fasting
studies, but the mean level then fell to a significantly low¬
er level in the fasting study at 50 and 60 minutes after
the injection of glucose (P < 0.05). Following the meal,
the blood glucose levels were significantly higher after hy¬
poglycaemia in comparison with the fasting study, at all
times of measurement (P < 0.001). However, the incre¬
mental rise from the different preprandial mean blood glu¬
cose levels and the subsequent pattern of glucose tolerance
were similar in both studies. This differs markedly from
the postprandial blood glucose levels observed after hypo¬
glycaemia alone (Fig. 3: shaded area).
Plasma IRI and CPR concentrations both rose in response
to the infusion of glucose, and in individual subjects the
increments of both plasma IRI and CPR were smaller fol¬
lowing hypoglycaemia. The mean increment of plasma IRI in
response to this infusion was 23.5 ± 7.2 mU/1 in the hypo¬
glycaemia study, compared to 36.8 ±11.7 mU/1 in the
fasting study; statistical significance was not achieved in
this small group of subjects. In response to the meal (pre¬
ceded by parenteral glucose) the pattern of insulin secre¬
tion was similar in both the hypoglycaemia and the fasting
studies, but significantly higher levels of plasma IRI and
CPR were observed in the subjects following hypoglyc¬
aemia at 90 and 120 minutes after the meal (P < 0.001).
Following hypoglycaemia plus a glucose infusion the rises
in plasma IRI and CPR were more rapid during the first
15 minutes after the meal in comparison with the equiva¬
lent rise after hypoglycaemia alone.
Catecholamines. The pattern of blood glucose, plasma IRI
and CPR observed in two subjects with preganglionic sym¬
pathectomy, in response to a meal following hypoglycaemia,
is shown in Fig. 4. In comparison with normal fasting sub¬
jects postprandial hyperglycaemia was again present, and
was accompanied by a later hypersecretion of insulin and
C-peptide. The pattern in these two subjects was similar
to that observed in normal subjects after hypoglycaemia.
Discussion
It is apparent that insulin-induced hypoglycaemia has a
marked effect on insulin secretion by the pancreatic beta
cell during the recovery from hypoglycaemia (Horwitz,
Rubenstein, Reynolds, Molnar and Yanaihara 1975; Ser¬
vice, Horwitz, Rubenstein, Kuzuya, Mako, Reynolds and
Molnar 1977; Frier et al. 1980). An impaired tolerance to
oral glucose after hypoglycaemia was described by Somo-
gyi (1951) and has been demonstrated following ingestion
of a mixed meal {Frier et al. 1980). The present study
confirms these observations, and suggests that the abnor¬
mal secretion of insulin following hypoglycaemia is not
caused by a reduced secretion of gastrointestinal hormones
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Fig. 2 Plasma concentrations (Mean ± SEM)
of gastrointestinal hormones in normal sub¬
jects (n = 6) in the hypoglycaemia (• •)
and fasting (o o) studies
in response to a meal. The impaired tolerance to parenteral
glucose following hypoglycaemia is also consistent with a
mechanism that does not involve an abnormal enteroinsu-
lar axis.
The reduction in insulin secretion in response to intrave¬
nous glucose following hypoglycaemia suggests that beta
cell function may be directly affected by preceding hypo¬
glycaemia. The early subnormal secretion of glucose and
the late hypersecretion of insulin, associated with glucose
intolerance, was less marked. Thus the impaired capacity
of the beta cell to respond to a meal following hypogly¬
caemia appeared to be partially reversed by a preceding
intravenous infusion of glucose.
Intracellular cAMP has been implicated in the process of
insulin secretion (Sharp 1979) and depletion of this nucleo¬
tide might explain the secretory pattern following hypo¬
glycaemia. The administration of the phosphodiesterase in¬
hibitor, aminophylline, has been reported to improve the
deficient insulin response to a glucose infusion in patients
with "prediabetes" (Cerasi and Luft 1969). In an attempt
therefore to inhibit phosphodiesterase activity, aminophyl¬
line was administered to two of our normal subjects prior
to the meal (250 mg i.v. followed by 4mg/min for 60
minutes). This had no significant effect on the postprandial
pattern of insulin secretion after hypoglycaemia, which
suggests that the transient disturbance of beta cell function
is not mediated by cAMP depletion.
A short infusion of adrenaline has been shown to produce
a prolonged suppression of insulin secretion (Robertson
and Porte 1973). We therefore investigated the possibility
that a rise in plasma catecholamines during hypoglycaemia
(Garber, Cryer, Santiago, Haymond, Pagliara and Kipnis
1976) might produce an abnormal pattern of insulin secre¬
tion in response to a subsequent meal. In the tetraplegic
patients with a pre-ganglionic sympathectomy, plasma nor¬
adrenaline levels did not rise following hypoglycaemia
(Frier, Corrall, Ashby, McClemont and Sever 1979). In
these two subjects the postprandial pattern of insulin se¬
cretion was similar to that of normal subjects, suggesting
that an adrenergic mechanism is not implicated.
The possibility that insulin may directly inhibit its own
secretion has been studied by maintaining euglycaemia
with a glucose clamp during the infusion of insulin (Liljen-
quist, Horwitz, Jennings, Chiasson, Kellar and Rubenstein
1978; Service, Nelson, Rubenstein and Go 1978). A par¬
tial suppression of plasma CPR concentrations was inter¬
preted as evidence for such a direct negative feedback. In
the present study, however, plasma insulin levels had re¬
turned to the normal fasting range prior to the ingestion
of the meal. It appears unlikely therefore that such a feed¬
back mechanism could explain the abnormal postprandial
insulin secretion observed after acute hypoglycaemia, but
it is not possible to prove that the initial high plasma in¬
sulin levels do not influence the pancreatic beta cells for
several hours.
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Summary
This study was designed to evaluate the influence of fructose
administration on glucose kinetics and the role of fructose
conversion to glucose in the maintenance of glucose homeo¬
stasis. Intravenous fructose infusion (4.5 mg/kg min"1) pro¬
duced a stable plasma fructose concentration of about 20
mg/dl and a small but sustained decrease (10 mg/dl) of plas¬
ma glucose levels. The latter effect was entirely attributable
to a rapid 30—35% fall in hepatic glucose output which
later returned slowly to pre-infusion levels. No significant
change in the rate of glucose utilization was observed. The
rate of fructose conversion to glucose rose progressively dur¬
ing fructose infusion reaching a plateau of 1.4 mg/kg min"1
which corresponded to about 40% of total glucose produc¬
tion. Furthermore, as much as one third of the infused fruc¬
tose was convertet to circulating glucose. No appreciable
changes in plasma insulin and glucagon levels occurred dur¬
ing fructose infusion while plasma alanine concentration in¬
creased remarkably.
These data indicate that 1) fructose administration induces
a transient fall in endogenous glucose production not accom¬
panied by significant changes in glucose utilization; 2) the
rapid conversion of the infused fructose to circulating glu¬
cose provides for the restoration of normal rates of glucose
production; and 3) the glucoregulatory response to the ad¬
ministration of fructose occurs in the absence of detectable
changes in plasma pancreatic hormone concentration.
Key-Words: Fructose Conversion — Glucoregulatory Re¬
sponse — Dog
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Introduction
The existence of a close relationship between fructose and
glucose metabolism in vivo is well recognized. Following
intravenous administration, fructose is taken up by the
liver and to a great extent, converted to glycogen (Berg-
strom, Fiirst, Gallyas, Hultman, H.son Nilsson, Roch-Nor-
lund and Vinnars 1972; H:son Nilsson and Hultman 1974;
Miller, Craig, Drucker and Woodward 195 6; Roch-Norlund,
Hultman and H. son Nilsson 1972). This process is very
fast and appears to be independent of insulin availability
(Bergstrom, Fiirst, Gallyas, Hultman, H.son Nilsson, Roch-
Norlund and Vinnars 1972; Roch-Norlund, Hultman and
H.son Nilsson 1972). Little information is, however, avail¬
able regarding the influence of fructose administration on
glucose homeostasis. Human studies based on the hepatic
vein catheter technique have suggested that splanchnic glu¬
cose output is inhibited during high dose i.v. fructose in¬
fusion (Bergstrom and Hultman 1967). Tracer studies have
also indicated that fructose is a good glucogenetic substrate
and that it may be converted to circulating glucose in sig¬
nificant amounts (Atwell and Waterhouse 1971; Landau,
Marshall, Craig, Hostetler and Genuth 1971). The extent
to which the conversion of infused fructose to plasma glu¬
cose may contribute to glucose production and the mech¬
anisms whereby glucose homeostasis is maintained during
the disposal of a fructose load remain, however, poorly
understood. Furthermore, the question as to whether the
administration of fructose modifies the rate of glucose
utilization has not been explored.
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The present study was, therefore, undertaken to determine
the effects of fructose administration on glucose kinetics
in normal conscious dogs (i.e., hepatic glucose output and
overall glucose utilization), and to quantitate the relative
contribution of glucogenesis from fructose to total glucose
production.
Materials and Methods
Experimental procedures. Experiments were performed on six male
dogs (11—22 kg) which had been fed Purina dog chow for at least
one week prior to study. All dogs were studied in the postabsorp-
tive state after a 16 to 18-h overnight fast. On the morning of the
study, a polyethylene catheter was inserted percutaneously into a
saphenous vein for infusion of 3-3H-glucose (Amersham) and fruc¬
tose. Another catheter was similarly inserted into a femoral artery
for blood sampling. A priming dose of tritiated glucose was admin¬
istered rapidly (at -90 min) followed by a continuous tracer infu¬
sion at a rate of 100 nCi/min. The priming dose was 120-fold great¬
er than the continuous infusion rate/min. A 90-min equilibration
period was employed to insure that the plasma specific activity of
3-3H-glucose had reached a stable plateau before measurement of
changes in glucose kinetics. Then fructose was infused as a 40%
solution at a rate of 4.5 mg/kg min"1 for 180 min. Twenty micro-
curies of 14C-(U)-fructose (Amersham) were added to the solution
of cold fructose so as to infuse approximately 80 nCi of labeled
fructose per min.
Analyses. Plasma glucose concentration was measured by the glu¬
cose oxidase method with a Beckman glucose analyzer (Beckman
Instruments, Inc., Fullerton, Calif.). Plasma fructose was determined
by the method of Heyrovsky (1956). Alanine was measured by an
enzymatic method using alanine dehydrogenase (Williamson 1974).
The methods used for the determination of plasma immunoreactive
insulin and glucagon (antibody 30K) have been previously described
(Saccit, Perez, Carteni and Rengo 1977; Saccct, Trimarco, Perez and
Rengo 1977). For the assay of 3-3H-glucose radioactivity, plasma
samples were deproteinized with Ba(OH)2-ZnS04 and the superna¬
tant was evaporated to dryness at 70 °C to remove tritiated water.
The dry residue was dissolved with 1 ml of water and counted with
10 ml of Insta-Gel (Packard Instruments, Downers Grove, 111.). In
order to quantitate fructose conversion to glucose it was necessary
to determine the plasma specific activity of 14C-fructose and 14C-
glucose. The specific activity of 14C-fructose was assumed equal to
the specific activity of the infused fructose since there is no endo¬
genous production of this hexose. This assumption was verified ex¬
perimentally as described below. For the determination of 14C-glu-
cose specific activity, the separation of this tracer from other la¬
beled compounds was accomplished as follows. A two-mi aliquot
of the Somogyi filtrate was passed through a first ion-exchange
resin (Bio-Rad AG-2X8, 100-200 mesh) packed in a small column
(0.4 x 5 cm) to remove acid components. Preliminary tests estab¬
lished that 14C-glucose passes quantitatively through the column
while the adsorption of 14C-lactate and 14C-pyruvate exceeded
98%. The effluent of the first column, containing mainly 14C-glu-
cose and 14C-fructose, was then treated with glucose oxidase (20
U/ml) at 37 °C for 15 min in order to convert 14C-glucose to 14C-
gluconic acid. The mixture was then applied to a second column
containing the same resin (AG-2X8). Since the second chromato¬
graphy was performed under the identical conditions of the first,
only 14C-gluconic acid was adsorbed while 14C-fructose and other
eventual labeled compounds not adsorbed by the first column also
passed through the second column. 14C-gluconic acid was then
eluted with hydrochloric acid, collected into scintillation vials and
mixed with Insta-Gel. The determination of radioactivity was car¬
ried out in a computerized Liquid Scintillation System (Tricarb
2660, Packard Instruments) which automatically corrected quench
and spillover of 14C in the tritium channel. In some experiments
the difference in the counts of 14C between the eluate of the first
column (containing essentially 14C-fructose and 14C-glucose) and
that of the second column (containing 14C-gluconic acid) was used
to estimate the specific activity of plasma 14C-fructose. As expect¬
ed, the values so obtained corresponded closely to the specific ac¬
tivity of the infused 14C-fructose. The determination of 14C-glucose
specific activity by the current method is highly specific and ac¬
curate. The specificity is practically dependent on the glucose oxi¬
dase used. In preliminary tests we found no cross-reaction of the
enzyme with fructose, even in the presence of fructose concentra¬
tions much higher than those occurring in our samples. Further¬
more, every step of the method can be monitored in terms of re¬
covery of 14C-glucose so that precise corrections can eventually be
made. This is possible since each plasma sample also contains 3-3H-
glucose which is initially counted and used as an internal standard
through the subsequent steps involved in the method.
Calculations. Rates of endogenous glucose production and uptake
were calculated in the steady state by the isotope dilution equation
and during nonsteady states by Steele's equations in their derivative
form (Steele 1959; Cowan and Hetenyi 1971). The time curves for
glucose concentration and specific activity were fitted with poly¬
nomial functions by the method of least squares. The value of
0.65 of the initial glucose pool was used as the rapidly mixing
compartment to compensate for nonuniform mixing with the en¬
tire glucose space (Cowan and Hetenyi 1971). The evaluation of
the rates of glucose turnover based on the primed-continuous infu¬
sion and the pool fraction technique has recently been validated
for both steady and nonsteady states (Radziuk, Norwich and
Vranic 1978). The conversion of the administered fructose to plas¬
ma glucose was quantitated by the following parameters: 1) rate
of fructose conversion to glucose (mg/kg min"1); 2) per cent of
glucose derived from fructose; and 3) per cent of fructose convert¬
ed to glucose. The first parameter was calculated by dividing the
rate of appearance of 14C-glucose by the specific activity of plas¬
ma 14C-fructose. The rate of appearance of 14C-glucose was ob¬
tained by Steele's equation, as described above, using plasma 3-3H-
glucose concentration and replacing the concentration of cold glu¬
cose with that of 14C-glucose. This method has been validated in
previous studies by comparing the rates of 14C-glucose production
determined isotopically with those obtained simultaneously with
hepatic A-V difference technique (Chiasson, Liljenquist, Jennings,
Lacy and Cherrington 1977). The per cent of glucose derived from
fructose was calculated by dividing the rate of glucose production
from fructose (which equals the rate of fructose conversion to glu¬
cose) by the rate of hepatic glucose production. Finally, the per
cent of fructose converted to glucose was obtained by dividing the
amount of glucose derived from fructose by the rate of fructose
utilization. The latter is equal to the rate of fructose infusion dur¬
ing steady state conditions, when the plasma concentration of fruc¬
tose is stable. This condition was actually present for the greater
part of the fructose infusion, except in the first 40-60 min. As
previously shown by Chiasson et al. (1977), by comparing the
double isotope method to the hepatic A-V difference technique,
the current approach provides an accurate estimate of the rate at
which a circulating precursor is converted to glucose. However, it
should be noted that this parameter cannot be equated to the rate
of glucose production via gluconeogenesis due to the possible ex¬
change of 14C-atoms in the hepatic oxalo-acetate pool. Neverthe¬
less, it certainly provides a reliable index of gluconeogenesis in
vivo. Statistical analysis was performed with the Student's t-test
for paired samples. Data are presented as means ± SE.
Results
Figure 1 shows the changes in plasma fructose and glucose
concentration, and in glucose turnover during intravenous
fructose infusion. Plasma fructose concentration increased
rapidly to about 20 mg/dl by 50—60 min and remained
remarkably stable for the rest of the infusion period. Plas¬
ma glucose (100 ± 4 mg/dl, pre-infusion) fell by 8-10
mg/dl in the first 40 min of fructose infusion (p < 0.005)
and remained unchanged thereafter. This mild decrease of
plasma glucose concentration was due to a temporary fall
in the rate of glucose output (3.07 ± 0.2 mg/kg min"1,
pre-infusion) which reached levels 33 % below baseline at
10 min (p < 0.005) and then returned slowly to basal
levels by 40—50 min. Glucose uptake decreased slightly
Paraplegia 17 (1979-80) 314-318
RECOVERY MECHANISMS FROM ACUTE HYPOGLYCAEMIA
IN COMPLETE TETRAPLEGIA
By R. J. M.Corrall, B.Sc.,M.B.Ch.B.,M.R.C.P., M.D., B. M. Frier, B.Sc., M.B.Ch.B.,
M.R.C.P., E. J. W. McClemont, M.B.Ch.B., D.C.H., S. J. Taylor and N. E. Christie
Spinal Unit, Edenhall Hospital, Musselburgh, and Metabolic Unit,
University Department of Medicine, Western General Hospital, Edinburgh
Abstract. Acute hypoglycaemia has been achieved in tetraplegic subjects and in healthy
controls using insulin. The recovery from hypoglycaemia has been followed by measur¬
ing appropriate substrate levels in blood. Abnormal responses of lactate and free fatty
acid concentrations were observed; blood glucose recovery proceeded at a normal rate.
Key words: Hypoglycaemia; Tetraplegia; Blood lactate; Free fatty acids.
Introduction
In the tetraplegic patient, transection of the cervical cord above the first thoracic
segment interrupts the major motor and sensory tracts and also disrupts the
efferent sympathetic pathway. In effect this produces a total pre-ganglionic
sympathectomy. This can result in characteristic clinical problems such as reflex
hypertension following bladder distension. Metabolic consequences of this auto¬
nomic denervation have received little attention, and could be of practical signific¬
ance in situations such as prolonged fasting during general anaesthesia. We have
therefore examined the metabolic response to acute hypoglycaemia in tetraplegia.
Methods
Six normal male subjects (age range 22-64 years) and four male tetraplegic
patients (age range 20-44 years) with complete post-traumatic cervical cord tran¬
sections at the C5/6 level, were studied after an overnight fast. All subjects
gave informed consent to the study and none were greater than 10 per cent over
their ideal body weight. After resting supine in bed for at least 30 minutes an
intravenous teflon catheter was inserted for blood sampling. Soluble insulin
(0-15 units/kg body weight) was given intravenously; blood samples were with¬
drawn in control subjects at regular intervals for 180 minutes after the onset of the
hypoglycaemic reaction. This was manifested as a sudden tachycardia coinciding
with the symptoms of hypoglycaemia in the normal group. In the tetraplegic
subjects blood samples were taken for 210 minutes after the administration of
insulin.
Continuous heart rate was monitored by pulse and ECG tape recording, and
skin surface sweating was measured in all of the normal and two of the teiraplegic
subjects (Cohen, 1966). Serial estimates of blood glucose (Hill & Kessler, 1961),
blood lactate (Hohorst, 1970) and plasma non-esterified fatty acids (NEFA'S)
(Baird et al., 1967) were made. Results are expressed as mean vlaues±one
standard error of the mean (S.E.M.).
314
PAPERS READ AT THE ANNUAL SCIENTIFIC MEETING, 1978 315
Results
In the normal subjects the autonomic hypoglycaemic reaction occurred
between 20 and 44 minutes (mean 30 minutes) after the administration of insulin.
Pulse rate rose from 60 ± 2 to 89 ± 3 beats per min at the time of the initial hypo¬
glycaemic symptoms. In all the control subjects sweating occurred coincidentally
with the tachycardia and the onset of subjective hypoglycaemia. In the tetraplegic
group no change in resting pulse (63 ±5 beats/min) was observed, and in the two
subjects in whom skin sweating was monitored, there was no detectable increase
with hypoglycaemia. Both groups experienced mild degrees of typical neuro-
glycopenic symptoms of hunger and drowsiness.
The changes in the metabolic parameters measured in both groups are shown
in Figures 1-3. Blood glucose fell rapidly from similar mean basal levels in control
and tetraplegic subjects following the administration of insulin with a more pro¬
found fall in the normal group (Fig. 1). The rate of recovery of blood glucose
was parallel in the two groups and in the tetraplegic subjects the mean basal
fasting level was attained by 150 minutes after insulin injection.
In the control group mean blood lactate levels doubled after hypoglycaemia
with a subsequent steady decline to normal fasting values (Fig. 2). In the tetra¬
plegic subjects the mean basal lactate level was similar, but the striking increase
after hypoglycaemia was not observed.
Following the injection of insulin, non-esterified fatty acids initially fell in
the control group, then rose coincidentally with blood glucose recovery, increasing
to above basal levels (Fig. 3). In the tetraplegic subjects the mean fasting N.E.F.A.
level was higher and a similar fall was noted following insulin. However, the
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Changes in plasma free fatty acids following injection of insulin
in control and tetraplegic subjects.
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subsequent increase in N.E.F.A. levels was delayed compared to the control
group.
Discussion
Electrical stimulation experiments in the rat have indicated that the activa¬
tion of recovery from acute hypoglycaemia originates in the ventromedial nucleus
of the hypothalamus (Frohman & Bernardis, 1971). Efferent pathways connect
with nerve cell bodies in the thoraco-lumbar grey matter which emerge as the
sympathetic outflow and synapse in peripheral ganglia. The adrenal medulla may
be considered a modified ganglion, the activation of which causes humoral secre¬
tion of adrenaline and noradrenaline (Bloom et al., 1975). The liver with its
central role in carbohydrate homeostasis receives a rich sympathetic nerve supply
(Holzbauer & Sharman, 1972). Adrenaline and noradrenaline levels rise markedly
in peripheral blood following hypoglycaemia and the initiation of recovery from
hypoglycaemia bears a close temporal relationship to this acute secretion (Garber
et al., 1976). Blood glucose recovery is also impaired by adrenergic blockade
(Corrall et al., 1978) and during total autonomic blockade with hexamethonium
(Lawrence & Stacey, 1952).
Following the injection of insulin, a lesser fall of blood glucose occurred in
the tetraplegic subjects. This relative insulin insensitivity is a recognised con¬
sequence of physical inactivity (Lipman et al., 1970). The rate of recovery in the
tetraplegic group, however, is similar to that observed in the control subjects,
indicating that recovery from hypoglycaemia is relatively normal. This suggests
that non-adrenergic mechanisms may be invoked to restore blood glucose to
normal. However, it is possible that carbohydrate homeostasis could be severely
impaired during the early period following traumatic transection of the cervical
cord, and this merits further study.
The lack of response of blood lactate to hypoglycaemia in the tetraplegic
group is an interesting finding. The blood lactate rise following hypoglycaemia is
thought to result from breakdown of muscle glycogen and this is activated by
raised circulating adrenaline levels. Thus it is blocked by hexamethonium which
prevents secretion of adrenaline, and also by adrenalectomy (Di Salvo et al.,
1956). The formation of glucose from lactate has been implicated as an important
factor in the recovery from hypoglycaemia in man (Corrall et al., 1978). It is of
interest therefore that recovery proceeds normally in the tetraplegic group where
lactate production appears to be impaired.
In both the control and tetraplegic subjects the fall in N.E.F.A. levels follow¬
ing insulin injection results from inhibition of fat cell lipolysis. The subsequent
re-activation of lipolysis is delayed in the tetraplegic subjects and probably results
from adrenergic denervation. In the later stages of blood glucose recovery, other
lipolytic hormones including glucagon, growth hormone and Cortisol may be
responsible for the raised N.E.F.A. levels which are eventually attained.
These preliminary observations indicate that following cervical cord tran¬
section in man significant metabolic dysfunction occurs. Blood lactate and
plasma N.E.F.A. responses to hypoglycaemia are abnormal, but restoration of
euglycaemia appears to be relatively intact.
Summary
The metabolic response to insulin-induced hypoglycaemia was studied in
six normal and four tetraplegic subjects. In the tetraplegic group the normal
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autonomic reaction to hypoglycaemia was absent, but blood glucose recovery was
not impaired. The normal increase in blood lactate was markedly attenuated and
the rise in plasma free fatty acids following hypoglycaemia was delayed. The sig¬
nificance of these metabolic changes in tetraplegia is discussed.
Resume
L'hypoglycemie aigiie a ete provoquee chez les sujets tetraplegiques et les cas controles
sains par l'utilisation de l'insuline. Le retablissement de l'hypoglycemie a ete etudie en
mesurant les niveaux substratums appropries dans le sang. Des reactions anormales de
lactate et de concentrations acides gras libre etaient observees. La guerison du glucose du
sang continua a un cours normal.
zusammenfassung
Die akute Hypoglykamie ist in den tetraplegien Patienten und gesunden Kontrollen
durch die Benutzung des Insulins untersucht worden. Die Heilung der Hypoglykamie ist
in der Blutglukose studiert worden. Abnormale Werte von Lacticaecid und von freien,
fettigen Sauren wurden gemessen.
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SUMMARY
The contributions of adrenergic and cholinergic mechanisms to recovery from
acute hypoglycaemia induced by insulin (015 units/kg i.v.) were examined in
eleven normal subjects, six subjects with a pre-ganglionic sympathectomy
(adrenergic denervation) and six sympathectomized subjects given atropine
(combined adrenergic denervation and cholinergic blockade).
Blood glucose recovery was impaired only in the sympathectomized subjects
given atropine. The blood lactate response was reduced and the rise in free fatty
acids was delayed in both groups of sympathectomized subjects, in whom the
normal rises of plasma cyclic AMP and noradrenaline were absent. The plasma
pancreatic glucagon response was appropriate to the prevailing blood glucose
concentrations in all three groups. The Cortisol response was impaired and the
pattern of ACTH secretion was abnormal in sympathectomized subjects given
atropine. Growth hormone levels were higher in both sympathectomized
groups.
Blood glucose homeostasis was impaired during combined adrenergic
denervation and cholinergic blockade. Glucagon secretion was activated
independently of vagal control. In the sympathectomized group given atropine,
the rise in plasma Cortisol was blunted despite a greater degree of hypoglycae¬
mia. A blockade of central cholinergic receptors producing impaired activation
of ACTH secretion at hypothalamic level may explain, at least in part, this
delayed restoration of normoglycaemia.
Acute hypoglycaemia is associated with an activation of the sympatho-adrenal system
which produces classical autonomic symptoms. Early investigators drew attention to the
possible relationship between activation of this system and the initiation of metabolic
Correspondence: Dr B. M. Frier, Metabolic Unit, University Department of Medicine, Western General
Hospital, Edinburgh EH4 2XU.
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recovery (Cannon et al., 1924; Houssay et al., 1924), and subsequent studies concentrated
on adrenergic mechanisms. During acute hypoglycaemia however, there is evidence for
the activation of post-ganglionic cholinergic nerves which promote gastric acid secretion
and innervate skeletal muscle (Allwood & Ginsburg, 1959) and stimulate the parotid
salivary glands (Corrall et al., 1976). Furthermore, a vagal cholinergic mechanism has
been implicated in the control of glucagon (Bloom et al., 1974a; 1974b) and pancreatic
polypeptide secretion (Adrian et al., 1977) in response to hypoglycaemia. In the present
paper we describe studies in man in which we have examined the contributions of
adrenergic and cholinergic activity to the homeostatic recovery mechanism from acute
hypoglycaemia.
SUBJECTS
Control group: Eleven normal volunteers (nine male, two female), age range 20-29
years, were all within 10% of their ideal body weight, and taking no medications.
Tetraplegic group: Six, non-obese male patients, age range 21-44 years, with complete
post-traumatic transection of the cervical spinal cord above CI, which had occurred at
least 6 months earlier (Table 1).
Tetraplegic and atropine group: Six, non-obese male tetraplegic patients (two from the
above group) with a similar neurological lesion, age range 19-28 years (Table 1).
Informed consent was obtained from all subjects, none ofwhom had known endocrine
or metabolic disorders. The protocol was approved by the local Medical Ethics
Committee.
METHODS
All subjects were studied supine after an overnight fast. Insulin (015 u/kg body weight)
was injected after basal blood samples had been withdrawn through an indwelling teflon
Table 1. Clinical details of tetraplegic subjects (two groups)
Duration of Level of
Subject (no.) Age (years) cervical transection transection
With atropine
1 21 5 years C4/5
2 22 9 months C6/7
3 19 1 year C5/6
4 28 4 years C5/6
5 27 6 months C4/5
6 19 4 months C4/5
Without atropine
1 21 5 years C4/5
2 22 8 months C6/7
7 44 13 years C5/6
8 23 6 months C5/6
9 40 19 years C5/6
10 35 7 years C5/6
























Fig. 1. Pulse rate in individual tetraplegic subjects given atropine. Insulin was administered at
time 0 min. A = atropine (i.v.); 'discontinued because of neuroglycopenia.
cannula. Atropine (15 ^g/kg body weight) was administered 30 min prior to the insulin in
six tetraplegic subjects. The heart rate was monitored, and if necessary, a further dose of
atropine was administered (Fig. 1).
Serial blood sampling was performed for 210 min after the administration of insulin,
and measurements ofblood glucose (Hill & Kessler, 1961), blood lactate (Hohorst, 1970),
plasma free fatty acids (FFA) (Baird et al., 1967), plasma cyclic AMP (cAMP) (Brown et
ai, 1972), C-terminal glucagon-like immunoreactivity (Stout et al., 1976), plasma
noradrenaline (Henry et al, 1975), plasma Cortisol (Mattingly, 1962), plasma ACTH
(Feek et al., 1981) and plasma growth hormone (GH) (Hunter, 1976) were taken.
Statistics
Results are expressed as mean + the standard error of the mean (SEM). Statistical
significance between groups of subjects was estimated using Student's t test for paired
(within group) or unpaired data, except when data was not normally distributed about the
mean value. The Wilcoxon rank test was used to assess statistical significance for
pancreatic glucagon, GH and ACTH which were not distributed in a normal manner.
RESULTS
Approximately 30 min after the injection of insulin the normal subjects experienced a
typical hypoglycaemic reaction, manifested by sweating, tachycardia and symptoms of
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neuroglycopenia. In the tetraplegic patients without atropine there was no consistent
change in pulse rate, sweating was not observed and only mild neuroglycopenia occurred.
With atropine, the tetraplegic patients all had an elevated heart rate (Fig. 1), and during
hypoglycaemia, visible sweating was absent, but the neuroglycopenic symptoms were
worse and more persistent. Two of these patients complained of severe neuroglycopenia
during cholinergic blockade, which necessitated discontinuing the study with parenteral
glucose 90 min after insulin.
Plasma substrate concentrations (Fig. 2)
Blood glucose. Following insulin, the rate of fall of blood glucose was slower in both
groups of tetraplegic subjects and was significantly different from the normal group at 30
min (P< 0-001). In the group of tetraplegic patients who did not receive atropine, blood
glucose recovery proceeded at a normal rate.With atropine, blood glucose recovery in the
tetraplegic patients was greatly impaired, in comparison with both the control group and
Atropine
Time (min)
Fig. 2. Changes in blood glucose, blood lactate, plasma free fatty acids and plasma cyclic AMP
concentrations (mean +SEM) in response to insulin-induced hypoglycaemia, in normal subjects
and in tetraplegic subjectswith or without atropine. Insulin was administered at time 0min. Mean
+ SEM, 2 normal; £ tetraplegia; £ tetraplegia and atropine.
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Fig. 3. Changes in plasma pancreatic glucagon, growth hormone, Cortisol and ACTH (mean
+ SEM) in response to hypoglycaemia in normal subjects and in tetraplegic subjects with or
without atropine. Insulin was injected at time 0 min. Mean +SEM, J normal; J tetraplegia; I
tetraplegia and atrophine.
the tetraplegic group without atropine, at 60 min (/><0-01), 90 min (/"< 0-001) and 150
min (.P<0-001).
Blood lactate. In the control subjects blood lactate increased to a peak value at 60 min
(P <0-001 v. mean basal value of control group) (Fig. 2). In the tetraplegic subjects
without atropine the mean blood lactate at 60 min was significantly lower (P < 0-05) than
the corresponding value observed in the control group. Blood lactate was measured in
two tetraplegic subjects given atropine; these were similar to the levels observed in the
tetraplegic group without atropine.
Plasma FFA. In all three groups, mean plasma FFA levels fell after insulin (Fig. 2). A
subsequent rise was observed in the control group to levels above basal and a similar, but
delayed, pattern was present in the tetraplegic groups. This delay wasmore pronounced in
the group given atropine.
Plasma cAMP. In the control group, mean plasma cAMP increased rapidly to a peak
more than double the basal value at 30 min. This rise was absent in both groups of
tetraplegic patients.
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Plasma hormone concentrations (Fig. 3)
Plasma pancreatic glucagon. Mean plasma pancreatic glucagon rose to a peak value at
60 min in the control group and in the tetraplegic group without atropine. In the
tetraplegic group with atropine the pancreatic glucagon secretory response was
prolonged, reaching a peak value at 90 min, which was not significantly greater than the
control group (PcO-l) but was greater than the tetraplegic group without atropine
CP <0-02).
Plasma noradrenaline. In the control group the plasma noradrenaline rose from a mean
basal value of 201 + 103 ng/1 to 430+ 114 ng/1 at 45 min after insulin. In both tetraplegic
groups, the mean basal values were lower than the control group at 25 + 6 ng/1 (without
atropine) and 63 + 24 ng/1 (with atropine), with no measurable response to hypoglycaemia.
Plasma Cortisol. The rise in plasma Cortisol (Fig. 3) was very similar in the control
subjects and in the tetraplegic subjects without atropine. In the tetraplegic group given
atropine, despite prolonged hypoglycaemia, plasma Cortisol was lower. This difference
was significant at 90 min compared with the control group (P<005).
Plasma ACTH. In the control group, and in the tetraplegic group without atropine,
plasma ACTH levels rose to a peak value at 45 min. A different pattern of secretion was
observed in the tetraplegic group given atropine, with a slower rise to a peak at 60 min,
and a higher mean value than both of these groups at 90 min, but this did not achieve
statistical significance.
Plasma GH. In the control group the expected rise in plasma GH levels was observed
following hypoglycaemia, but in both tetraplegic groups the peak mean values of GH at
60 min were more than double that of the control group. This was not statistically
significant.
DISCUSSION
The production of a pre-ganglionic sympathectomy in traumatic tetraplegia provides an
excellent model for the evaluation of adrenergic mechanisms in vivo. The administration
of atropine to these subjects has enabled an examination of residual cholinergic control
mechanisms. A significant degree of cholinergic blockade is demonstrated by the
persistent elevation in heart rate in the tetraplegic subjects given atropine (Fig. 1).
In the sympathectomized subjects the blood glucose recovery proceeded at a normal
rate and was unaffected by the absence of a catecholamine response. In the present study
the administration ofatropine to sympathectomized subjects significantly impaired blood
glucose recovery.
In normal subjects the rise in blood lactate in response to hypoglycaemia results from
muscle glycogenolysis (Haugaard et al., 1976). The rises of lactate and FFA following
hypoglycaemia are reduced by adrenergic antagonists (Billington et al., 1954; Di Salvo et
al., 1956; Werk et al., 1961; Abramson et al., 1966; Abramson & Arky, 1968) and are
absent in response to intracellular glucopenia induced by 2-deoxy-glucose in sympathec¬
tomized patients (Brodows et al., 1973; 1975). In the present study, the impaired rise
following hypoglycaemia in blood lactate and plasma FFA in the sympathectomized
subjects can therefore be attributed to adrenergic denervation. Although lactate is an
important precursor for hepatic gluconeogenesis during recovery from hypoglycaemia
(Young & Landsberg, 1977; Exton, 1979), impairment of lactate production had no effect
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on blood glucose recovery in the tetraplegic subjects without atropine, and is unlikely to
be the primary cause of the retarded glucose recovery during cholinergic blockade. In the
present study the absence of a cyclic AMP rise in response to hypoglycaemia in all
tetraplegic subjects, despite normal glucagon secretion, suggests that the activation of
hepatic adenyl cyclase by hypoglycaemia is mediated by catecholamines.
The rise in plasma pancreatic glucagon concentrations was proportional to the degree
of hypoglycaemia attained in both groups of tetraplegic subjects, confirming that
adrenergic mechanisms are not the prime mediators of pancreatic glucagon release
following hypoglycaemia in man (Walter el al., 1974; Ensinck et al., 1976; Palmer et al.,
1976). Studies of hypoglycaemia in the calf (Bloom et al., 1974a) and in vagotomized
human subjects (Bloom et al., 1974b) have suggested that glucagon secretion is primarily
via cholinergic vagal control. However, recent human studies have shown that neither
truncal vagotomy nor cholinergic blockade prevent glucagon secretion in response to
hypoglycaemia (Palmer et al., 1979), and it is apparent from the present studies that
secretion can occur independently of these neural control mechanisms.
The delayed rise in plasma ACTH, and the reduced plasma Cortisol response in the
tetraplegic patients under cholinergic blockade, may have been responsible for the
impaired blood glucose recovery in these subjects, despite apparently adequate secretion
of pancreatic glucagon and growth hormone. Cortisol influences gluconeogenesis by a
permissive effect on the action of glucagon and catecholamines on hepatic glycogenolysis
and gluconeogenesis (Exton et al., 1972) and by its effect upon catecholamine-induced
release of lactate from skeletal muscle and glycerol from adipose tissue (Steele, 1975).
Impaired blood glucose recovery from hypoglycaemia has been described in states of
primary and secondary adrenal insufficiency (Fraser et al., 1941; De Bodo & Altszuler,
1958; Shahmanesh et al., 1980), although this was not apparent when replacement
corticosteroid therapy had been given prior to the induction of hypoglycaemia (Ginsburg
&Paton, 1956; Ensinck etal., 1976, Brodowse/a/., 1976). A relative deficiency ofCortisol
following hypoglycaemia might therefore diminish blood glucose recovery through its
permissive interaction with glucagon, particularly if the availability of lactate for
gluconeogenesis was limited. A cholinergic mechanism has been implicated in the
secretion of corticotrophin-releasing factor in the murine hypothalamus (Jones et al.,
1976). The present data suggest that a similar mechanism may exist in man; atropine
crosses the blood-brain barrier (Innes & Nickerson, 1975) and could have delayed the
activation of ACTH secretion in the tetraplegic group under cholinergic blockade.
Recovery from hypoglycaemia requires an integrated activation of various counter-
regulatory mechanisms which provide substrates for gluconeogenesis and stimulate
hepatic glycogenolysis and gluconeogenesis. The present studies indicate that in the
absence of peripheral adrenergic mechanisms alone this homeostatic process is relatively
intact. With the administration of atropine both classical components of the autonomic
nervous system are impeded and an impaired blood glucose recovery becomes manifest.
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Attenuation of the Pancreatic Beta Cell Response to a Meal
Following Hypoglycaemia in Man
B. M. Frier, R. J. M. Corrall, J. P. Ashby, and J. D. Baird
Metabolic Unit, University Department of Medicine, Western General Hospital, Edinburgh, Scotland
Summary. The plasma concentration of C-peptide,
insulin (IRI) and glucose was measured in 9 healthy
subjects during insulin-induced hypoglycaemia fol¬
lowed by a meal. Identical observations were made in
the same subjects after an equivalent period of
fasting without hypoglycaemia (control study).
Endogenous secretion of insulin was suppressed fol¬
lowing administration of exogenous insulin and this
persisted long after the blood glucose concentration
had returned to normal. After the meal the mean
blood glucose rose to a peak of 8.4 ± 0.3 mmol/1
(mean ± SEM) at 60 min and was still raised at 7.5 ±
0.3 mmol/1 at 120 min, compared with a peak value
of only 5.1 ± 0.2 mmol/1 at 30 min after the meal in
the control study. Following hypoglycaemia the mean
plasma IRI rose from 8.3 ±1.3 mU/1 to a delayed
peak of 81.6 ± 12.7 mU/1 at 60 min and was 123.5 ±
14 mU/1 at 120 min post-prandially, comparedwith a
peak of 72.4 ± 0.5 mU/1 at 30 min after the meal in
the control study. Acute hypoglycaemia may thus
induce an abnormal pattern of insulin secretion in
response to a meal, with impaired carbohydrate
tolerance in normal subjects.
Key words: Hypoglycaemia, beta-cell function, C-
peptide, insulin secretion.
The study of insulin secretion during hypoglycaemia
in man has, until recently, been restricted by an ina¬
bility to interpret levels of immunoreactive insulin
(IRI) in plasma following the administration of
exogenous insulin [1]. Attempts to circumvent this
problem have included the induction of hypogly¬
caemia by the administration of alcohol [2] or fish
insulin [1J. Connecting (C-) peptide and insulin are
released in equimolar amounts by the pancreatic beta
cell. The development of a radioimmunoassay for
connecting peptide reactivity (CPR) has made it
possible to study the secretion of insulin in vivo dur¬
ing insulin-induced hypoglycaemia [3-6]. We have
extended these observations by examining the
response of the beta cell to a meal following acute
hypoglycaemia.
Subjects and Methods
Eleven healthy subjects (9 male, 2 female), age range 20-29 years
(mean 23.8 years) were studied after an overnight fast. None of
the subjects were taking any medications, and all were within ten
per cent of their ideal body weight (mean 96 per cent, range
91-102 per cent). The approval of the Medical Ethics Committee
was obtained for the study and informed consent was given by each
subject.
Hypoglycaemia Study
Crystalline beef insulin (0.15 units/kg. body weight) was adminis¬
tered as a bolus by rapid intravenous injection and blood samples
were taken via an indwelling teflon cannula for estimation of blood
glucose [7], plasma CPR [8] (effective detection limit 0.06 nmol/1)
and plasma IRI levels [9] in the fasting state, and at intervals for
210 min after the injection of insulin. Nine of these subjects were
then given a standard mixed meal containing 30g protein, 85g
carbohydrate and 40g fat, and blood sampling was continued for a
further 120 min. All subjects experienced symptoms and signs of
hypoglycaemia between 20 and 30 min (mean 24 min) after the
injection of insulin.
Control Study
The same 9 subjects were restudied after an interval of at least one
week. The meal was given after an overnight fast plus an equiva¬
lent period of fasting without the administration of insulin, and the
same parameters were measured. In both studies all subjects con¬
sumed the meal within 15 min.
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Fig. 1. Blood glucose concentration (mean ± SEM) following
injection of insulin and in response to a subsequent meal (Hypo¬
glycaemia study) and in response to a meal alone after an equiva¬




Fig. 2. Log plasma CPR concentration (mean ± SEM) in the
hypoglycaemia and control studies. The effective detection limit of
the assay is marked as a horizontal dotted line (0.06 nmol/1). 5 Z















Fig. 3. Plasma IRI concentration (mean ± SEM) in the hypogly¬
caemia and control studies. J—3 Hypoglycaemia, 5 f Control
The results are expressed as mean ± one standard error of the




In the hypoglycaemia study the mean fasting blood
glucose fell from 3.9 ± 0.1 to 1.2 ± 0.1 mmol/1 at the
time of the acute hypoglycaemic reaction, and
regained the fasting level by 150 min after the injec¬
tion of insulin (Fig. 1). Following the meal, the mean
blood glucose concentration rose to a peak of 8.4 ±
0.3 mmol/1 at 60 min and was still raised (7.5 ±
0.3 mmol/1) at 120 min post-prandially.
In the control study the mean blood glucose con¬
centration of the same subjects reached a peak value
of only 5.1 ± 0.2 mmol/1 at 30 min after the meal and
regained the fasting level (3.6 ± 0.3 mmol/1) by
60 min post-prandially. The difference in the mean
blood glucose concentrations following the meal be¬
tween the two studies was highly significant at 30, 60
and 120 min (p < 0.001).
Plasma C-peptide
In the hypoglycaemia study the mean plasma CPR
fell rapidly after administration of insulin from a fast¬
ing level of 0.39 ± 0.04 nmol/1 (range 0.20 to 0.69
nmol/1) to the effective detection limit of the assay,
60 min after the injection of insulin (Fig. 2). It
remained low throughout the period of blood glucose
recovery and at 210 min after insulin was only 0.11 ±
0.03 nmol/1. CPR levels rose following the meal
reaching 1.72 ± 0.24 nmol/1 at 60 min and 2.58 ±
0.47 nmol/1 at 120 min post-prandially.
In the control study, mean plasma CPR rose from
0.35± 0.01 nmol/1 to a peak of 1.76 ± 0.08 nmol/1 at
30 min, falling to 1.16 ± 0.14 nmol/1 at 120 min. The
differences in the mean plasma CPR concentrations
between the two studies were significant (p < 0.001)
at 15, 30 and 120 min after the meal.
Plasma Insulin
In the hypoglycaemia study the expected rise in
plasma IRI after the injection of exogenous insulin
was observed (Fig. 3), and was followed by an expo-
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nential fall. At the time of the meal the plasma IRI
had returned to the fasting level. After ingestion of
food, mean plasma IRI rose from 8.3 ±1.3 mU/1 to
81.6 ± 12.7 mU/1 at 60 min and 123.5 ± 14 mU/1 at
120 min.
In the control study, the mean plasma IRI rose
from 9.1 ± 0.6 mU/1 to 72.4 ± 0.5 mU/1 at 30 min,
falling to 51.0 ± 7.2 mU/1 at 60 min and 29.5 ±
4.5 mU/1 at 120 min. The differences in plasma IRI
between the two studies were statistically significant
(p < 0.001) at all four times of measurement after
the meal.
Discussion
The value of the CPR assay as an index of endoge¬
nous insulin secretion is now well recognised [3-6].
The plasma IRI concentrations after the administra¬
tion of endogenous insulin closely resemble those
reported by Garber et al. [10] and had fallen to
within the fasting range prior to ingestion of the
meal. The decline in the mean plasma IRI concentra¬
tion during recovery from hypoglycaemia was not
however comparable with the marked fall in plasma
CPR concentration to undetectable levels, and is
inconsistent with the short half-life of insulin in
plasma. Appropriately low levels of plasma IRI were
observed in three subjects with concentrations falling
to less than 6.0 mU/1 by 150 minutes after the
administration of insulin, but we are unable to ex¬
plain the overall discrepancy between mean plasma
IRI and CPR concentrations prior to the meal. The
prolonged suppression of plasma CPR concentration
following hypoglycaemia is consistent however with
the observations of Horwitz et al. [3],
The demonstration in man of impaired tolerance
to oral glucose following the administration of insulin
has previously been described [11] and attributed to
the presence of insulin antagonists. The response of
the pancreatic beta cell to the ingestion of food fol¬
lowing hypoglycaemia has not been reported. The
present study shows that following recovery from
hypoglycaemia, insulin secretion in response to a
meal is abnormal and is associated with impaired car¬
bohydrate tolerance. The initial delay in the secretion
of insulin after hypoglycaemia must be partly
responsible for the elevated post-prandial blood glu¬
cose concentrations. The hypersecretion of insulin
observed 120 minutes after the meal may be a direct
response to sustained hyperglycaemia.
The mechanism underlying the abnormal secre¬
tion of insulin in response to a meal after hypogly¬
caemia has not been elucidated. The possibility that
insulin directly inhibits its own secretion has been
studied by maintaining euglycaemia with a glucose
infusion during the administration of insulin [12-14],
Partial suppression of CPR levels without hypogly¬
caemia was interpreted as evidence for the existence
of such a direct negative feedback [12, 13] but this
was not confirmed by Shima et al. [14], Plasma
catecholamines, which inhibit insulin secretion and
rise markedly during hypoglycaemia [10], could also
cause pancreatic beta cell suppression. The pattern of
insulin secretion in the present study is similar to that
observed during and after the infusion of adrenaline,
where insulin secretion is suppressed until adrenaline
is discontinued [15, 16]; insulin secretion is initially
delayed during the recovery period but subsequently
hypersecretion of insulin is observed. The early
inhibition of insulin secretion after food ingestion
could be explained by altered function of the entero-
insular axis following hypoglycaemia. Plasma gastro-
inhibitory peptide and pancreatic polypeptide levels
rise during hypoglycaemia [13, 17, 18], but the
response of those hormones to the subsequent inges¬
tion of food is not known. Finally, the secretion of
insulin could be inhibited by a direct effect of hypo¬
glycaemia on the metabolism of the beta cell.
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